FORM 2
THE PATENTS ACT 1970
(Act 39 of 1970)
COMPLETE SPECIFICATION
(SECTION 10)
NOVEL TRICYCLIC COMPOUNDS AS PDE-4 INHIBITORS
Glenmark Pharmaceuticals Limited, an Indian Company,
registered under the Indian company's Act 1957 and
having its registered office at
B/2, Mahalaxmi Chambers, 22, Bhulabhai Desai Road
Post Box No. 26511
Mumbai - 400 026, India
THE FOLLOWING SPECIFICATION DESCRIBES THE NATURE OF THE INVENTION: AND THE MANNER IN, WHICH IT IS TO BE PERFORMED

2
Field of the Invention
The present invention relates to novel heterocyclic compounds, their analogs, their tautomers, their regioisomers, their stereoisomers, their enantiomers, their diastereomers, their polymorphs, their pharmaceutically acceptable salts, their appropriate N-oxides, their pharmaceutically acceptable solvates and their pharmaceutical compositions containing them. The present invention more particularly relates to novel Phosphodiesterase type 4 (PDE4) inhibitors of the formula (1), their analogs, their tautomers, their enantiomers, their diasteromers, their regioisomers, their stereoisomers, their polymorphs, their pharmaceutically acceptable salts, their appropriate N-oxide, their pharmaceutically acceptable solvates and the pharmaceutical compositions containing them.
The invention thus relates to compounds of the formula (1)

P—R1
(1)
wherein:
R1, R2 and R3 may be same or different and are independently selected for each occurrence from the groups consisting of hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstitued alkynyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted cycloalkylakyl, substituted or unsubstituted cycloalkenyl, substituted or unsubstituted aryl, substituted or unsubstituted arylalkyl, substituted or unsubstituted heteroaryl, substituted or unsubstituted heterocyclic group,

3
substituted or unsubstituted heterocyclylalkyl, substituted or unsubstituted heteroarylalkyl , nitro, -OH, cyano, formyl, acetyl, halogen, protecting groups, -C(0)-Ra, -C(0)0-Ra, -C(0)NRaRa, -S(0)q-Ra, -S(0)q-NRaRa, -NRaRa, ,-ORa, -SRa or when two R3 substitutents ortho to each other, may be joined to a form a saturated or unsaturated ring 3-7 membered ring, which may optionally include up to two heteroatoms which may be same or different selected from O, NRa or S;
wherein R4 is -NR5R6; wherein R5 and R6 may be same or different and are independently selected from the groups consisting of hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstitued alkynyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted cycloalkylakyl, substituted or unsubstituted cycloalkenyl, substituted or unsubstituted aryl, substituted or unsubstituted arylalkyl, substituted or unsubstituted heteroaryl, substituted or unsubstituted heterocyclic ring, substituted or unsubstituted heterocyclylalkyl, substituted or unsubstituted heteroarylalkyl , nitro, -OH, cyano, halogen, -C(0)-Ra, -C(0)0-Ra, -C(0)NRaRa, -S(0)q-Ra, -S(0)q-NRaRa, -C(=NRa)-Ra, -C(=NRa)-NRaRa, -C(=S)-NRaRa, -C(=S)-Ra, -N=C(RaRa), -NRaRa, -ORa, -SRa, protecting groups or R5 and R6 to each other may be joined to a form a saturated or unsaturated 3-7 membered cyclic ring, which may optionally include up to two heteroatoms which may be same or different selected from O, NRa or S;
Ar is selected from the group consisting of substituted or unsubstituted aryl, substituted or unsubstituted arylalkyl, substituted or unsubstituted heterocyclic ring and substituted or unsubstituted heteroaryl ring;
Preferably Ar is optionally substituted phenyl, optionally substituted benzyl, optionally substituted pyrimidine, optionally substituted pyridyl selected from 4-pyridyl, 3-pyridyl and 2-pyridyl or optionally substituted pyridyl-N-oxide selected from 4-pyridyl-N-oxide, 3-pyridyl-N-oxide and 2-pyridyl-N-oxide in which optional substituents (one or more) may be same or different and are independently selected from the groups consisting of hydrogen, hydroxyl, halogen, cyano, nitro, carboxyl, trifluoroalkyl, substituted or unsubstituted alkyl,

4
substituted or unsubstituted alkoxy, substituted or unsubstituted alkoxycarbonyl, substituted or unsubstituted alkylcarbonyl, substituted or unsubstituted alkylcarbonyloxy, substituted or unsubstituted amino or mono or di substituted or unsubstituted alkylamino
X is selected from the group consisting of O, S(0)q and NRa;
Y is selected from the group consisting of -C(0)NR7, -NR7S(0)q, -S(0)qNR7 and -
NR7C(0);
R7 is selected from the group consisting of hydrogen, substituted or unsubstituted alkyl,
hydroxyl, -ORa, substituted or unsubstituted aryl, and substituted or unsubstituted
heterocyclic ring ;
wherein P is chosen from the group consisting of O and S;
wherein m represents 0-3;
wherein n represents 1-4;
wherein q represents 0,1 or 2;
with the proviso that R4 is not NH2
wherein Ra is selected from the group consisting of hydrogen, substituted or unsubstituted
alkyl, substituted or unsubstituted alkenyl, substituted or unsubstitued alkynyl, substituted
or unsubstituted cycloalkyl, substituted or unsubstituted cycloalkylakyl, substituted or
unsubstituted cycloalkenyl, substituted or unsubstituted aryl, substituted or unsubstituted
arylalkyl, substituted or unsubstituted heteroaryl, substituted or unsubstituted heterocyclic
ring, substituted or unsubstituted heterocyclylalkyl , substituted or unsubstituted
heteroarylalkyl, nitro, -OH, cyano, formyl, acetyl, halogen, protecting groups, -C(0)-Ra, -
C(0)0-Ra, -C(0)NRaRa, -S(0)q-Ra, -S(0)q-NRaRa, -NRaRa, -0Ra and -SRa;
and their analogs, their tautomers, their regioisomers, their stereoisomers, their enantiomers,
their diastereomers, their polymorphs, their pharmaceutically acceptable salts, their N-
oxides, their pharmaceutically acceptable solvates and their pharmaceutical compositions
containing them or a pharmaceutical acceptable salts thereof.
The present invention also relates to a process for the preparation of the above said novel
heterocyclic compounds of formula 1 as defined above.
The compounds of general formula (1) more particularly, down regulate or inhibit the production of TNF-a as they are PDE4 inhibitors and therefore are useful in the treatment

5
of variety of allergic and inflammatory diseases including asthma, chronic bronchitis, atopic dermatitis, urticaria, allergic rhinitis, allergic conjunctivitis, vernal conjuctivitis, eosinophilic granuloma, psoriasis, rheumatoid arthritis, septic shock, ulcerative colitis, Crohn's disease, reperfusion injury of the myocardium and reperfusion injury of the brain, chronic glomerulonephritis, endotoxic shock and adult respiratory distress syndrome. The compounds of the present invention are particularly useful for the treatment of asthma or chronic obstructive pulmonary disease (COPD).
Background of the Invention
Airway inflammation characterizes a number of severe lung diseases including asthma and chronic obstructive pulmonary disease (COPD). Events leading to airway obstruction include edema of airway walls, infiltration of inflammatory cells into the lung, production of various inflammatory mediators and increased mucous production. The airways of asthmatic patients are infiltrated by inflammatory leukocytes, of which the eosinophil is the most prominent component. The magnitude of asthmatic reactions is correlated with the number of eosinophils present in lungs.
The accumulation of eosinophils is found dramatically in the lungs of asthmatic patients although there are very few in the lungs of a normal individual. They are capable of lysing and activating cells and destroying tissues. When activated, they synthesize and release inflammatory cytokines such as IL-1, IL-3, TNF-cc and inflammatory mediators such as PAF, LTD4 and related oxygen species that can produce edema and broncho-constriction. Tumor necrosis factor (TNF-a) was also known to be involved in the pathogenesis of a number of autoimmune and inflammatory diseases. Consequently, manipulation of the cytokine signaling or biosynthetic pathways associated with these proteins may provide therapeutic benefit in those disease states. It has been well demonstrated that TNF-a production in pro-inflammatory cells becomes attenuated by an elevation of intracellular cyclic adenosine 3',5'-monophosphate (cAMP). This second messenger is regulated by the phosphodiesterase (PDE) family of enzymes. The phosphodiesterase enzymes play an integral role in cell signaling mechanisms by hydrolyzing cAMP and cGP to their inactive 5' forms. Inhibition of PDE enzymes thus results in an elevation of cAMP and /or cGP levels and alters intracellular responses to extra cellular signals by affecting the processes

6
mediated by cyclic nucleotides. Since eosinophilis are believed to be a critical proinflammatory target for asthma, identification of the expression of the PDE 4 gene family in eosinophils led to PDE 4 as potential therapeutic target for asthma [Rogers, D.F., Giembycz, M.A., Trends Pharmacol. Set, 19, 160-164(1998); Barnes, P.J., Trends Pharmacol Sci., 19, 415-423 (1998) herein incorporated by reference in their entirety]. The mammalian cyclic nucleotide phosphodiesterases (PDEs) are classified into ten families on the basis of their amino acid sequences and/or DNA sequence, substrate specificity and sensitivity to pharmacological agents [Soderling, S.H., Bayuga, S.J., and Beavo, J.A., Proc. Natl. Acad. Sci., USA, 96,7071-7076 (1999); Fujishige, K, Kotera, J., Michibata, H., Yuasa, K., Takebayashi, Si, Okamura, K. and Omori, K., J. Biol. Chem., 274, 18438-18445 (1999) herein incorporated by reference in their entirety]. Many cell types express more than one PDE and distribution of isoenzymes between the cells varies markedly. Therefore development of highly isoenzyme selective PDE inhibitors provides a unique opportunity for selective manipulation of various pathophysiological processes.
Phosphodiesterase type 4 (PDE4) is an enzyme which regulates activities in cells which lead to inflammation in the lungs. PDE4, a cAMP-specific and Ca -independent enzyme, is a key isozyme in the hydrolysis of cAMP in mast cells, basophils, eosinophils, monocytes and lymphocytes. The association between cAMP elevation in inflammatory cells with airway smooth muscle relaxation and inhibition of mediator release has led to widespread interest in the design of PDE4 inhibitors [Trophy,T.J., Am. J. Respir. Crit. Care Med., 157, 351-370 (1998) herein incorporated by reference in their entirety]. Excessive or unregulated TNF-a production has been implicated in mediating or exacerbating a number of undesirable physiological conditions such as diseases including osteoarthritis, and other arthritic conditions; septic shock, endotoxic shock, respiratory distress syndrome and bone resorption diseases since TNF-a also participates in the onset and progress of autoimmune diseases, PDE4 inhibitors may find utility as therapeutic agents for rheumatoid arthritis, multiple sclerosis and Crohn's disease. [Nature Medicine, I, 211-214 (1995) and ibid., 244-248 herein incorporated by reference in their entirety].
Strong interest in drugs capable of selective inhibition of PDE 4 is due to several factors. Tissue distribution of PDE-4 suggests that pathologies related to the central nervous and immune systems could be treated with selective PDE-4 inhibitors. In addition, the increase

7
in intracellular cAMP concentration, the obvious biochemical consequence of PDE-4 inhibition, has been well characterized in immuno-competent cells where it acts as a deactivating signal.
Recently the PDE4 family has grown to include four subtypes - PDE4A to PDE4D, each encoded by a distinct gene (British Journal of Pharmacology; 1999; v.128; p. 1393-1398), herein incorporated by reference in its entirety.
It has been demonstrated that increasing cAMP levels within these cells results in suppression of cell activation, which in turn inhibits the production and release of proinflammatory cytokines such as TNF-a. Since eosinophilis are believed to be a critical proinflammatory target for asthma, identification of the expression of the PDE-4 gene family in eosinophils led to the PDE-4 as a potential therapeutic target for asthma. The usefulness of several PDE-4 inhibitors, unfortunately, is limited due to their undesirable side effect profile which include nausea and emesis (due to action on PDE-4 in the central nervous system) and gastric acid secretion due to action on PDE-4 in parietal cells in the gut. Barnette, M.S., Grous, M., Cieslinsky, L.B., Burman, M, Christensen, S.B., Trophy, T J., J. Pharmacol. Exp. Ther., 273,1396-1402 (1995) herein incorporated by reference in their entirety. One of the earliest PDE-4 inhibitors, Rolipram™, was withdrawn from clinical development because of its severe unacceptable side effect profile. Zeller E. et. al., Pharmacopsychiatry J/7, 188-190 (1984) herein incorporated by reference in its entirety. The cause of severe side effects of several PDE-4 inhibitor molecules in human clinical trials has recently become apparent.
There exist two binding sites on mammalian PDE-4 at which inhibitor molecules may bind. Also PDE-4 exists in two distinct forms which represent different conformations. They are designated as High affinity Rolipram binding site PDE-4H and Low affinity Rolipram binding site PDE-4L [Jacobitz, S., McLaughlin, M.M., Livi, G.P., Burman, M., Trophy, T.J., Mol. Pharmaco., 50, 891-899 (1996) herein incorporated by reference in their entirety]. It was shown that certain side effects (vomiting and gastric acid secretion) are associated with inhibition of PDE-4H whereas some beneficial actions are associated with PDE-4L inhibition. It was also found that human recombinant PDE-4 exists in 4 isoforms A, B, C and D [Muller, T., Engels, P., Fozard, J.R., Trends Pharmacol. Sci., 17, 294-298 (1996) herein incorporated by reference in its entirety]. Accordingly, compounds displaying more

8
PDE-4D isoenzyme selectivity over the A, B or C are found to have fewer side effects than Rolipram [Hughes. B et.al, Br. J. Pharmacol. 1996, 118, 1183-1191 herein incorporated by reference in their entirety]. Therefore, selective inhibitors of PDE-4 isozymes would have therapeutic effects in inflammatory diseases such as asthma and other respiratory diseases. Although several research groups all over the world are working to find highly selective PDE-4 isozyme inhibitors, so far success has been limited. Various compounds have shown PDE-4 inhibition.



.COOH O.
Me02SO'
ARIFLO A

Roflumilast D

Bay-19-8004 E




PD-168787 G
Filaminast H

SmithKline Beecham's "Ariflo" which has the formula A, Byk Gulden's Roflumilast which has the formula D and Bayer's Bay-19-8004 which has the formula E have reached advanced stage of human clinical trials. Other compounds which have shown potent PDE-4 inhibitory activity include Celltech's CDP-840 of the formula B, Schering Plough's D-4418 of the formula C, Pfizer's 5CP-220,629 which has the formula F, Parke Davis's PD-168787 which has the formula G and Wyeth's Filaminast which has the formula H. However, recently due to efficacy and side effects problems, Ariflo, CDP-840 and Bay-19-8004 were

9
discontinued from clinical trials as a treatment for asthma. Other compounds of the formulae C and F are presently undergoing phase-1 clinical trials.
During the course of our research aimed at the development of novel anti-asthmatic compounds having potential PDE4 inhibitory activity, we have filed a WTO patent application in India bearing No. 922/MUM/2002 dated October 23, 2002 and PCT application No PCT/IB03/04442 dated October 8, 2003 herein incorporated by referene in their entirety for a novel series of tricyclic compounds useful for the treatment of inflammatory and allergic disorders
SUMMARY OF THE INVENTION
Accordingly, the present invention provides novel heterocyclic compounds of the general formula

P—R1
(1)
wherein:
R1, R2 and R3 may be same or different and are independently selected for each occurrence from the groups consisting of hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstitued alkynyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted cycloalkylakyl, substituted or unsubstituted cycloalkenyl, substituted or unsubstituted aryl, substituted or unsubstituted arylalkyl, substituted or unsubstituted heteroaryl, substituted or unsubstituted heterocyclic group, substituted or unsubstituted heterocyclylalkyl, substituted or unsubstituted heteroarylalkyl ,

10
nitro, -OH, cyano, formyl, acetyl, halogen, protecting groups, -C(0)-Ra, -C(0)0-Ra, -C(0)NRaRa, -S(0)q-Ra, -S(0)q-NRaRa, -NRaRa, ,-ORa, -SRa or when two R3 substitutents ortho to each other, may be joined to a form a saturated or unsaturated 3-7 membered cylic ring which may optionally include up to two heteroatoms which may be same or different selected from O, NRa or S;
wherein R4 is -NR5R6 ; wherein R5 and R6 may be same or different and are independently selected from the groups consisting of hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstitued alkynyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted cycloalkylakyl, substituted or unsubstituted cycloalkenyl, substituted or unsubstituted aryl, substituted or unsubstituted arylalkyl, substituted or unsubstituted heteroaryl, substituted or unsubstituted heterocyclic ring, substituted or unsubstituted heterocyclylalkyl, substituted or unsubstituted heteroarylalkyl , nitro, -OH, cyano, halogen, -C(0)-Ra, -C(0)0-Ra, -C(0)NRaRa, -S(0)q-Ra, -S(0)q-NRaRa, -C(=NRa)-Ra, -C(=NRa)-NRaRa, -C(=S)-NRaRa, -C(=S)-Ra, -N=C(RaRa), -NRaRa, -ORa, -SRa, protecting groups or R5 and R6 to each other may be joined to a form a saturated or unsaturated 3-7 membered cyclic ring, which may optionally include up to two heteroatoms which may be same or different selected from O, NRa or S;
Ar is selected from the group consisting of substituted or unsubstituted aryl, substituted or unsubstituted arylalkyl, substituted or unsubstituted heterocyclic ring and substituted or unsubstituted heteroaryl ring;
Preferably Ar is optionally substituted phenyl, optionally substituted benzyl, optionally substituted pyrimidine, optionally substituted pyridyl selected from 4-pyridyl, 3-pyridyl and 2-pyridyl or optionally substituted pyridyl-N-oxide selected from 4-pyridyl-N-oxide, 3-pyridyl-N-oxide and 2-pyridyl-N-oxide in which optional substituents (one or more) may be same or different and are independently selected from the groups consisting of hydrogen, hydroxyl, halogen, cyano, nitro, carboxyl, trifluoroalkyl, substituted or unsubstituted alkyl, substituted or unsubstituted alkoxy, substituted or unsubstituted alkoxycarbonyl, substituted

11
or unsubstituted alkylcarbonyl, substituted or unsubstituted alkylcarbonyloxy, substituted or unsubstituted amino or mono or di substituted or unsubstituted alkylamino
X is selected from the group consisting of O, S(0)q and NRa;
Y is selected from the group consisting of -C(0)NR7, -NR7S(0)q, -S(0)qNR7 and -
NR7C(0);
R7 is selected from the group consisting of hydrogen, substituted or unsubstituted alkyl,
hydroxyl, -ORa, substituted or unsubstituted aryl, and substituted or unsubstituted
heterocyclic ring ;
wherein P is chosen from O and S;
wherein m represents 0-3;
wherein n represents 1-4;
wherein q represents 0,1 or 2;
with the proviso that R4 is not NH2;
wherein Ra is selected from the group consisting of hydrogen, substituted or unsubstituted
alkyl, substituted or unsubstituted alkenyl, substituted or unsubstitued alkynyl, substituted
or unsubstituted cycloalkyl, substituted or unsubstituted cycloalkylakyl, substituted or
unsubstituted cycloalkenyl, substituted or unsubstituted aryl, substituted or unsubstituted
arylalkyl, substituted or unsubstituted heteroaryl, substituted or unsubstituted heterocyclic
ring, substituted or unsubstituted heterocyclylalkyl , substituted or unsubstituted
heteroarylalkyl, nitro, -OH, cyano, formyl, acetyl, halogen, protecting groups, -C(0)-Ra, -
C(0)ORa, -C(0)NRaRa, -S(0)q-Ra, -S(0)q-NRaRa, -NRaRa, -ORa or -SRa;
and their analogs, their tautomers, their regioisomers, their stereoisomers, their
enantiomers, their diastereomers, their polymorphs, their pharmaceutically acceptable salts,
their N-oxides, their pharmaceutically acceptable solvates and their pharmaceutical
compositions containing them or a pharmaceutical acceptable salts thereof;
The present invention also relates to a process for the preparation of the above said novel heterocyclic compounds of the formula (1) as defined above. The compounds of general formula (1) more particularly, down regulate or inhibit the production of TNF-oc as they are PDE4 inhibitors and therefore are useful in the treatment of variety of allergic and

12
inflammatory diseases including asthma, chronic bronchitis, atopic dermatitis, urticaria, allergic rhinitis, allergic conjunctivitis, vernal conjuctivitis, eosinophilic granuloma, psoriasis, rheumatoid arthritis, septic shock, diabetes, ulcerative colitis, Crohn's disease, reperfusion injury of the myocardium and brain, chronic glomerulonephritis, endotoxic shock and adult respiratory distress syndrome. The compounds of the present invention are particularly useful for the treatment of asthma and chronic obstructive pulmonary disease (COPD).
Further prefered are when the substituents in the 'substituted alkyl', 'substituted alkoxy' 'substituted alkenyl' 'substituted alkynyl 'substituted cycloalkyl' 'substituted cycloalkylalkyl 'substituted cyclocalkenyl' 'substituted arylalkyl' 'substituted aryl' 'substituted heterocyclic ring', 'substituted heteroaryl ring,' 'substituted heteroarylalkyl', 'substituted heterocyclylalkyl ring', 'substituted amino', 'substituted alkoxycarbonyl', 'substituted cyclic ring' 'substituted alkylcarbonyl', 'substituted alkylcarbonyloxy' and may be the same or different which one or more are selected from the groups such as hydrogen, hydroxy, halogen, carboxyl, cyano, nitro, oxo (=0), thio(=S), substituted or unsubstituted alkyl, substituted or unsubstituted alkoxy, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted aryl, substituted or unsubstituted arylalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted cycloalkenyl, substituted or unsubstituted amino, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, 'substituted heterocyclylalkyl ring' substituted or unsubstituted heteroarylalkyl, substituted or unsubstituted heterocyclic ring, substituted or unsubstiuted guanidine, -COORx, -C(0)Rx, -C(S)Rx, -C(0)NRxRy, -C(0)ONRxRy, -NRxCONRyRz, -N(Rx)SORy, -N(Rx)S02Ry, -(=N-N(Rx)Ry), - NRxC(0)ORy, -NRxRy, -NRxC(0)Ry-, -NRxC(S)Ry -NRxC(S)NRyRz, -SONRxRy-, -S02NRxRy-, -ORx, -ORxC(0)NRyRz, -ORxC(0)ORy-, -OC(0)Rx, -OC(0)NRxRy, - RxNRyC(0)Rz, -RxORy, -RxC(0)ORy, -RxC(0)NRyRz, -RxC(0)Rx, -RxOC(0)Ry, -SRx, -SORx, -S02Rx, -ON02, wherein Rx, Ry and Rz in each of the above groups can be hydrogen atom, substituted or unsubstituted alkyl, substituted or unsubstituted alkoxy, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted aryl, substituted or unsubstituted arylalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted cycloalkenyl, substituted or unsubstituted amino, substituted or unsubstituted aryl,

13
substituted or unsubstituted heteroaryl, 'substituted heterocyclylalkyl ring' substituted or
unsubstituted heteroarylalkyl, substituted or unsubstituted heterocyclic ring,
Further prefered is where R1 is unsubstituted alkyl.
Further prefered is where R1 is methyl.
Further prefered is where R1 is substituted alkyl.
Further prefered is where R1 is -CHF2.
Further prefered is where P is O.
Further prefered is where X is O, N-CH3, S.
Further prefered is where Y is -C (O)NH.
Further prefered is where Ar is selected from the group consisting of substituted or unsubstituted 4-pyridyl; substituted or unsubstituted 4-pyridyl-N-oxide; substituted or unsubstituted 3-pyridyl;
Further prefered is where said Ar substituent is halogen.
Further prefered is where said Ar substituent is chloro.
Further prefered is where Ar is selected from the group consisting of


f

Further prefered is where Ar is
N
^
Further prefered is when m=0, n=l and R4 is selected from the group consisting of

14

o
H II ,N-S-

O
H II / ,N-S-NX

O
H II ,N-S-
II O

n

H ,N.

^Cl

H °~\\ ,N„
OC2H5

OH

V

v<
-N
y<

Y

V- ^ k v^-

V^. 5'NY"
'VC

u H I
H CF3 ^NYN.

V^o

H
-v
o

H
•NYN
O

OH H I
O

o

H H o

H t! o

H a
-vN-
o

H H S
,N^^

OH

H H
o

and

H tl il
'V °H

Further prefered is when m=0, n=l and where R4 is selected from the group consisting of

15
,!LA0H. ,.dU \-"~fr ■ pBV"^^ M*
H H ?~\ HA H
o o o * J

The present invention specifically excludes the following compound:
CI, H
,o

DETAILED DESCRIPTION OF THE INVENTION
The term 'alkyl' refers to a straight or branched hydrocarbon chain radical consisting solely of carbon and hydrogen atoms, containing no unsaturation, having from one to eight carbon atoms, and which is attached to the rest of the molecule by a single bond, e.g., methyl, ethyl, n-propyl, 1-methylethyl (isopropyl), n-butyl, n-pentyl, 1,1-dimethylethyl (t-butyl), and the like .
The term "alkenyl " refers to aliphatic hydrocarbon group containing a carbon-carbon r double bond and which may be a straight or branched or branched chain having about 2 to about 10 carbon atoms, e.g., ethenyl, 1-propenyl, 2-propenyl (allyl), iso-propenyl, 2-methyl -1-propenyl, 1-butenyl, 2-butenyl and the like.
The term " alkynyl" refers to straight or branched chain hydrocarbyl radicals having at least one carbon-carbon triple bond, and having in the range of about 2 up to 12 carbon atoms (with radicals having in the range of about 2 up to 10 carbon atoms presently being preferred) e.g., ethynyl, propynyl, butnyl and the like.

16
The term "alkoxy" denotes alkyl group as defined above attached via oxygen linkage to the
rest of the molecule. Representative examples of those groups are -OCH3, -OC2H5 and the
like.
The term "alkylcarbonyl" denotes alkyl group as defined above attached via carbonyl
linkage to the rest of the molecule. Representative examples of those groups are -C(0)CH3,
- C(0)C2H5 and the like.
The term "alkoxycarbonyl" denotes alkoxy group as defined above attached via carbonyl
linkage to the rest of the molecule. Representative examples of those groups are -C(O)-
OCH3, - C(0)-OC2H5 and the like.
The term "alkylcarbonyloxy" denotes alkylcarbonyl group as defined above attached via oxygen linkage to the rest of the molecule. Representative examples of those groups are -O-C(0)CH3, - 0-C(0)C2H5 and the like.
The term "alkylamino" denotes alkyl group as defined above attached via amino linkage to the rest of the molecule. Representative examples of those groups are -NH2CH3, -NH(CH3)2 , -N(CH3)3 and the like.
The term "cycloalkyl" denotes a non-aromatic mono or multicyclic ring system of about 3 to 12 carbon atoms such as cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl and examples of multicyclic cycloalkyl groups include perhydronapththyl, adamantyl and norbornyl groups bridged cyclic group or sprirobicyclic groups e.g sprio (4,4) non-2-yl.
The term " cycloalkylalkyl" refers to cyclic ring-containing radicals containing in the range of about 3 up to 8 carbon atoms directly attached to alkyl group which are then attached to the main structure at any carbon from alkyl group that results in the creation of a stable structure such as cyclopropylmethyl, cyclobuyylethyl, cyclopentylethyl, and the like.

17
The term " cycloalkenyl" refers to cyclic ring-containing radicals containing in the range of about 3 up to 8 carbon atoms with at least one carbon- carbon double bond such as cyclopropenyl, cyclobutenyl, cyclopentenyl and the like.
The term "aryl" refers to aromatic radicals having in the range of 6 up to 14 carbon atoms such as phenyl, naphthyl, tetrahydronapthyl, indanyl, biphenyl and the like.
The term "arylalkyl" refers to an aryl group as defined above directly bonded to an alkyl group as defined above, e.g., -CH2C6H5, -C2H5C6H5 and the like.
The term "heterocyclic ring" refers to a stable 3- to 15 membered ring radical which consists of carbon atoms and from one to five heteroatoms selected from the group consisting of nitrogen, phosphorus, oxygen and sulfur. For purposes of this invention, the heterocyclic ring radical may be a monocyclic, bicyclic or tricyclic ring system, which may include fused, bridged or spiro ring systems, and the nitrogen, phosphorus, carbon, oxygen or sulfur atoms in the heterocyclic ring radical may be optionally oxidized to various oxidation states. In addition, the nitrogen atom may be optionally quaternized; and the ring radical may be partially or fully saturated (i.e., heteroaromatic or heteroaryl aromatic). Examples of such heterocyclic ring radicals include, but are not limited to, azetidinyl, acridinyl, benzodioxolyl, benzodioxanyl, benzofurnyl, carbazolyl, cinnolinyl, dioxolanyl, indolizinyl, naphthyridinyl, perhydroazepinyl, phenazinyl, phenothiazinyl, phenoxazinyl, phthalazinyl, pyridyl, pteridinyl, purinyl, quinazolinyl, quinoxalinyl, quinolinyl, isoquinolinyl, tetrazoyl, imidazolyl, tetrahydroisouinolyl, piperidinyl, piperazinyl, 2-oxopiperazinyl, 2-oxopiperidinyl, 2-oxopyrrolidinyl, 2-oxoazepinyl, azepinyl, pyrrolyl, 4-piperidonyl, pyrrolidinyl, pyrazinyl, pyrimidinyl, pyridazinyl, oxazolyl, oxazolinyl, oxasolidinyl, triazolyl, indanyl, isoxazolyl, isoxasolidinyl, morpholinyl, thiazolyl, thiazolinyl, thiazolidinyl, isothiazolyl, quinuclidinyl, isothiazolidinyl, indolyl, isoindolyl, indolinyl, isoindolinyl, octahydroindolyl, octahydroisoindolyl, quinolyl, isoquinolyl, decahydroisoquinolyl, benzimidazolyl, thiadiazolyl, benzopyranyl, benzothiazolyl, benzooxazolyl, furyl, tetrahydrofurtyl, tetrahydropyranyl, thienyl, benzothienyl, thiamorpholinyl, thiamorpholinyl sulfoxide thiamorpholinyl sulfone, dioxaphospholanyl , oxadiazolyl, chromanyl, isochromanyl and the like.

18
The term "heteroaryl" refers to heterocyclic ring radical as defined above. The heteroaryl ring radical may be attached to the main structure at any heteroatom or carbon atom that results in the creation of a stable structure.
The heterocyclic ring radical may be attached to the main structure at any heteroatom or carbon atom that results in the creation of a stable structure.
The term "heteroarylalkyl" refers to heteroaryl ring radical as defined above directly bonded to alkyl group. The heteroarylalkyl radical may be attached to the main structure at any carbon atom from alkyl group that results in the creation of a stable structure.
The term "heterocyclyl" refers to a heterocylic ring radical as defined above. The heterocylcyl ring radical may be attached to the main structure at any heteroatom or carbon atom that results in the creation of a stable structure.
The term "heterocyclylalkyl" refers to a heterocylic ring radical as defined above directly bonded to alkyl group. The heterocyclylalkyl radical may be attached to the main structure at carbon atom in the alkyl group that results in the creation of a stable structure.
The term "cyclic ring" refers to a cyclic ring containing 3-10 carbon atoms.
The term "protecting group" refers to carbobenzyloxy (CBZ) or Tert butyloxy carbonyl (BOC) and the like.
The term "halogen" refers to radicals of fluorine, chlorine, bromine and iodine.
Pharmaceutically acceptable salts forming part of this invention include salts derived from--inorganic bases such as Li, Na, K, Ca, Mg, Fe, Cu, Zn, Mn; salts of organic bases such as N,N'-diacetylethylenediamine, glucamine, triethylamine, choline, hydroxide/' dicyclohexylamine, metformin, benzylamine, trialkylamine, thiamine, and the like; chiral bases like alkylphenylamine, glycinol, phenyl glycinol and the like, salts of natural amino y

19
acids such as glycine, alanine, valine, leucine, isoleucine, norleucine, tyrosine, cystine, cysteine, methionine, proline, hydroxy proline, histidine, ornithine, lysine, arginine, serine, and the like; quaternary ammonium salts of the compounds of invention with alkyl halides, alkyl sulphats like Mel, (Me)2S04 and the like, non-natural amino acids such as D-isomers or substituted amino acids; guanidine, substituted guanidine wherein the substituents are selected from nitro, amino, alkyl, alkenyl, alkynyl, ammonium or substituted ammonium salts and aluminum salts. Salts may include acid addition salts where appropriate which are, sulphates, nitrates, phosphates, perchlorates, borates, hydrohalides, acetates, tartrates, maleates, citrates, fumarates, succinates, palmoates, methanesulphonates, benzoates, salicylates, benzenesulfonates, ascorbates, glycerophosphates, ketoglutarates and the like. Pharmaceutically acceptable solvates may be hydrates or comprise other solvents of crystallization such as alcohols.
Another object of the invention is a method of treating inflammatory diseases, disorders and conditions characterized by or associated with an undesirable inflammatory immune response and all disease and conditions induced by or associated with an excessive secretion of TNF-a and PDE-4 which comprises administering to a subject a therapeutically effective amount of a compound according to Formula I.
Another object of the invention is a method of treating inflammatory conditions and immune disorders in a subject in need thereof which comprises administering to said subject a therapeutically effective amount of a compound according to Formula I. Preferred inflammatory conditions and immune disorders are chosen from the group consisting of asthma, bronchial asthma, chronic obstructive pulmonary disease, allergic rhinitis, eosinophilic granuloma, nephritis, rheumatoid arthritis, cystic fibrosis, chronic bronchitis, multiple sclerosis, Crohns disease, psoraisis, uticaria, adult vernal cojunctivitis, respiratory distress syndrome, rhematoid spondylitis, osteoarthritis, gouty arthritis, uteltis, allergic conjunctivitis, inflammatory bowel conditions, ulcerative coalitis, eczema, atopic dermatitis and chronic inflammation. Further preferred are allergic inflammatory conditions.
Further preferred are inflammatory conditions and immune disorders selected from the group consisting of inflammatory conditions or immune disorders of the lungs, joints, eyes, bowels, skin and heart.

20
Further preferred are inflammatory conditions chosen from the group consisting of bronchial
asthma, nepritis, and allergic rhinitis.
Another object of the invention is a method for abating inflammation in an affected organ or
tissue including delivering to the organ or tissue a therapeutically effective amount of a
compound represented by a compound according to Formula 1.
Another object of the invention is a method of treating diseases of the central nervous
system in a subject in need thereof which comprises administering to said subject a
therapeutically effective amount of a compound according to Formula 1.
Preferred diseases of the central nervous system are chosen from the group consisting of
depression, amnesia, dementia, Alzheimers disease, cardiac failure, shock and
cerebrovascular disease.
Another object of the invention is a method of treating insulin resistant diabetes in a subject
in need thereof which comprises administering to said subject a therapeutically effective
amount of a compound according to Formula 1.
"Treating" or "treatment" of a state, disorder or condition includes:
(1) preventing or delaying the appearance of clinical symptoms of the state, disorder or condition developing in a mammal that may be afflicted with or predisposed to the state, disorder or condition but does not yet experience or display clinical or subclinical symptoms of the state, disorder or condition,
(2) inhibiting the state, disorder or condition, i.e., arresting or reducing the development of the disease or at least one clinical or subclinical symptom thereof, or
(3)relieving the disease, i.e., causing regression of the state, disorder or condition or at least
one of its clinical or subclinical symptoms.
The benefit to a subject to be treated is either statistically significant or at least perceptible
to the patient or to the physician
A "therapeutically effective amount" means the amount of a compound that, when
administered to a mammal for treating a state, disorder or condition, is sufficient to effect
such treatment. The "therapeutically effective amount" will vary depending on the
compound, the disease and its severity and the age, weight, physical condition and
responsiveness of the mammal to be treated.

21
The four classic symptoms of acute inflammation are redness, elevated temperature, swelling, and pain in the affected area, and loss of function of the affected organ. Symptoms and signs of inflammation associated with specific conditions include:
• rheumatoid arthritis- pain, swelling, warmth and tenderness of the involved joints; generalized and morning stiffness;
• insulin-dependent diabetes mellitus- insulitis; this condition can lead to a variety of complications with an inflammatory component, including: retinopathy, neuropathy, nephropathy; coronary artery disease, peripheral vascular disease, and cerebrovascular disease;
• autoimmune thyroiditis- weakness, constipation, shortness of breath, puffmess of the face, hands and feet, peripheral edema, bradycardia;
• multiple sclerosis- spasticity, blurry vision, vertigo, limb weakness, paresthesias;
• uveoretinitis- decreased night vision, loss of peripheral vision;
• lupus erythematosus- joint pain, rash, photosensitivity, fever, muscle pain, puffmess of the hands and feet, abnormal urinalysis (hematuria, cylinduria, proteinuria), glomerulonephritis, cognitive dysfunction, vessel thrombosis, pericarditis;
• scleroderma- Raynaud's disease; swelling of the hands, arms, legs and face; skin thickening; pain, swelling and stiffness of the fingers and knees, gastrointestinal dysfunction, restrictive lung disease; pericarditis,; renal failure;
• other arthritic conditions having an inflammatory component such as rheumatoid spondylitis, osteoarthritis, septic arthritis and polyarthritis- fever, pain, swelling, tenderness;
• other inflammatory brain disorders, such as meningitis, Alzheimer's disease, AIDS dementia encephalitis- photophobia, cognitive dysfunction, memory loss;
• other inflammatory eye inflammations, such as retinitis- decreased visual acuity;
• inflammatory skin disorders, such as , eczema, other dermatites (e.g., atopic, contact), psoriasis, burns induced by UV radiation (sun rays and similar UV sources)- erythema, pain, scaling, swelling, tenderness;
• inflammatory bowel disease, such as Crohn's disease, ulcerative colitis- pain, diarrhea, constipation, rectal bleeding, fever, arthritis;

22
• asthma- shortness of breath, wheezing;
• other allergy disorders, such as allergic rhinitis- sneezing, itching, runny nose
• conditions associated with acute trauma such as cerebral injury following stroke-sensory loss, motor loss, cognitive loss;
• heart tissue injury due to myocardial ischemia- pain, shortness of breath;
• lung injury such as that which occurs in adult respiratory distress syndrome-shortness of breath, hyperventilation, decreased oxygenation, pulmonary infiltrates;
• inflammation accompanying infection, such as sepsis, septic shock, toxic shock syndrome- fever, respiratory failure, tachycardia, hypotension, leukocytosis;
• other inflammatory conditions associated with particular organs or tissues, such as nephritis (e.g., glomerulonephritis)-oliguria, abnormal urinalysis;
• inflamed appendix- fever, pain, tenderness, leukocytosis;
• gout- pain, tenderness, swelling and erythema of the involved joint, elevated serum and/or urinary uric acid;
• inflamed gall bladder- abdominal pain and tenderness, fever, nausea, leukocytosis;
• chronic obstructive pulmonary disease- shortness of breath, wheezing;
• congestive heart failure- shortness of breath, rales, peripheral edema;
• Type II diabetes- end organ complications including cardiovascular, ocular, renal, and peripheral vascular disease ,lung fibrosis- hyperventilation, shortness of breath, decreased oxygenation;
• vascular disease, such as atherosclerosis and restenosis- pain, loss of sensation, diminished pulses, loss of function and alloimmunity leading to transplant rejection-pain, tenderness, fever.
Subclinical symptoms include without limitation diagnostic markers for inflammation the appearance of which may precede the manifestation of clinical symptoms. One class of subclinical symptoms is immunological symptoms, such as the invasion or accumulation in an organ or tissue of proinflammatory lymphoid cells or the presence locally or peripherally of activated pro-inflammatory lymphoid cells recognizing a pathogen or an antigen specific to the organ or tissue. Activation of lymphoid cells can be measured by techniques known in the art.

23
"Delivering" a therapeutically effective amount of an active ingredient to a particular location within a host means causing a therapeutically effective blood concentration of the active ingredient at the particular location. This can be accomplished , e.g., by local or by systemic administration of the active ingredient to the host. "A subject" or "a patient" or "a host" refers to mammalian animals, preferably human.
Some of the representative compounds according to the present invention are specified below but should not construed to be limited thereto;
1. N-(3,5-dichloropyrid-4-yl)-4-methoxy-8-methanesulfonamido-dibenzo[b,d]furan-l-carboxamide
2. N-(3,5-dichloropyrid-4-yl)-4-methoxy-8-(N,N-dimethylsulphonamido)-dibenzo [b,d] furan-1 -carboxamide
3. N-(3,5-dichloropyrid-4-yl)-4-methoxy-8-(ethanesulphonamido)-dibenzo[b,d]furan-l-carboxamide
4. N-(3,5-dichloropyrid-4-yl)-4-methoxy-8-acetamido-dibenzo [b,d]furan-1 -carboxamide
5. N-(3,5-dichloropyrid-4-yl)-4-methoxy-8-(3-chloropropylcarboxamido)-dibenzo[b,d]furan-l-carboxamide
6. N-(3,5-dichloropyrid-4-yl)-4-methoxy-8-ethylcarboxamido-dibenzo[b,d]furan-l-carboxamide
7. N-(3,5-dichloropyrid-4-yl)-4-methoxy-8-t-butylcarboxamido-dibenzo [b,d]furan-1 -carboxamide
8. N-(3,5-dichloropyrid-4-yl)-4-methoxy-8-ethoxycarbonylcarboxamido-dibenzo[b,d]furan-l -carboxamide
9. N-(3,5-dichloropyrid-4-yl)-4-methoxy-8-hydroxycarbonylcarboxamido-dibenzo[b,d]furan-1 -carboxamide
10. N-(3,5-dichloropyrid-4-yl)-4-methoxy-8-hydroxycarbonylcarboxamido-dibenzo[b,d]furan-l-carboxamide sodium salt
11. N-(3,5-dichloropyrid-4-yl)-4-methoxy-8-(fur-2-yl-carboxamido)-dibenzo[b,d]furan-l-carboxamide
12. N-(3,5-dichloropyrid-4-yl)-4-methoxy-8-(cyclopropylcarbonylamino)-dibenzo[b,d]furan-1 -carboxamide

24
13.N-(3,5-dichloropyrid-4-yl)-4-methoxy-8-(N,N-dicyclopropylcarbonylamino)-
dibenzo [b,d] furan-1 -carboxamide
14. N-(3,5 -dichloropyrid-4-yl)-4-methoxy-8-trifluoroacetamido-dibenzo [b,d] furan-1 -
carboxamide
15.N-(3,5-dichloropyrid-4-yl)-4-methoxy-8-ethoxycarboxamido-dibenzo[b,d]furan-l-
carboxamide
16. N-(3,5-dichloropyrid-4-yl)-4-methoxy-8-isobutyloxycarboxamido-dibenzo[b,d]furan-l-carboxamide
17. N-(3,5-dichloropyrid-4-yl)-4-methoxy-8-phenoxycarboxamido-dibenzo[b,d]furan-l-carboxamide
18. N-(3,5 -dichloropyrid-4-y l)-4-methoxy- 8 -cyclopropylmethoxycarboxamido-dibenzo [b,d] furan-1 -carboxamide
19. N-(3,5-dichloropyrid-4-yl)-4-methoxy-8-trifluoromethylmethoxycarboxamido-dibenzo[b,d]furan-l-carboxamide
20. N-(3,5-dichloropyrid-4-yl)-4-methoxy-8-N,N-diethylaminocarboxamido-dibenzo [b,d] furan-1 -carboxamide
21. N-(3,5-dichloropyrid-4-yl)-4-methoxy-8-cyclopentylaminocarboxamido-dibenzo[b,d]furan-l-carboxamide
22. N-(3,5-dichloropyrid-4-yl)-4-methoxy-8-(N-methylpiperazin-4-yl carboxamido-dibenzo[b,d]furan-1 -carboxamide
23. N-(3,5-dichloropyrid-4-yl)-4-methoxy-8-(N-methylpiperazin-4-yl carboxamido-dibenzo[b,d] furan-1 -carboxamide hydrochloride
24. N-(3,5-dichloropyrid-4-yl)-4-methoxy-8-(4-hydroxypiperidin-1 -yl carboxamido-dibenzo [b,d] furan-1 -carboxamide
25. N-(3,5-dichloropyrid-4-yl)-4-methoxy-8-(morphol-4-yl carboxamido-dibenzo[b,d]furan-1-carboxamide
26. N-(3,5-dichloropyrid-4-yl)-4-methoxy-8-isopropylamino carboxamido-dibenzo[b,d] furan-1 -carboxamide
27. N-(3,5-dichloropyrid-4-yl)-4-methoxy-8-n-hexylamino carboxamido-dibenzo[b,d]furan-1 -carboxamide

25
28. N-(3,5-dichloropyrid-4-yl)-4-methoxy-8-ethylamino carboxamido-dibenzo[b,d]furan-l-carboxamide
29. N-(3,5-dichloropyrid-4-yl)-4-methoxy-8-methylamino carboxamido-dibenzo[b,d]furan-1 -carboxamide
30. N-(3,5-dichloropyrid-4-yl)-4-difluoromethoxy-8-methanesulfonamido-dibenzo[b,d]furan-l-carboxamide
31. N-(3,5-dichloropyrid-4-yl)-4-difluoromethoxy-8-methanesulfonamido-dibenzo[b,d]furan-l-carboxamide sodium salt
32. N-(3,5-dichloropyrid-4-yl)-4-difluoromethoxy-8-ethanesulfonamido- dibenzo[b,d]furan-1-carboxamide
33.N-(3,5-dichloropyrid-4-yl)-4-difluoromethoxy-8-N,N-dimethylaminosulfonamido-dibenzo[b,d]furan-1 -carboxamide
34. N-(3,5-dichloropyrid-4-yl)-4-difluoromethoxy-8-acetamido-dibenzo[b,d]furan-l-carboxamide
35. N-(3,5-dichloropyrid-4-yl)-4-difluoromethoxy-8-( 1 -chloropropylcarboxamido)-dibenzo[b,d]furan-l-carboxamide
36. N-(3,5-dichloropyrid-4-yl)-4-difluoromethoxy-8-cyclopropylcarboxamido-dibenzo [b,d] furan-1 -carboxamide
37. N-(3,5-dichloropyrid-4-yl)-4-difluoromethoxy-8-ethoxycarbonylcarboxamido-dibenzo[b,d]furan-l -carboxamide
38.N-(3,5-dichloropyrid-4-yl)-4-difluoromethoxy-8-hydroxycarbonylcarboxamido-dibenzo[b,d] furan-1 -carboxamide
39. N-(3,5-dichloropyrid-4-yl)-4-difluoromethoxy-8-hydroxycarbonylcarboxamido-dibenzo[b,d]furan-l-carboxamide disodium salt
40. N-(3,5-dichloropyrid-4-yl)-4-difluoromethoxy-8-fur-2-ylcarboxamido-dibenzo[b,d] furan-1 -carboxamide
41. Nl-phenyl-4-methoxy-8-acetamido-dibenzo[b,d]furan-l-carboxamide
42. Nl-(4-methoxyphenyl)-4-methoxy-8-acetamido-dibenzo[b,d]furan-l-carboxamide
43. Nl -benzyl-4-methoxy-8-acetamido-dibenzo[b,d]furan-l -carboxamide
44. N-(3,5-dichloropyrid-4-yl)-4-methoxy-8-(ethylaminothiocarboxamido)-dibenzo[b,d] furan-1 -carboxamide

26
45.N-(3,5-dichloropyrid-4-yl)-4-methoxy-8-(n-butylaminothiocarboxamido)-dibenzo[b,d]furan-l -carboxamide
46. Nl-(pyrid-3-yl)-4-methoxy-8-acetamido-dibenzo[b,d]furan-l-carboxamide
47. N-(3,5-dichloropyrid-4-yl)-4-methoxy-8-acetamido-dibenzo[b,d]furan-l-carboxamide-N-oxide
4 8. N-(3,5 -dichloropyrid-4-y l)-4-methoxy- 8 -methanesulfonamido-dibenzo [b,d] furan-1 -carboxamide-N-oxide
49. N-(pyrid-4-yl)-4-methoxy-8-acetamido-dibenzo[b,d]furan-1 -carboxamide
50. N-(3,5-dichloropyrid-4-yl)-4-methoxy-8-(2-ethoxy-2-oxo-ethylaminocarbonylamino)-dibenzo [b,d] furan-1 -carboxamide
51. N-(3,5-dichloropyrid-4-yl)-4-methoxy-8-(2-hydroxy-2-oxo-ethylaminocarbonylamino)-dibenzo[b,d]furan-1 -carboxamide
52. N-(3,5-dichloropyrid-4-yl)-4-methoxy-8-(2-ethoxy-2-oxo-ethylamino)-dibenzo [b,d] furan-1 -carboxamide
53.N-(3,5-dichloropyrid-4-yl)-4-methoxy-8-(2-hydroxy-2-oxo-ethylamino)-dibenzo[b,d]furan-l-carboxamide
54. N-(3,5-dichloropyrid-4-yl)-l-methoxy-9-methyl-6-acetamido-P7/-4-carbazolecarboxamide
55. N-(3,5 -dichloropyrid-4-yl)-1 -methoxy-9-methyl-6-methanesulphonamido-9//-4-carbazolecarboxamide
56. N-(3,5-dichloropyrid-4-yl)-1 -methoxy-9-methyl-6-ethanesulphonamido-P//-4-carbazolecarboxamide
57. N-(3,5-dichloropyrid-4-yl)-l-methoxy-9-methyl-6-propionamido-P//-4-carbazolecarboxamide
58. N-(3,5-dichloropyrid-4-yl)-4-difiuoromethoxy-8-methanesulfonamido-dibenzo[b,d]furan-l-carboxamide disodium salt
59. N-(3,5-dichloropyrid-4-yl)-l-methoxy-6-acetamido-dibenzo[b,d]thiophene -4-carboxamide
60. N-(3,5-dichloropyrid-4-yl)-4-difluoromethoxy-8-acetamido-dibenzo[b,d]furan-l-carboxamide sodium salt

27
61.N-(3,5-dichloropyrid-4-yl)-4-difluoromethoxy-8-fur-2-ylcarboxamido-dibenzo[b,d]furan-l-carboxamide sodium salt and pharmaceutically acceptable salts of the foregoing where applicable.
The compounds according to the invention may be prepared by the following processes. The symbols P, Ar, X, Y, R1, R2, R3 and R4 when used in the below formulae are to be understood to present those groups described above in relation to formula (1) unless otherwise indicated.
The present invention discloses a process for the preparation of compounds of general formula (1).

In one embodiment, the desired compounds of the formula (1) wherein Y is -CONR7; R4 is -NR5R6 ; P, Ar, X, Y, R1, R2, R3, R5, R6 R7, m and n are as described in the general description, can be synthesized from a common intermediate of the formula (16).
The common intermediate of the formula (16) can be synthesized by using the general process described in synthetic scheme I.


28
SYNTHETIC SCHEME I.
(14) (15) (16)
In the above mentioned scheme a compound of the general formula (10) wherein Z is a halogen, preferably a fluorine, is reacted with a compound of the general formula (11) wherein W is a halogen, preferably bromine or iodine, under basic conditions (potassium salts in DMF or DMSO, NaH in DMF or DMSO and the like) to obtain the intermediate of the general formula (12). The intermediate of the general formula (12) can be cyclised using metal compound or metal catalysed coupling conditions (palladium acetate in DMF or glacial acetic acid, nickel catalyst in pyridine or DMF, tetrakistriphenylphosphinepalladium in DMF and the like), preferably palladium acetate in DMF, to the tricyclic intermediate (13). The tricyclic intermediate of the general formula (13) is then oxidized to the intermediate of the general formula (14) using standard methods (such as sodium chlorite or potassium permanganate and the like) known in the literature. The intermediate of the general formula (14) is then converted to the intermediate of the general formula (15), wherein Y is -CONR7, by reacting the appropriately activated carboxylic acid (acid halide or mixed anhydride or active ester) intermediate of the general formula (14) with the optionally substituted aryl or heteroaryl amines (ArNHR7) under appropriate basic conditions (NaH in DMF, diisopropylamine or triethylamine or pyridine in THF and the like) reported in the literature. The intermediate of the general formula (15) is then reduced using conventional methods (raney nickel / hydrazine, iron / ammonium chloride, hydrogenation using Pd/C, and the like) known in the literature to the intermediate of the general formula (16).
The intermediate of the general formula (16) is then converted to the desired compound of the general formula (1) wherein Y is -CONR7, R4 is -NR5R6 ; P, Ar, X, Y, R1,

29

R2, R3, R5, R6 R7 m and n are the same as described in the general description, using the conventional methods known in the literature.
(R3)m
(H2N)n
Y-Ar
The desired compounds of the general formula (1) obtained are then converted into their salts and/or the N-oxides and, if desired, salts of the compounds of the formula (1) obtained are then converted into the free form.
In another embodiment, the desired compounds of the formula (1) wherein Y is -CONR7; R4 is -NR5R6 ; P, Ar, X, Y, R1, R2, R3, R5, R6 ,R7, m and n are the same as described in the general description, can be synthesized from a common intermediate of the formula (16). The common intermediate of the formula (16) can be synthesized by using the general process described in synthetic scheme II. SYNTHETIC SCHEME II.


-Ha^o
(R3)m-€X + / z
(02N)n
(17)

HX

FG
PR1 (18)

(02N)n

Y-Ar
(R^m-T/ I
(H2N)n'

(02N)n'

COOH
(14)

(02N)n' PR1
(15)

Y-Ar

In the above mentioned scheme a compound of the general formula (17) wherein Z is a halogen, preferably a fluorine, and wherein W is also a halogen, preferably bromine or iodine, is reacted with a compound of the general formula (18) wherein FG is CHO, COCH3, CN or -COORa,

30
under basic conditions (potassium salts in DMF or DMSO, NaH in DMF or DMSO and the like) to obtain the intermediate of the general formula (19). The intermediate of the general formula (19) can be cyclised using metal compound or metal catalysed coupling conditions, nickel chloride , palladium acetate and the like preferably palladium acetate, to the tricyclic intermediate (20). The tricyclic intermediate of the general formula (20) is then oxidized using KMnC>4, NaOCb and the like to, if FG is CHO or COCH3, or hydrolysed by using NaOH or H2SO4 to, if FG is CN or -COORa, the intermediate of the general formula
(14) using methods known in the literature. The intermediate of the general formula (14) is then converted to the intermediate of the general formula (15), wherein Y is -CONR7, by reacting the appropriately activated carboxylic acid (acid halide or mixed anhydride or active ester) intermediate of the general formula (14) with the optionally substituted aryl or heteroaryl amines (ArNHR ) under appropriate basic conditions such as NaH in DMF or triethyiamine and the like reported in the literature. The intermediate of the general formula
(15) is then reduced using the conventional methods known in the literature (palladium chloride or Raney nickel) to the intermediate of the general formula (16).
The intermediate of the general formula (16) is then converted to the desired compound of the general formula (1) wherein Y is -CONR7, R4 is -NR5R6; P, Ar, X, Y, R1, R", R\ R\ R° , R' ,m and n are the same as described in the general description, using conventional methods known in the literature.

(16) (1)
The desired compounds of the general formula (1) obtained are then converted into their salts and/or the N-oxides m-chloro per benzoic acid or H2O2 and the like and, if desired, salts of the compounds of the formula (1) obtained are then converted into the free form.
In yet another embodiment, the desired compounds of the formula (1) wherein Y is -CONR7, R4 is -NHCOCH3, n= 1; and P, Ar, X, Y, R1, R2, R3, R5, R6 R7 and m are the same as described in the general description, can be synthesized as in scheme III, Further the R4

31
wherein R4 is -NHCOCH3 can be converted to,-NR5R6 using the methods known in the literature.
SYNTHETIC SCHEME HI

(R )m (i H3COC
3, ^VN02
21

+

HX

^ R2
PR1 H3COC PR1 H3COC PR1
22 23 24

CHO

PR! H3COCHN PR
26
(^■f/P^-1^ (R3)
H3C0C
7^x
25

(R3)m-rr/
"^x-V
H3COCHN PR1
27

COOH

(1)

Y-Ar

In the above mentioned scheme a compound of the formula (21) wherein Z is a halogen, preferably a fluorine, is reacted with a compound of the general formula (22) under basic conditions (potassium salts in DMF or DMSO, NaH in DMF or DMSO and the like) to obtain the intermediate of the general formula (23). The intermediate of the general formula (23) is then reduced to the intermediate of the general formula (24) using standard reducing agents such as raney nickel/hydrazine or palladium on carbon in hydrogen atmosphere. The intermediate of the general formula (24) is then cyclised to the tricyclic intermediate of the general formula (25) by diazotization followed by standard coupling methods (cuprous oxide in O.IN sulfuric acid, copper in DMSO). The acetyl group of tricyclic intermediate of the general formula (25) is then converted to the acetamido group using Beckmann rearrangement to obtain the intermediate of the general formula (26). The intermediate of the general formula (26) is formylated using standard formylating conditions such as dichloromethyl methyl ether in tin (IV) chloride and the like to obtain the

32
intermediate of the general formula(27). The intermediate of the general formula (27) is then oxidized using KMnC>4 or NaOCb to the intermediate of the general formula (28) using standard methods known in the literature. The intermediate of the general formula (28) is then converted to the desired compound of the general formula (1), wherein Y is -CONR7, R4 is -NHCOCH3 , n=l; and P, Ar, X, Y, R1, R2, R3, R5, R6 R7 and m are the same as described in the general description, by reacting the appropriately activated carboxylic acid (acid halide or mixed anhydride or active ester) intermediate of the general formula (28) with the optionally substituted aryl or heteroaryl amines (ArNHR ) using conventional methods known in the literature. Further the R4 wherein R4 is -NHCOCH3 can be converted to,-NR5R6 using the methods known in the literature
The desired compounds of the formula (1) obtained are then converted into their salts and/or the N-oxides and, if desired, salts of the compounds of the formula (1) obtained are then converted into the free form.
The N-oxidation is carried out in a manner likewise familiar to the person of ordinary skill in the art, e.g with the aid of m-chloroperoxybenzoic acid in dichloromethane at room temperature. The person of ordinary skill in the art is familiar with the reaction conditions which are necessary for carrying out the process on the basis of his knowledge.
The substances according to the invention are isolated and purified in a manner known per se, e.g. by distilling off the solvent in vacuum and recrystallizing the residue obtained from a suitable solvent or subjecting it to one of the customary purification methods, such as column chromatography on a suitable support material.
Salts are obtained by dissolving the free compound in a suitable solvent, e.g in a chlorinated hydrocarbon, such as methylene chloride or chloroform, or a low molecular weight aliphatic alcohol (ethanol, isopropanol) which contains the desired acid or base, or to which the desired acid or base is then added. The salts are obtained by filtering, reprecepitating, precipitating with a non-solvent for the addition salt or by evaporating the solvent. Salts obtained can be converted by basification or by acidifying into the free compounds which, in turn can be converted into salts.
In general, the ethereal solvents used in the above described processes for the preparation of compounds of the formula (1) are selected from diethyl ether, 1,2-dimethoxyethane, tetrahydrofuran, diisopropyl ether, 1,4 dioxane and the like. The

33
chlorinated solvent which may be employed may be selected from dichloromethane, 1,2-dichloroethane, chloroform, carbontetrachloride and the like. The aromatic solvents which may be employed may be selected from benzene and toluene. The alchoholic solvents which may be employed may be selected from methanol, ethanol, n-propanol, iso propanol, tert-butanol and the like. The aprotic solvents which may be employed may be selected from N, N-dimethylformamide, dimethyl sulfoxide and the like.
In general, the compounds prepared in the above described processes are obtained in pure form by using well known techniques such as crystallization using solvents such as pentane, diethyl ether, isopropyl ether, chloroform, dichloromethane, ethyl acetate, acetone, methanol, ethanol, isopropanol, water or their combinations, or column chromatography using alumina or silica gel and eluting the column with solvents such as hexane, petroleum ether (pet.ether), chloroform, ethyl acetate, acetone, methanol or their combinations.
Various polymorphs of a compound of general formula (1) forming part of this invention may be prepared by crystallization of compound of formula (1) under different conditions, example, using different solvents commonly used or their mixtures for recrystallization; crystallizations at different temperatures, various modes of cooling, ranging from very fast to very slow cooling during crystallizations. Polymorphs may also be obtained by heating or melting the compound followed by gradual or fast cooling. The presence of polymorphs may be determined by solid probe NMR spectroscopy, IR spectroscopy, differential scanning calorimetry, powder X-ray diffraction or such other techniques.
The present invention provides novel heterocyclic compounds, their analogs, their tautomers, their regioisomers, their stereoisomers, their enantiomers, their diastreomers, their polymorphs, their pharmaceutically acceptable salts, their appropriate N-oxides and their pharmaceutically acceptable solvates.
The present invention also provides pharmaceutical compositions, containing compounds of general formula (1) as defined above, their derivatives, their analogs, their tautomeric forms, their stereoisomers, their polymorphs, their enantiomers, their diasteromers, their pharmaceutically acceptable salts or their pharmaceutically acceptable solvates in combination with the usual pharmaceutically employed carriers, diluents and the like. The

34
pharmaceutical compositions according to this invention can be used for the treatment of allergic disorders.
It will be appreciated that some of the compounds of general formula (1) defined above according to the invention can contain one or more asymmetrically substituted carbon atoms. The presence of one or more of these asymmetric centers in the compounds of general formula (1) can give rise to stereoisomers and in each case the invention is to be understood to extend to all such stereoisomers, including enantiomers and diastereomers and their mixtures, including racemic mixtures. The invention may also contain E & Z geometrical isomers wherever possible in the compounds of general formula (1) which includes the single isomer or mixture of both the isomers
The pharmaceutical compositions may be in the forms normally employed, such as tablets, capsules, powders, syrups, solutions, suspensions and the like and may contain flavorants, sweeteners etc. in suitable solid or liquid carriers or diluents, or in suitable sterile media to form injectable solutions or suspensions. The active compounds of formula (1) will be present in such pharmaceutical compositions in the amounts sufficient to provide the desired dosage in the range as described above. Thus, for oral administration, the compounds of formula (1) can be combined with a suitable solid, liquid carrier or diluent to form capsules, tablets, powders, syrups, solutions, suspensions and the like. The pharmaceutical compositions, may, if desired, contain additional components such as flavorants, sweeteners, excipients and the like. For parenteral administration, the compounds of the formula (1) can be combined with sterile aqueous or organic media to form injectable solutions or suspensions. For example, solutions in sesame or peanut oil, aqueous propylene glycol and the like can be used as well as aqueous solutions of water-soluble pharmaceutically-acceptable acid addition salts or salts with base of the compounds of formula (1) The injectable solutions prepared in this manner can then be administered intravenously, intraperitoneally, subcutaneously, or intramuscularly, with intramuscular administration being preferred in humans.
The compounds can also be administered by inhalation when application within the respiratory tract is intended. Formulation of the present compounds is especially significant for respiratory inhalation, wherein the compound of Formula (1) is to be delivered in the form of an aerosol under pressure. It is preferred to micronize the compound of Formula (1)

35
after it has been homogenised, e.g., in lactose, glucose, higher fatty acids, sodium salt of dioctylsulfosuccinic acid or, most preferably, in carboxymethyl cellulose, in order to achieve a microparticle size of 5 :m or less for the majority of particles. For the inhalation formulation, the aerosol can be mixed with a gas or a liquid propellant for dispensing the active substance. An inhaler or atomizer or nebulizer may be used. Such devices are known. See, e.g., Newman et al., Thorax, 1985, 4061-676; Berenberg, M., J. Asthma USA, 1985, 22:87-92; incorporated herein by reference in their entirety. A Bird nebulizer can also be used. See also U.S. Patents 6,402,733; 6,273,086; and 6,228,346, incorporated herein by reference in their entirety. The compound of the structure (1) for inhalation is preferably formulated in the form of a dry powder with micronized particles. The compounds of the invention may also be used in a metered dose inhaler using methods disclosed in U.S. Patent 6, 131,566, incorporated herein by reference in its entirety.
In addition to the compounds of formula (1) the pharmaceutical compositions of the present invention may also contain or be co-administered with one or more known drugs selected from other clinically useful therapeutic agents.
The invention is explained in detail in the examples given below which are provided by way of illustration only and therefore should not be construed to limit the scope of the invention.
The following intermediates have been used to synthesize the rerpesentative examples of the compounds of the invention.
Intermediate 1
N-(3,5-dichloropyrid-4-yl)-4-methoxy-8-amino dibenzo[b,d]furan-l-carboxamide


H,N

Step 1: 2-Bromoisovanillin

36
Isovanillin (5 gm, 0.033 mol) was dissolved in glacial acetic acid (30 ml). Anhydrous sodium acetate (5.4 gm) was added to the above solution followed by powdered iron (0.15 gm). The system was flushed thoroughly with nitrogen. A solution of bromine (5.79 gm, 0.0362 mol) in glacial acetic acid (10 ml) was added to the above stirred suspension at room temperature over a period of 15 min. The reaction mixture was stirred at room temperature for 45 min. The reaction mixture was poured into aqueous 2% sodium bisulfite (200 ml) and stirred for 10 min. The precipitate was filtered washed with water (100 ml), and dried to obtain 3.5 gm of 2-bromoisovanillin as white powder mp: (200-202°C).
IR (KBr) 3233, 2990, 2891, 2844, 1669, 1593, 1564, 1494, 1463, 1286, 1238, 1205, 1019, 987,805,786 cm-1.
!H NMR (300 MHz, CDC13) 5 3.99 (s, 3H), 6.13 (s, 1H), 6.89 (d, 1H, J= 8.4 Hz), 7.55 (d, 1H, J= 8.4 Hz), 10.23 (s, 1H).
Step 2: 2-Bromo-3-(p-nitrophenoxy)-4-methoxy benzaldehyde
To a stirred suspension of potassium fluoride (1.89 gm, 0.0326 mol) in dry DMSO (10 ml) was added a solution of 2-bromoisovanillin (5.0 gm, 0.0217 mol) in DMSO (10 ml). A solution of 4-fluoronitrobenzene (5.0 gm, 0.0260 mol) in DMSO (5 ml) was added to the above suspension and the reaction mixture was stirred at 140°C for 4 h. The reaction mixture was cooled to room temperature and the contents were poured into water (150 ml) and extracted with ethyl acetate (50 ml x 3). The organic extracts were combined and washed with IN sodium hydroxide (25 ml x 2), water and brine and dried over anhydrous sodium sulfate. The dried organic layer was concentrated in vacuo and the residue was purified by silica-gel column chromatography using 20% ethyl acetate-petroleum ether as the eluent to give 2-bromo-3-(p-nitrophenoxy)-4-methoxy benzaldehyde as a pale yellow solid ( 5.0 gm) mp: 132-140°C.
IR (KBr) 3084, 2874, 1689, 1584, 1506, 1486, 1348, 1285, 1253, 1234, 1114, 1025, 848, 815,747 cm"1.
'H NMR (300 MHz, CDCI3) 5 3.86 (s, 3H), 6.89 (d, 2H, J= 7.2 Hz), 7.07 (d, 1H, J= 9.0 Hz), 7.92 (d, 1H, J= 8.4 Hz), 8.17 (d, 2H, J= 9.0 Hz), 10.24 (s, 1H).

37
Step 3: 4-methoxy-8-nitro-l-formyl dibenzo[b,d]furan
2-Bromo-3-(p-nitrophenoxy)-4-methoxy benzaldehyde (3.5 gm, 0.0087 mol), anhydrous sodium carbonate (1.125 gm, 0.0106 mol) and palladium (II) acetate (0.19 gm, 0.0008 mol), in dimethylacetamide (15 ml) are heated and stirred under nitrogen at 170°C for 2h. Water (90 ml) is added to the cooled reaction mixture. The precipitated solid is collected by Alteration and washed with 5% hydrochloric acid followed by water. The product was obtained as a yellow solid (3.4 gm).
IR(KBr)3115,2925,2856, 1682, 1609, 1576, 1522, 1343, 1295, 1076,846,829 cm"1.
'H NMR (300 MHz, DMSO) 5 4.13 (s, 3H), 7.53 (d, 1 H, J= 9.0 Hz), 8.01 (d, 1H, J= 9.0 Hz), 8.16 (d, 1H, J= 9.0 Hz), 8.48 (dd, 1H, J= 9.0 Hz, 3.0 Hz), 9.79 (d, 1H, J= 3.0 Hz), 10.1 (s, 1H).
Step 4: 4-methoxy-8-nitro dibenzo[b,d]furan-l-carboxylic acid
4-methoxy-8-nitro-l-formyl dibenzo[b,d]furan (1.1 gm, 0.0034 mol) in acetone (5 ml) was heated to 60-70°C for 10 min. To the above suspension was added dropwise a hot solution of potassium permanganate (1.07 gm, 0.0068 mol) in water: acetone (1: 3) (15 ml) for 10 min. The reaction was heated to 60-70°C for 10 min., cooled to room temperature and filtered. The residue washed with acetone and the filterate was extracted with 10% sodium hydroxide solution. Acidification, followed by Alteration and washing of the precipitate yielded 4-methoxy-8-nitro-dibenzo[b,d]furan-l-carboxylic acid (0.6 gm) as white solid; mp: 178°C (dec.)
IR (KBr) 3467, 2942, 1711, 1694, 1633, 1610, 1574, 1522, 1453, 1417, 1344, 1278, 1069, 846,826,743 cm"1.
*H NMR (300 MHz, DMSO) 8 4.08 (s, 3H), 7.36 (d, 1 H, J= 8.4 Hz), 7.98 (d, 1H, J= 9.0 Hz), 8.07 (d, 1H, J= 8.4 Hz), 8.44 (dd, 1H, J= 9.0 Hz, 2.7 Hz), 9.79 (d, 1H, J= 2.4 Hz),
Step 5a : 4-methoxy-8-nitro dibenzo[b,d]furan-l-carboxylic acid chloride

38
A suspension of 4-methoxy-8-nitro dibenzo[b,d]furan-l-carboxylic acid (150mg, 0.52
mmol) (from step 4) in a mixture of benzene (2 ml) and freshly distilled thionyl chloride (2
ml) was heated to reflux temperature for 4 h. The excess thionyl chloride was removed
under vacuum to get the corresponding acid chloride which was subjected the next reaction
as such.
Step 5b: N-(3,5-dichloropyrid-4-yl) - 4-methoxy-8-nitro dibenzo[b,d]furan-l-
carboxamide
To a pre-washed suspension of sodium hydride (52 mg, 2.5 equiv., 1.3 mmol, 60% oil
dispersion) in DMF (2 ml) was added drop wise a solution of 4-amino-3,5-dichloropyridine
(93 mg, 0.52 mmol) in DMF (2 ml) at -10°C. A pre-cooled solution of above acid chloride
(0.52 mmol) (from step 5a) in THF (2 ml) was added, all at once, to the reaction mixture and
the contents were stirred at -10°C for 30 min. The reaction was quenched with brine, diluted
with water and filtered to give a crude solid which was washed with ethanol to give N-(3, 5-
dichloropyrid-4-yl)-4-methoxy-8-nitro-dibenzo[b,d]furan-l-carboxamide as a white solid (
80mg);mp: 315-317°C.
IR(KBr): 3245, 3092, 2845, 1662, 1614, 1581, 1554, 1519, 1483, 1461, 1439, 1391, 1337, 1282,1205,1181, 1067 cm-1.
*H NMR (300 MHz, DMSO) 8 4.12 (s, 3H), 7.48 (d, 1 H, J= 8.1 Hz), 8.03 (d, 1H, J= 8.1 Hz), 8.06 (d, 1H, J= 8.4 Hz), 8.44 (dd, 1K,J = 7.2 Hz), 8.81 (s, 2H). 9.43 (d, 1H, J= 1.2 Hz), 10.95 (s, 1H).
Step 6: N-(3,5-dichloropyrid-4-yl) - 4-methoxy-8-amino-dibenzo[b,d]furan-l-carboxamide
Iron powder (467 mg, 8.35 mmol) and ammonium chloride (742 mg, 13.5 mmol) were heated at 80°C for 15 min. N-(3,5-pyrid-4-yl)-4-methoxy-8-nitro dibenzo[b,d]furan-l-carboxamide (800 mg, 1.85 mmol) was suspended in methanol and allowed to trickle down into the above reaction mixture at reflux. The reaction was refluxed for 3 h and filtered hot. Methanol was evaporated, and the solid was washed with water and taken directly without purification to synthesize the following examples.

39

Intermediate
2 N-(3,5-dichloropyrid-4-yl)-4-difluoromethoxy-8-amino dibenzo[b,d]furan-l-

carboxamide
H,N
OCHF2
ci

Step 1: 4-cyclopentoxy-3-hydroxy-benzaldehyde
A suspension of 3,4-dihydroxybenzaldehyde (5.0 gm, 0.0362 mol), anhydrous potassium carbonate (6.0 gm, 0.0434 mol) and cyclopentyl bromide (6.5 gm, 0.0434 mol) in dry DMF (50 ml) was heated and stirred at 80°C for 24 hrs. Reaction mixture was then cooled and diluted with water (500 ml), acidified with IN HC1 and extracted with ethyl acetate (3 x 100 ml). The ethyl acetate extract was washed 5 % sodium bicarbonate and brine and dried over anhydrous sodium sulfate. The dried extract on concentration afforded a residue which was purified by silica gel chromatography using 10 % ethyl acetate in petroleum ether as the eluent to provide 5.0 gm of the title product as white solid, mp: 87-89°C.
IR(KBr)2964, 1670, 1605, 1580, 1500, 1463, 1358, 1271,1122,976,806,748 cm"1
lU NMR (300 MHz, CDC13) 5 1.65-2.04 (m, 8H), 4.93 (m, 1H), 5.83 (s, 1H), 6.94 (d, 1H), 7.38-7.43 (m, 2H), 9.82 (s, 1H).
Step 2: 2-bromo-4-cyclopentoxy-3-hydroxy-benzaldehyde
4-cyclopentoxy-3-hydroxy-benzaldehyde (1.0 gm, 4.84 mmol) was dissolved in glacial acetic acid (20 ml). Anhydrous sodium acetate (0.8 gm, 9.7 mmol) was added to the above solution followed by powdered iron (0.022 gm). The system was flushed thoroughly with nitrogen. A solution of bromine (0.854 gm, 5.32 mmol) in glacial acetic acid (10 ml) was added to the above stirred suspension at 15°C over a period of 15 min. The reaction mixture

40
was stirred at 15°C for 45 min. The reaction mixture was poured into aqueous 2% sodium bisulfite (100 ml) and stirred for 10 min. The precipitate was filtered washed with water (100 ml), and dried to obtain 800 mg of 2-bromo-4-cyclopentoxy-3-hydroxy-benzaldehyde as white powder mp: 107-109°C.
*H NMR (300 MHz, CDC13) 5 1.66-2.03 (m, 8H), 4.92 (m, 1H), 6.15 (s, 1H), 6.90 (d, 1H), 7.54 (d, 1H), 10.25 (s, 1H).
Step 3 : 2-bromo-4-cyclopentoxy-3-(p-nitrophenoxy)-benzaldehyde
To a stirred suspension of potassium fluoride (125 mg, 2.104 mmol) in dry DMSO (2.5 ml) was added a solution of 2-bromo-4-cyclopentoxy-3-hydroxy-benzaldehyde (500 mg, 1.754 mmol) in DMSO (2.5 ml). A solution of 4-fluoronitrobenzene (500 mg, 2.631 mmol) in DMSO (2.5 ml) was added to the above suspension and the reaction mixture was stirred at 140°C for 6 h. The reaction mixture was cooled to room temperature and the contents were poured into water (100 ml) and extracted with ethyl acetate (50 ml x 3). The organic extracts were combined and washed with IN sodium hydroxide (25 ml x 2), water and brine and dried over anhydrous sodium sulfate. The dried organic layer was concentrated in vacuo to give 2-bromo-3-(p-nitrophenoxy)-4-methoxy benzaldehyde as a pale yellow solid ( 500 mg) mp: 115-117°C.
1H NMR (300 MHz, CDCI3) 5 1.18-1.23 (m, 2H), 1.39-1.53 (m, 4H), 1.73-1.81 (m, 2H), 5.01 (m, 1H), 7.09 (dd, 2H), 7.43 (d, 1H), 7.87 (d, 1H), 8.24 (dd, 2H), 10.13 (s, 1H).
Step 4 : 4-cyclopentyloxy-8-nitro-l-formyl dibenzo[b,d]furan
Intermediate 2-bromo-4-cyclopentoxy-3-(p-nitrophenoxy)-benzaldehyde (500 mg, 1.09 mmol), anhydrous sodium carbonate (150 mg, 1.325 mmol) and palladium (II) acetate (25 mg, 0.096 mmol), in dimethylformamide (10 ml) are heated and stirred under nitrogen at 130°C for 7 h. Water (90 ml) is added to the cooled reaction mixture and extracted with ethyl acetate (2 x 25 ml). The combined organic layer was washed with 5% hydrochloric acid followed by water and dried over anhydrous sodium sulfate to afford the product as a yellow solid (200 mg). mp: 230-240°C.

41
'H NMR (300 MHz, DMSO) 5 1.70 (m, 2H), 1.77-1.92 (m, 4H), 2.09 (m, 2H), 5.25 (m, 1H), 7.53 (d, 1H), 8.05 (d, 1H), 8.14 (d, 1H), 8.51 (d, 1H), 9.80 (s, 1H), 10.14 (s, 1H).
Step 5 : 4-hydroxy-8-nitro-l-formyl dibenzo[b,d]furan
4-cyclopentyloxy-8-nitro-l-formyl dibenzo[b,d]furan (200 mg, 0.530 mol) was heated in HBr (47 % in acetic acid) (5 ml) in glacial acetic acid (10 ml) at 50°C for 7-8 h. The reaction contents were poured in ice-water (200 ml) and extracted with ethyl acetate (3 x 50 ml). The combined organic layer was washed with saturated sodium bicarbonate, and water and dried over anhydrous sodium sulfate. Removal of the organic solvent in vacuo afforded the crude product as a white solid (150 mg). The crude white solid was used as such without further purification, mp: >270°C.
*H NMR (300 MHz, DMSO) 5 7.28 (d, 1H), 8.01 (d, 1H), 8.04 (d, 1H), 8.50 (d, 1H), 9.83 (s, 1H), 10.09 (s, 1H), 11.92 (s, 1H).
Step 6 : 4-difluoromethoxy-8-nitro-l-formyl dibenzo[b,d]furan
A suspension of 4-hydroxy-8-nitro-l-formyl dibenzo[b,d]furan (150 mg, 0.485 mmol) and anhydrous potassium carbonate (200 mg, 1.455 mmol) in dry DMF (5.0 ml) was stirred at 80°C for 10 min. Chlorodifluoromethane gas was purged into the reaction mixture for 45 min. The reaction mixture was cooled, diluted with water (50 ml), and extracted with ethyl acetate (3 x 25 ml). The combined organic layer was washed with water and dried over anhydrous sodium sulfate. Removal of the organic solvent in vacuo afforded the product as a white solid (150 mg). mp: 245-248°C.
Step 7 : 4-difluoromethoxy-8-nitro dibenzo[b,d]furan-l-carboxylic acid
4-difluoromethoxy-8-nitro-l-formyl dibenzo[b,d]furan (150 mg, 0.48 mmol) in acetone (20 ml) and water (5 ml) was heated to 60-70°C for 10 min. To the above solution was added dropwise a solution of potassium permanganate (150 mg, 0.973 mmol) in water (5 ml) for 10 min. The reaction was heated to 60-70°C for 30 min., and filtered hot through celite bed. Acidification of the filterate resulted in a precipitate which on filteration and washing with water yielded 4-difluoromethoxy-8-nitro-dibenzo[b,d]furan-l-carboxylic acid (100 mg) as white solid; mp: >270°C.

42
lH NMR (300 MHz, DMSO) 6 7.61 (t, 1H, J = 72 Hz), 7.60 (d, 1H), 8.07 (d, 1H), 8.13 (d,
1H), 8.52 (d, 1H), 9.77 (s, 1H), 13.80 (s, 1H).
Step 8: N-(3,5-dichloropyrid-4-yl)-4-difluoromethoxy-8-nitro-dibenzo[b,d]furan-l-
carboxamide
A solution 4-difluoromethoxy-8-nitro dibenzo[b,d]furan-l-carboxylic acid (lOOmg, 0.30 mmol), in a mixture of benzene (2 ml) and freshly distilled thionyl chloride (2 ml) was heated to reflux temperature for 4 h. The excess thionyl chloride was removed under vacuum to get the corresponding acid chloride.
To a pre-washed suspension of sodium hydride (25 mg, 60% oil dispersion) in DMF (3 ml) was added dropwise a solution of 4-amino-3,5-dichloropyridine (53 mg, 0.30 mmol) in DMF (2 ml) at -10°C. A pre-cooled solution of above acid chloride (0.30 mmol) in THF (5 ml) was added, all at once, to the reaction mixture and the contents were stirred at -10°C for 30 min. The reaction was quenched with brine, diluted with water and filtered to give a crude solid which was purified by silica gel chromatography using 10 % acetone in chloroform as the eluent to provide 100 mg of N-(3,5-dichloropyrid-4-yl) - 4-difluoromethoxy-8-nitro-dibenzo[b,d]furan-l-carboxamide as white solid, mp: >270°C. IR(KBr): 3213, 2926, 1664, 1555, 1526, 1488, 1339, 1285, 1199, 1090, 904, 823 cm-1. 'H NMR (300 MHz, DMSO) 8 7.63 (t, 1H, J= 72 Hz), 7.77 (d, 1H), 8.09 (d, 1H), 8.13 (d, 1H), 8.52 (dd, 1H, J= 9.3 Hz, 2.4 Hz), 8.86 (s, 2H), 9.39 (d, 1H, J= 2.7 Hz), 11.21 (s, 1H).
Step 9: N-(3,5-dichloropyrid-4-yl)-4-difluoromethoxy-8-amino-dibenzo[b,d]furan-l-carboxamide
A mixture of N-(3,5-dichloropyrid-4-yl) - 4-difluoromethoxy-8-nitro-dibenzo[b,d]furan-l-carboxamide (step 8) (100 mg), methanol (10 ml) and 10 % Pd/C (10 mg) was hydrogenated at 60 psi for 12 h. Filteration of the reaction mixture over celite bed and removal of solvent methanol under reduced pressure afforded N-(3,5-dichloropyrid-4-yl) - 4-difluoromethoxy-8-amino-dibenzo[b,d]furan-l-carboxamide as white solid, mp: >270°C. IR(KBr): 3436, 3360, 3185, 2921, 1659, 1555, 1484, 1391, 1292, 1195, 1133, 1055, 910, 811, 674 cm-1.

43
lU NMR (300 MHz, DMSO) 5 5.14 (brs, 2H), 6.86 (dd, IH, J= 8.7 Hz, 2.4 Hz), 7.53 (t, IH, J= 72 Hz), 7.46-7.51 (m, 2H), 7.80 (d, IH, J= 9.0 Hz), 8.80 (s, 2H), 10.96 (s, IH).
Intermediate 3
N-(3,5-dichloropyrid-4-yl)-l-methoxy-9-methyl-6-amino-9/f-4-carbazolecarboxamide


HoN

Step 1: methyl-3-(2-bromo-4-nitroanilino)-4-methoxybenzoate
3-amino-4-methoxy methyl benzoate (3.5 gm, 0.0193 mol) (commercial) was dissolved in DMF (20 ml) and added to a suspension of sodium hydride (60 % dispersion) (1.54 gm, 0.0386 mol) in DMF (20 ml). The reaction mixture was stirred under nitrogen for 30 minutes at room temperature, followed by addition of a solution of 3-bromo-4-fluoro nitrobenzene (5.05 gm, 0.023 lmol) in DMF (20 ml) at 0°C over a period of 10 minutes. The reaction was stirred at room temperature for 18 hrs. The reaction was then quenched with brine and diluted with ice cold water (500 ml) to get a precipitate which was filtered and dried to get the crude product. The crude product was purified by column chromatography using 40% ethyl acetate in petroleum ether as eluent to get pure product as a yellow solid.
IR(KBr): 3363, 3103, 3005, 2952, 2951, 1720, 1600, 1581, 1506, 1492, 1443, 1327, 1295, 1255, 1144, 1117, 1103, 1020, 1003, 824, 760, 743 cm"1.
1H NMR (300 MHz, DMSO): 5 3.83 (s, 3H), 3.85 (s, 3H), 6.50 (d, 1 H, J= 9.0 Hz), 7.29 (d, IH, J= 9.0 Hz), 7.86 (s, IH ), 8.01 (d, IH, J = 7.2 Hz ), 8.03 (d, IH, J= 7.2 Hz), 8.19 (s, 1H),8.37(S,1H).

44
Step 2: methyl-l-methoxy-6-nitro-9//-4-carbazolecarboxylate
Methyl-3-(2-bromo-4-nitroanilino)-4-methoxybenzoate (3 gm, 0.0093 mol), anhydrous sodium carbonate (2.96 gm, 0.0275 mol) and palladium (II) acetate (1 gm, 0.0046 mol), in dimethylformamide (60 ml) were heated and stirred under nitrogen at 140°C for 18hr. The reaction mixture was cooled and filtered through celite bed. Water (90 ml) was added to the cooled reaction mixture. The precipitated solid was acidified and collected by filtration and washed with water. The product was obtained as a yellow solid (3.4 gm).
IR (KBr): 3404, 3133, 3017, 2964, 1724, 1626, 1615, 1571, 1513, 1461, 1435, 1318, 1267, 1231, 1200, 1070, 920, 741 cm"1.
1 N MR (300 MHz, DMSO): 5 3.99 (s, 3H), 4.11 (s, 3H), 7.24 (d, 1 H, J= 8.7 Hz), 7.67 (d, IH, J= 9.0 Hz), 8.01 (d, IH, J= 9.0 Hz ), 8.34 (dd, IH, J= 8.7 and 2.4 Hz), 9.95 (d, IH, J = 2.4 Hz), 12.57 (s,lH).
Step 3: methyl-l-methoxy-9-methyl-6-nitro-9//-4-carbazolecarboxylate
Methyl-l-methoxy-6-nitro-9H-4-carbazolecarboxylate (1 gm, 0 .0026 mol) was dissolved in DMF (10 ml) and added to a suspension of sodium hydride (104 mg, 0.0052 mol) in DMF (10ml) at room temperature over a period of 10 minutes. Solution of methyl iodide (549 mg, 0.0039 mol) in DMF (10ml) was added to the reaction mixture and it was stirred further for a period of 1 hr. The reaction was then quenched with brine and diluted with water .The precipitate obtained was acidified and then filtered to get a yellow solid.
IR (KBr): 3131, 2943, 2846, 1730, 1618, 1572, 1514, 1438, 1324, 1251, 1136, 1068, 1017, 809,740 cm"1.
'H NMR (300 MHz, DMSO): 5 3.97 (s, 3H), 4.05 (s, 3H), 4.19 (s, 3H), 7.22 (d, 1H,J= 8.7 Hz), 7.75 (d, IH, J= 9.0 Hz), 7.95 (d, IH, J = 9.0 Hz ), 8.34 (dd, IH, J= 8.7 and 2.4 Hz), 9.90 (d, IH, J = 2.4 Hz).

45
Step 4: l-methoxy-9-methyl-6-nitro-9//-4-carbazolecarboxylic acid
Methyl-l-methoxy-9-methyl-6-nitro-9H-4-carbazolecarboxylate (500 mg) was suspended in methanol (15ml) and added with 1 M NaOH (10ml).The reaction mixture was refluxed for 18 hrs. Methanol was evaporated and the compound was diluted with water followed by addition of HC1. The precipitate was filtered to get a brown solid.
!H NMR (300 MHz, DMSO): 6 4.06 (s, 3H), 4.23 (s, 3H), 7.24 (d, 1 H, J= 8.7 Hz), 7.82 (d, 1H, J= 9.0 Hz), 7.95 (d, 1H, J= 9.0 Hz ), 8.36 (dd, 1H, J= 9.0 and 2.4 Hz), 10.03 (d, 1H, J = 2.4 Hz), 13.01 (brs,lH).
Step 4a: l-methoxy-9-methyl-6-nitro-9//-4-carbazolecarboxy acid chloride:
l-methoxy-9-methyl-6-nitro-y//-4-carbazolecarboxylic acid (300 mg) was suspended in freshly distilled thionyl chloride (2 ml) was heated to reflux temperature for 4 hr. The excess thionyl chloride was removed under vacuum to get the corresponding acid chloride which was subjected the next reaction as such.
Step 4: N-(3,5-dichloropyrid-4-yl)--l-methoxy-9-methyl-6-nitro-9/7-4-carbazolecarboxamide:
To a pre-washed suspension of sodium hydride (100 mg, 2.5 equiv., 0.0025, 60% oil dispersion) in DMF (3 ml) was added drop wise a solution of 4-amino-3,5-dichloropyridine (244 mg, 0.0015 mol) in DMF (3 ml) at -10°C. A pre-cooled solution of above acid chloride (from step 4a) in THF (5 ml) was added, all at once, to the reaction mixture at -50°C and the contents were stirred at -50°C for lhr. The reaction was quenched with brine, diluted with water and filtered to give N-(3,5-dichloropyrid-4-yl)~l-methoxy-9-methyl-6-nitro-P//-4-carbazolecarboxamide as a yellow solid ( 250 mg); mp: >250°C.
IR(KBr): 3432,3199,2936,2841, 1662, 1575, 1513, 1479, 1398, 1323, 1313, 1275, 1254, 1095,1067,1018,809,745 cm-1.

46
'H NMR (300 MHz, DMSO): 6 4.08 (s, 3H), 4.25 (s, 3H), 7.32 (d, 1H, J= 8.4 Hz), 7.76-7.83 (m, 2H), 8.36 (dd, 1H, J= 9.0 and 2.4 Hz), 8.84 (s, 2H), 10.03 (d, 1H, J = 2.4 Hz), 10.89 (s, 1H).
Step 5: N-(3,5-dichIoropyrid-4-yl)-l-methoxy-9-methyl-6-amino-9H-4-carbazolecarboxamide:
: N-(3,5-dichloropyrid-4-yl)— l-methoxy-9-methyl-6-nitro-9#-4-carbazolecarboxamide (250 mg ) was suspended in DMF (20 ml) and methanol (10 ml ) and added with raney nickel (25 mg, 10% w/w) and reduced under pressure (60 psi) for 18 hrs at room temperature. The reaction mixture was filtered through celite and DMF was evaporated to get a green solid which was washed with water to give N-(3,5-dichloropyrid-4-yl)-l-methoxy-9-methyl-6-amino-P//-4-carbazolecarboxamide. Confirmed by ninhydrin.
.The compound was taken directly without purification to synthesize the following example no 54, 55, 56 and 57
Representative compounds of the invention, which should not be construed as limiting in any way, are found at Table 1 given below for General Structural of Formula (1).

47
Table 1
©—



(R )m I|

(R4)n
P—R'
General Structural of formula (1)


O

O

-CONH

0

1

CH3

O
H II ,N-S-

O

o

-CONH

CH3

O
H II / ^N-S-N
\ II

O

o

-CONH

CH3

O
H II ^N-S-

0

o

-CONH

CH3

r
o

o

o

-CONH

CH3

CI

o

o

-CONH

CH3

48
Table Icontd.
©"



(R )m 11

(R4)n
p—R'
General Structural of formula (1)

7. 0 0 -CONH CIHi)CI 0 1 CH3 0
8. 0 o -CONH CI CI 0 1 CH3 H I ^NY^OC2H5 0
9. 0 0 -CONH CI CI 0 1 CH3 H ° 0
10. 0 0 -CONH CIKZ)CI 0 1 CH3 H ° 0 Na
11. 0 0 -CONH CIKZ)CI 0 1 CH3 0
12. 0 0 -CONH CI CI 0 1 CH3 0

49
Table Icontd.


(R )m l|

(R4)n
P—R1
General Structural of formula (1)


13.

O

O

-CONH

0

1

CH3

N

14.

O

o

-CONH

CH3

u
-N^/CF3 O

15.

O

O

-CONH

CH3

NY^-

16.

O

O

-CONH

CH3

NY°

17.
18.

O
O

O
O

-CONH
-CONH

CH3
CH3

H
o
H O

50
Table Icontd.
©-


(R )m M

(Rr„
General Structural of formula (1)


19.

O

O

-CONH

CH,

•v*

.CF3

20.

O

o

-CONH

CH3

r
H
V
o

21.

O

O

-CONH

CH,

Vr>

22.
23.
24.

O
O
O

O
O
O

-CONH
-CONH
-CONH

CH,
CH3
CH3

H I | NyNj
o
N
H I
'V
o
H
V
O

/
OH

HC1

51
Table Icontd.
©-*

(^Im—jK I II 1 "'
(R4)n
P—R'
General Structural of formula (1)




25.
26.
27.

O
O
O

O
O
O

-CONH
-CONH
-CONH

0

1

CH3
CH3
CH,

H
'V
o
H W
■v-
o
H H

28.

O

O

-CONH

CH3

H W
YN-
o

29.

O

O

-CONH

CH,

H t!
•YN-
o

30.

O

O

-CONH

CHF2

O
H II ,N-S—

52
Table Icontd.

General Structural of formula (1)


31.

O

O

-CONH

CHF-,

O H II ,N-S-

32.

O

O

-CONH

CHF,

O
H II N-S-

33.

O

O

-CONH

CHF,

O
H II / .N-S-N
II

34.

O

O

-CONH

CHF2

H ,N

Y

35.

O

O

-CONH

CHF,

CI

36.

O

O

-CONH

a

J L

CHF2

53
Table Icontd.
0"
(R )m 11
(R4)n
P—R1
General Structural of formula (1)

37. 0 0 -CONH CIHI)CI 0 1 CHF2 H ° /NY^OC2H5 0
38. 0 o -CONH CIHi)CI 0 1 CHF2 H ° 0
39. 0 0 -CONH CI CI 0 1 CHF2 H ° 0 2Na
40. 0 0 -CONH CICI 0 1 CHF2 0
41. 0 0 -CONH i-O 0 1 CH3 Ho
42. 0 0 -CONH i-^O"0Me 0 1 CH3 H 0

54
Table lcontd.
©-A



(R3)m—[r

General Structural of formula (1)

43.

O

O

-CONH

\ /

CH3

Y
O

44.

O

O

-CONH

CH3

H H
!-V-
S

45.

O

O

-CONH

CH3

H H
.NYN.
s

\ /
46.

O

O

-CONH

CH3

r
o

N^-O
47.

O

O

-CONH

CH3

N^O
48.

O

O

-CONH

CH3

O
H II ,N-S-

55
Table Icontd.


(R )m M
P—R1
General Structural of formula (1)

49.

O

O

-CONH

\J

0

1

CH,

V

50.

O

o

-CONH

CH,

H H II O

51.

O

O

-CONH

CH,

H H y O

52.

O

O

-CONH

CH,

53.

O

O

-CONH

CH,

OH

54.

O

N-CH3

-CONH

CH3

H ,N

Y

56
Table Icontd.
©-

(R7n
p—R'
General Structural of formula (1)

55. 0 N-CH3 -CONH CI CI 0 1 CH3 OH IIi-T0
56. 0 N-CH3 -CONH CI CI 0 1 CH3 0H II /O
57. 0 N-CH3 -CONH CI CI 0 1 CH3 H 0
58. 0 O -CONH CICI 0 1 CHF2 OH II ^N-S—\ II 0 2Na
59. 0 s -CONH CI CI 0 1 CH3 H 0
60. 0 0 -CONH CIKZ)CI 0 1 CHF2 H 0 Na
61. 0 0 -CONH CIKZ) 0 1 CHF2 0 Na
CI | |

57
Example 1 N-(3,5-dichloropyrid-4-yl)-4-methoxy-8-methanesuIfonamido-dibenzo[b,d]furan-l-
carboxamide
N-(3,5-dichloropyrid-4-yl) - 4-methoxy-8-amino-dibenzo[b,d]furan-l-carboxamide (100 mg, 0.249 mmol) (intermediate 1) was treated with methanesulfonyl chloride (24 mg, 0.299 mol) in THF (10 ml) containing pyridine (23 mg, 0.299 mmol) at 0°C and allowed to warm to room temperature. The reaction was stirred at room temperature for 30 min. THF was evaporated and the residue was washed with saturated sodium bicarbonate solution, water. The solid obtained was purified by silica gel column chromatography using 30 % acetone-chloroform as eluent to obtain 30 mg of N-(3,5-dichloropyrid-4-yl) - 4-methoxy-8-methanesulfonylamido-dibenzo[b,d]furan-l-carboxamide as white solid; mp: 315°C. IR(KBr): 3272,3147,2925, 1661, 1607, 1490, 1393, 1313, 1288, 1145, 1101,810 cm-1. lH NMR (300 MHz, DMSO) 5 2.91 (s, 3H), 4.07 (s, 3H), 7.35 (d, 1H, J= 8.4 Hz), 7.44 (d, 1H, J= 8.4 Hz), 7.73 (d, 1H, J= 8.4 Hz), 7.80 (d, 1H, J= 8.4 Hz), 8.31 (s, 1H), 8.77 (s, 2H), 9.65 (s, 1H), 10.80 (s, 1H).
Example 2 and 3 were synthesized using reaction conditions similar to Example 1 except for using the appropriate substituted sulfonyl chloride instead of methanesulfonyl chloride.
Example 2
N-(3,5-dichloropyrid-4-yl)-4-methoxy-8-(N,N-dimethylsulphonamido)-
dibenzo[b,d]furan-l-carboxamide
IR(KBr): 3370, 2922, 1675, 1608, 1483, 1278, 1147, 963, 899, 801, 701 cm-1. lH NMR (300 MHz, DMSO) 8 2.65 (s, 6H), 4.07 (s, 3H), 7.33 (d, 1H, J= 8.7 Hz), 7.43 (dd, 1H, J = 8.7 and 1.8 Hz), 7.68 (d, 1H, J= 8.7 Hz), 7.88 (d, 1H, J= 8.7 Hz), 8.31 (d, 1H, J = 1.8 Hz), 8.77 (s, 2H), 9.82 (s, 1H), 10.79 (s, 1H).
Example 3
N-(3,5-dichloropyrid-4-yl)-4-methoxy-8-(ethanesulphonamido)-dibenzo[b,d]furan-l-
carboxamide

58
lH NMR (300 MHz, DMSO-d6) 5 1.19(t, 3H, J= 7.2 Hz), 5 2.99 (q, 2H, J= 7.5Hz), 5 4.07 (s, 3H),5 7.36 (d, IH, J= 8.4 Hz), 8 7.41 (dd, IH, J= 8.7Hz and J = 2.4 Hz), 8 7.72 (d,lH, J = 8.7Hz), 8 7.91 (d,lH, J= 8.4 Hz), 8 8.32 (d,lH, J= 2.4 Hz), 8 8.77 (s,2H), 8 9.73 (s,lH), 8 10.80 (s,lH).
IR (KBr) 3304, 2968, 2933, 1680, 1608, 1484, 1461, 1332, 1282, 1196, 1143, 1101, 1022, 957, 810, 780,cm-l
Example 4
N-(3,5-dichloropy rid-4-yl)-4-methoxy-8-acetamido-dibenzo [b,d] furan-1 -carboxamide
N-(3,5-dichloropyrid-4-yl) - 4-methoxy-8-amino-dibenzo[b,d]furan-l-carboxamide (100 mg, 0.249 mmol) (intermediate 1) was treated with acetyl chloride (22 mg, 0.299 mmol) in THF (10 ml) containing pyridine (23 mg, 0.299 mmol) at 0°C and allowed to warm to room temperature. The reaction was stirred at room temperature for 30 min. THF was evaporated and the residue was washed with saturated sodium bicarbonate solution and water. The solid obtained was purified by silica gel column chromatography using 30 % acetone-chloroform as eluent to obtain 25 mg of N-(3,5-dichloropyrid-4-yl) - 4-methoxy-8-acetamido-dibenzo[b,d]furan-l-carboxamide as white solid; mp: 252°C. IR (KBr): 3271, 2961, 2925, 2852, 1660, 1607, 1542, 1499, 1468, 1392, 1285, 1261, 1101, 1021,805 cm"1.
2H NMR (300 MHz, DMSO) 8 2.01 (s, 3H), 4.07 (s, 3H), 7.32 (d, IH, J- 8.4 Hz), 7.65 (d, IH, J= 8.4 Hz), 7.93 (m, 2H), 8.41 (s, IH), 8.76 (s, 2H), 10.06 (s, IH), 10.76 (s, IH).
Example 5, 6, 7, 8, 11, 12 and 13 were synthesized using reaction conditions similar to Example 4 except for using the appropriate substituted acid chloride instead of acetyl chloride.
Example 5
N-(3,5-dichloropyrid-4-yl)-4-methoxy-8-(3-chloropropylcarboxamido)-
dibenzo [b,d] furan-1 -carboxamide

59
IR(KBr): 3244, 2940, 1655, 1606, 1543, 1493, 1446, 1393, 1283, 1222, 1199, 1099, 1022, 936, 810, 722, 670, 575 cm"1
'HNMR (300 MHz, DMSO): 5 2.00 (m, 2H), 2.50 (t, 2H), 3.7 (t, 2H), 4..07 (s, 3H), 7.34 (d, IH, J= 8.4 Hz), 7.68 (d, IH, J= 8.7 Hz) 7.94 (d, IH, J= 8.4 Hz), 7.94 (d, IH, J= 8.7 Hz) 8.44 (s, IH, J= 2.4 Hz) 8.76 (s, 2H,), 10.12 (s, IH), 10.77 (s,lH).
Example 6
N-(3,5-dichloropyrid-4-yl)-4-methoxy-8-ethylcarboxamido-dibenzo[b,d]furan-l-
carboxamide
IR(KBr): 3302, 2937, 1649, 1607, 1500, 1392, 1196, 1103, 809, 723 cm"1 JH NMR (300 MHz, DMSO) 5 1.10 (t, 2H), 2.34 (q, 3H) , 4..07 (s,3H), 7.33 (d, IH, J= 9 Hz), 7.66 (d, IH), 7.97-7.91 (m, 2H), 8.44 (s, IH, J = 2.4 Hz) , 8.75 (s, 2H), 9.95 (s, IH), 10.72 (s, IH).
Example 7
N-(3,5-dichloropyrid-4-yl)-4-methoxy-8-t-butylcarboxamido-dibenzo[b,d]furan-l-
carboxamide
IR(KBr): 3327, 3201, 2958, 1647, 1606, 1522, 1495, 1444, 1395, 1289, 1197, 1099, 1025, 936, 806, 779, 670, 540 cm"1
'H NMR (300 MHz, DMSO) 5 1.22 (s, 9H), 4..07 (s, 3H), 7.33 (d, IH, J= 9 Hz), 7.66 (d, IH) 7.79 (d, IH, J= 8.7 Hz), 7.93 (d, IH, J= 9 Hz), 8.51 (s, IH, J= 2.4 Hz), 8.75 (s, 2H). 9.38 (s, IH), 10.71 (s, IH).
Example 8
N-(3,5-dichloropyrid-4-yl)-4-methoxy-8-ethoxycarbonykarboxamido-
dibenzo[b,d]furan-l-carboxamide
IR (KBr): 3349, 3214, 2928, 1753, 1708, 1671, 1606, 1392, 1281, 1199, 1183, 1022, 806, 685 cm"1

60
'HNMR (300 MHz, DMSO) 8 1.33 (t, 3H), 4..08 (s, 3H), 4..32 (q, 2H), 7.37 (d, IH, 7= 8.4 Hz), 7.75 (d, \K,J= 8.7 Hz), 7.88 (d, IH, J=9 Hz), 7.95 (d, IH, J= 8.1 Hz), 8.69 (s, IH, J= 1.8 Hz) 8.77 (s, 2H,) 10.78 (s, IH), 10.95 (s, IH).
Example 9
N-(3,5-dichloropyrid-4-yl)-4-methoxy-8-hydroxycarbonylcarboxamido-
dibenzo[b,d]furan-l-carboxamide
Was synthesized by hydrolysis of N-(3,5-dichloropyrid-4-yl)-4-methoxy-8-
ethoxycarbonylcarboxamido-dibenzo[b,d]furan-l-carboxamide (Example 8) using
potassium hydroxide (3 eq.) in methanol.
mp: > 250°C.
This was directly used for preparation of Example 10 with out further characterisation.
Example 10
N-(3,5-dichloropyrid-4-yl)-4-methoxy-8-hydroxycarbonylcarboxamido-
dibenzo[b,d]furan-l-carboxamide sodium salt
Was synthesized from N-(3,5-dichloropyrid-4-yl)-4-methoxy-8-hydroxycarbonyl carboxamido-dibenzo[b,d]furan-l-carboxamide (Example 9) using 1 % methanolic sodium hydroxide (1.0 eq.).
1HNMR (300 MHz, DMSO) 5 4..08 (s, 3H), 7.32 (d, IH, J= 8.4 Hz), 7.68 (d, IH, 7= 8.7 Hz), 7.92 (d, 2H), 8.62 (s, IH) 8.74 (s, 2H,) 10.19 (s, IH), 10.80 (s, IH).
Example 11
N-(3,5-dichloropyrid-4-yI)-4-methoxy-8-(fur-2-yl-carboxamido)-dibenzo[b,d]furan-l-
carboxamide
IR(KBr): 3247,2925, 1660, 1606, 1566, 1548, 1491, 1465, 1391, 1333, 1221, 1093, 1023,
890,814,768,611cm-1.
'H NMR (300 MHz, DMSO) 8 4.08 (s, 3H), 6.68 (d, IH, J= 3.3 Hz), 7.36 (d, 2H, J = 8.4
Hz), 7.74 (d, IH, J= 9.0 Hz), 7.95-7.89 (m, 3H,) , 8.66 (s, IH, J = 1.8 Hz), 8.76 (s, 2H,).
10.36 (s,lH), 10.77 (s, IH).

61
Example 12
N-(3,5-dichloropyrid-4-yl)-4-methoxy-8-(cyclopropylcarbonylamino)-
dibenzo [b,d] furan-1 -carboxamide
*H NMR (300 MHz, DMSO-d6) 5 0.77 (m, 4H), 1.80 (m, 1H), 4.08 (s, 3H), 7.36 (d, 1H, J = 8.4 Hz), 7.69 (d, 1H, J= 9.0 Hz), 7.80 (m,2H), 8.47 (d, 1H, J= 1.8 Hz), 8.79 (s, 2H), 10.34 (s, 1H), 10.80 (s, 1H). IR(KBr) 3290, 3164, 1650, 1546, 1492, 1398, 1292, 1198, 1100, 960, 812, 640, cm"1
Example 13
N-(3,5-dichloropyrid-4-yl)-4-methoxy-8-(N,N-dicyclopropylcarbonylamino)-
dibenzo[b,d]furan-l-carboxamide
!H NMR (300 MHz, DMSO-d6) 5 0.98 (m, 4H), 1.14 (m, 4H), 1.82 (m,lH), 2.12 (m,lH), 4.07 (s,3H), 7.19 (d,lH, J= 8.7 Hz), 7.58 (d,lH, J = 8.7 Hz), 7.68 (d,lH, J = 9.0 Hz), 8.28 (s, 1H), 8.79 (s, 2H), 10.40 (s, 1H).
IR(KBr) 3311, 3059, 3009, 2843, 1711, 1677, 1631, 1607, 1556, 1470, 1393, 1314, 1297, 1282, 1197, 1173, 1105, 1016, 810, 648, cm"1
Example 14
N-(3,5-dichloropyrid-4-yl)-4-methoxy-8-trifluoroacetamido-dibenzo[b,d]furan-l-
carboxamide
N-(3,5-dichloropyrid-4-yl) - 4-methoxy-8-amino-dibenzo[b,d]furan-l-carboxamide (100 mg, 0.249 mmol) (intermediate 1) was treated with trifluoroacteic anhydride (57 mg, 0.27 mmol) in dichloromethane (5 ml) containing pyridine (19 mg, 0.25 mmol) at room temperature. The reaction was stirred at room temperature for 20 h. Dichloromethane was evaporated and the residue was triturated with cold water to obtain a white solid which was filtered . The solid was purified by silica gel column chromatography using 6 % acetone-chloroform as eluent to obtain 30 mg of N-(3,5-dichloropyrid-4-yl) - 4-methoxy-8-trifluoroacetamido-dibenzo[b,d]furan-l-carboxamide as white solid; mp: >300°C.

62
IR (KBr): 3281, 1717, 1668, 1608, 1500, 1394, 1290, 1203, 1154, 1099, 1024, 901, 809, 653 cm"1
'H NMR (300 MHz, DMSO) 5 4.09 (s, 3H), 7.38 (d, 1H, J= 9 Hz), 7.80 (d, 1H), 7.89 (d, 1H, J= 1.8 Hz), 7.98 (d, 1H, J= 8.4 Hz), 8.67 (s, 1H, J= 1.8 Hz), 8.76 (s, 2H), 10.77 (s, 1H), 11.42 (s, 1H).
Example 15
N-(3,5-dichloropyrid-4-yl)-4-methoxy-8-ethoxycarboxamido-dibenzo[b,d]furan-l-
carboxamide
N-(3,5-dichloropyrid-4-yl) - 4-methoxy-8-amino-dibenzo[b,d]furan-l-carboxamide (100 mg, 0.249 mmol) (intermediate 1) was treated with ethyl chloroformate (40 mg, 0.374 mmol) in THF (10 ml) containing pyridine (29 mg, 0.374 mmol) at OoC and allowed to warm to room temperature. The reaction was stirred at room temperature for 30 min. THF was evaporated and the residue was washed with water. The solid obtained was purified by silica gel column chromatography using 10 % acetone-chloroform as eluent to obtain 40 mg of N-(3,5-dichloropyrid-4-yl) - 4-methoxy-8-ethoxycarboxamido-dibenzo[b,d]furan-l-carboxamide as white solid; mp: 274°C.
IR(KBr): 3244, 3074, 2970, 2928, 1733, 1674, 1600, 1578, 1550, 1479, 1391, 1278, 1236, 1210,1102,1062,803 cm"1.
'HNMR (300 MHz, DMSO) 5 1.24 (t, 3H), 4.07 (s, 3H), 4.08 (q, 2H), 7.32 (d, 1H, J= 8.1 Hz), 7.60-7.67 (d, 2H), 7.88 (d, 1H, J= 8.1 Hz), 8.45 (s, 1H), 8.76 (s, 2H), 9.62 (s, 1H), 10. 76 (s, 1H).
Example 16 and 17 were synthesized using reaction conditions similar to Example 15 except for using the appropriately substituted chloroformate instead of ethyl chloroformate.
Example 16
N-(3,5-dichloropyrid-4-yl)-4-methoxy-8-isobutyloxycarboxamido-dibenzo[b,d]furan-l-
carboxamide

63
1HNMR(300MHz,DMSO-d6) 5: 0.91 (d, J= 6.6 Hz, 6H), 1.84-1.96 (m, 1H), 3.84 (d, J = 6.9 Hz, 2H), 4.08 (s, 3H), 7.34 (d,J= 8.4 Hz, 1H), 7.67 (s, 2H), 7.92 (d, J= 8.7 Hz, 1H), 8.48 (s, 1H), 8.79 (s, 1H), 9.69 (s, 2H), 10.78 (s, 1H) IR (KBr): (cm"1) 3318, 3175, 2960, 1688, 1293, 1102
Example 17
N-(3,5-dichloropyrid-4-yl)-4-methoxy-8-phenoxycarboxamido-dibenzo[b,d]furan-l-
carboxamide
*H NMR (300 MHz, DMSO-d6) 5 4.09 (s,3H), 8 7.12 (d,lH, J = 8.4 Hz), 8 7.23-7.47 (m,5H), 8 7.73 (d,lH, J = 9.0 Hz), 8 7.80 (d,lH, J = 8.7Hz), 8 8.02 (d,lH, J = 8.7 Hz), 8 8.31 (d,lH, J = 6.4 Hz), 8 8.97 (s,2H), 810.45 (s, 1H).
IR (KBr) 3358, 2918, 1777, 1750, 1610, 1560, 1493, 1391, 1284, 1235, 1192, 1003,803, 619, cm-1
Example 18
N-(3,5-dichloropyrid-4-yl)-4-methoxy-8-cyclopropylmethoxycarboxamido-
dibenzo[b,d]furan-l-carboxamide
A solution of cyclopropyl methanol (70 mg, 0.273 mmol) in THF (3 ml) was cooled to -30oC. To this solution was added triethylamine (37 mg, 0.374 mmol) and stirred for 10 min. A solution of triphosgene (73 mg, 0.249 mmol) in THF (3 ml) was added at -30oC to the above solution and stirred for 30 min at room temperature. This solution was then added to a suspension of N-(3,5-dichloropyrid-4-yl) - 4-methoxy-8-amino-dibenzo[b,d]furan-l-carboxamide (100 mg, 0.249 mmol) (intermediate 1) and triethylamine (37 mg, 0.374 mmol) in THF (5 ml). The reaction was stirred at room temperature for 30 min. THF was evaporated and the residue was washed with water. The solid obtained was purified by silica gel column chromatography using 10 % acetone-chloroform as eluent to obtain 15 mg of N-(3,5-dichloropyrid-4-yl)-4-methoxy-8-cyclopropylmethoxycarboxamido-dibenzo[b,d]furan-1-carboxamide as white solid; mp: 272°C.
*H NMR (300 MHz, DMSO-d6) 8 0.29(q, 2H, J= 6.0 Hz), 8 0.52 (q, 2H, J= 6.3Hz), 8 1.14 (m, 1H),8 3.88 (d, 2H, J= 7.2 Hz), 8 4.06 (s, 3H), 8 7.32(d,lH, J= 8.1Hz), 8 7.60 (d,lH, J =

64
8.4 Hz), 5 7.66 (d,lH, J= 8.7 Hz), 5 7.90 (ds,lH, J = 8.1Hz), 5 8.48 (d,lH, J = 2.4), 5 8.76 (s,2H), 8 9.69 (s,lH), 5 10.75 (s,lH).
IR(KBr) 2960, 2735, 1672, 1596, 1473, 1461, 1323, 1271, 1180, 1113, 1089, 1001,945, 817, 767, cm"1
Example 19
N-(3,5-dichloropyrid-4-yl)-4-methoxy-8-trifluoromethylmethoxycarboxamido-
dibenzo[b,d]furan-l-carboxamide
Was synthesized using reaction conditions similar to Example 17 except for using the 2,2,2-
trifluoroethanol instead of cyclopropylmethanol.mp: >250°C.
*H NMR (300 MHz, DMSO-d6) 5 4.07 (s, 3H), 4.77 (q, 2H, J = 9.0 Hz), 7.35 (d,lH, J =
8.4 Hz), 7.63 (d,lH, J = 9.3 Hz), 7.72 (d,lH, J = 9.0 Hz ), 7.93 (d, 1H, J = 8.4 Hz), 8.52
(s,lH), 8.76 (s,2H), 10.18 (brs,lH), 10.76 (s,lH).
IR(KBr) 3342, 2921, 1670,1640, 1547, 1482,1389,1284,1256, 1184, 954, 810, 758, cm1
Example 20
N-(3,5-dichloropyrid-4-yl)-4-methoxy-8-N,N-diethylaminocarboxamido-
dibenzo[b,d]furan-l-carboxamide
Step 1. N-(3,5-dichloropyrid-4-yl)-4-methoxy-8-phenoxycarboxamido-dibenzo [b,d] furan-1-carboxamide
N-(3,5-dichloropyrid-4-yl) - 4-methoxy-8-amino-dibenzo[b,d]furan-l-carboxamide (400 mg, 0.99 mmol) (intermediate 1) was treated with phenyl chloroformate (190 mg, 1.09 mmol) in THF (15 ml) containing pyridine (0.5 ml) at 0°C and allowed to warm to room temperature. The reaction was stirred at room temperature for 12 h. THF was evaporated and the residue was washed with water and hot ethanol to obtain 400 mg of N-(3,5-dichloropyrid-4-yl) - 4-methoxy-8-phenoxycarboxamido-dibenzo[b,d]furan-1 -carboxamide as white solid which was used as such in the next step.
Step 2. N-(3,5-dichloropyrid-4-yl)-4-methoxy-8-N,N-diethylaminocarboxamido-dibenzo [b,d] furan-1 -carboxamide

65
N-(3,5 -dichloropyrid-4-yl)-4-methoxy-8-phenoxycarboxamido-dibenzo [b,d] furan-1 -carboxamide (from step 1) (100 mg, 0.19 mmol), was dissolved in DMSO (2.0 ml) and a solution of N,N-diethylamine (20 mg, 0.28 mmol) in DMSO (1.0 ml) was added slowly to the above solution. The reaction mixture was stirred at 50°C for 5 h, cooled to room temperature and diluted with ice water (25 ml). The solid that separated as a result was filtered , dried and purified by silica gel column chromatography using 10 % methanol in chloroform as eluent to obtain 45 mg of N-(3,5-dichloropyrid-4-yl)-4-methoxy-8-N,N-diethylaminocarboxamido-dibenzo[b,d]furan-1-carboxamide as white solid; mp: >250°C . lH NMR (300 MHz, DMSO-d6) 5 1.08 (t, 6H, J= 7.2 Hz), 5 3.25 (q, 4H, J= 5.1Hz), 8 4.06 (s, 3H), 6 7.31(d,lH, J= 8.4Hz), 5 7.59 (s, 2H), 6 7.90 (d,lH, J= 8.4 Hz), 8 8.32 (s,lH), 8 8.75 (s,2H), 8 10.74 (s,lH).
IR (KBr) 3357, 2932, 1673, 1631, 1552, 1474, 1396, 1285, 1198, 1101, 952, 805, 670, cm-1 Example 21, 22, 24, 25, 26, 27, 28 and 29 were synthesized using reaction conditions similar to step 2 of Example 21 except for using the appropriate primary or secondary amine instead of N, N-diethylamine.
Example 21
N-(3,5-dichloropyrid-4-yl)-4-methoxy-8-cyclopentylaminocarboxamido-
dibenzo [b,d] furan-1 -carboxamide
'HNMR (300 MHz, DMSO) 8 1.355 (m, 2H), 1.57 (m, 4H), 1.81(m, 2H) 3.94 (m, 1H),
4.07 (s, 3H), 6.03 (d, 1H), 7.34 (d, 1H), 7.63 (d, 1H), 7.96 (m, 2H), 8.11 (1H), 8.43 (s, 1H),
8.79 (s, 2H), 10.8 (s, 1H)
IR(KBr): 3311, 3142, 2957, 1658, 1633, 1564, 1491, 1477, 1295, 1223, 1198, 1101, 1025,
806 cm"1.
Mass: (M+H) =513.3
Example 22
N-(3,5-dichloropyrid-4-yl)-4-methoxy-8-(N-methylpiperazin-4-ylcarboxamido)-
dibenzo[b,d]furan-l-carboxamide

66
lH NMR (300 MHz, DMSO-d6) 8 2.23 (s, 3H), 2.50 (brm, 4H), 3.43 (brm, 4H), 4.08 (s, 3H), 7.34 (d, IH, J= 8.7 Hz), 7.63 (s, 2H), 7.95 (d,lH, J= 8.4 Hz), 8.35 (s, IH), 8.68 (s, IH), 8.78 (s, 2H), 10.77 (s, IH).
IR(KBr) 3358, 2919, 1667, 1635, 1556, 1593, 1479, 1397, 1285, 1241, 1106, 1002,802, 619, cm-1
Example 23
N-(3,5-dichloropyrid-4-yl)-4-methoxy-8-(N-methylpiperazin-4-yl carboxamido)-
dibenzo[b,d]furan-l-carboxamide hydrochloride
Was synthesized from N-(3,5-dichloropyrid-4-yl)-4-methoxy-8-(N-methylpiperazin-4-yl carboxamido-dibenzo[b,d]furan-l-carboxamide using methanolic HCl.mp: >250°C. *H NMR (300 MHz, DMSO-d6) 5 2.77 (d, 3H, ./ = 4.2 Hz), 3.02 (m, 2H), 3.24-3.43 (brm, 4H), 4.08 (s, 3H), 4.23 (m, 2H), 7.34 (d, IH, J= 8.7 Hz), 7.63 (s, 2H), 7.89 (d,lH, J= 8.4 Hz), 8.37 (s, IH), 9.03 (s, IH), 10.63 (s, 2H), 11.23 (s, IH).
Example 24
N-(3,5-dichloropyrid-4-yl)-4-methoxy-8-(4-hydroxypiperidin-l-yl carboxamido)-
dibenzo[b,d]furan-l-carboxamide
'H NMR (300 MHz, DMSO-d6) 5 1.30 (m, 2H), 1.73 (m, 2H), 3.02 (m, 2H), 3.64 (m, IH), 3.64 (m, 2H), 4.08 (s, 3H), 4.75 (brs, IH), 7.34 (d, IH, J= 8.7 Hz), 7.63 (s, 2H), 7.94 (d, IH, J=SAUz), 8.35 (s, IH), 8.64 (s,lH), 8.78 (s, 2H), 10.77 (s, IH). IR(KBr) 3349, 2912, 1662, 1636, 1561, 1596, 1480, 1391, 1285, 1244, 1113, 1005,811, 621 cm-1
Example 25
N-(3,5-dichloropyrid-4-yl)-4-methoxy-8-(morphol-4-ylcarboxamido)-
dibenzo[b,d]furan-l-carboxamide
'H NMR (300 MHz, DMSO-d6) 5 3.40 (t, 4H, J = 5.1 Hz), 5 3.58 (t,4H, J= 5.1Hz), 8 4.06 (s, 3H), 8 7.32 (d,lH, J= 8.4Hz), 8 7.61 (s, 2H), 8 7.93 (d, IH, J= 8.4 Hz), 8 8.33 (s,lH), 8 8.66 (s, IH), 8 8.75 (s, 2H), 8 10.75 (s, IH).

67
IR(KBr) 3345, 2911,2782, 1665, 1642, 1551, 1479, 1397, 1278, 1251, 1187, 1026,945, 810, 761, cm"1
Example 26
N-(3,5-dichloropyrid-4-yl)-4-methoxy-8-isopropylamino carboxamido-
dibenzo[b,d]furan-l-carboxamide
'H NMR (300 MHz, DMSO-d6) 8 1.08 (d, 3H, .7=6.6 Hz), 1.23 (m, IH), 1.31 (d, 2H,J =
6.6 Hz), 4.07 (s, 3H), 7.33 (d, IH, J = 8.7 Hz), 7.38 (d,lH, J= 7.8 Hz), 7.66 (d,lH, J = 9.3
Hz), 7.72 (dd,lH, J = 9.3 Hz and J = 2.1 Hz), 7.91 (d, IH, J = 8.4 Hz), 8.39 (d, IH, J = 2.1
Hz), 8.75 (s, 2H), 9.68 (s, IH), 10.77 (s, IH).
IR (KBr) 3354, 2927, 1668, 1638, 1552, 1491, 1396, 1280, 1251, 1196, 951, 802, 761, cm'l
Example 27
N-(3,5-dichloropyrid-4-yl)-4-methoxy-8-n-hexylamino carboxamido-
dibenzo [b,d] furan-1 -carboxamide
]H NMR (300 MHz, DMSO-d6) 5 0.85 (t, 3H), 1.23 (m, 8H), 3.1 (q, 2H), 4.06 (s, 3H), 5.96 (t, IH), 7.30 (d,lH, J= 8.7 Hz), 7.60 (d,lH, J = 9.0 Hz), 7.90 (m, 2H), 8.10 (s, IH), 8.53 (s, IH), 8.75 (s, 2H), 10.76 (s,lH). IR (KBr) 3360, 2938, 1667, 1634,1582,1478,1398, 1284,1241, 1196, 953, 803, 671, cm"1
Example 28
N-(3,5-dichloropyrid-4-yl)-4-methoxy-8-ethylamino carboxamido-dibenzo[b,d]furan-l-
carboxamide
'H NMR (300 MHz, DMSO-d6) 5: 1.03 (t, J = 7.2 Hz, 3H), 3.07-3.12 (q, 2H), 4.07 (s, 3H), 5.96 (t, J= 6 Hz, IH), 7.33 (d, J = 8.7 Hz, IH), 7.62 (d, J= 9 Hz, IH), 7.92 (dd, J= 3.3 Hz,
8.7 Hz, 2H), 8.14 (d, J= 2.1 Hz, IH), 8.59 (s, IH), 8.79 (s, IH), 10.81 (s, 2H)
IR(KBr): 3322,3146, 1657, 1637, 1294, 1101, cm"1
Example 29

68
N-(3,5-dichloropyrid-4-yl)-4-methoxy-8-methylamino carboxamido-dibenzo[b,d]furan-
1-carboxamide
!H NMR (300 MHz, DMSO-d6) 5: 2.63 (d, J = 4.8 Hz, 3H), 4.07 (s, 3H), 5.86-5.89 (m, 1H), 7.33 (d, J = 8.7 Hz, 1H), 7.62 (d, J = 9 Hz, 1H), 7.92 (d, J = 8.7 Hz, 2H), 8.16 (d, J = 1.8 Hz, 1H), 8.66 (s, 1H), 8.79 (s, 1H), 10.81 (s, 2H) IR (KBr): 3337, 3149, 1659, 1637, 1295, 1098, cm-1
Example 30
N-(3,5-dichloropyrid-4-yl)-4-difluoromethoxy-8-methanesulfonamido-
dibenzo[b,d]furan-l-carboxamide
N-(3,5-dichloropyrid-4-yl) - 4-difluoromethoxy-8-amino-dibenzo[b,d]furan-l-carboxamide (70 mg, 0.159 mmol) (intermediate 2) was treated with methanesulfonyl chloride (22 mg, 0.194 mol) in THF (10 ml) containing pyridine (0.5 ml) at 0°C and allowed to warm to room temperature. The reaction was stirred at room temperature for 2 h. THF was evaporated and the residue was washed with saturated sodium bicarbonate solution, water. The solid obtained was purified by silica gel column chromatography using 12 % acetone-chloroform as eluent to obtain 37 mg of N-(3,5-dichloropyrid-4-yl) - 4-difluoromethoxy-8-methanesulfonylamido-dibenzo[b,d]furan-l-carboxamide as white solid; mp: >250°C.
*H NMR (300 MHz, DMSO-d6) 5 2.95 (s, 3H), 7.5 (dd, 1H, J = 8.7 Hz and J = 2.4 Hz), 7.58 (t, lH,J=72Hz), 7.6 (d,lH, J= 8.4 Hz), 7.85 (d,lH, J= 9.3 Hz), 7.93 (d,lH,J= 8.1 Hz), 8.30 (d,lH, J= 2.4 Hz), 8.82 (s, 2H), 9.77 (s, 1H), 11.06 (s, 1H). IR(KBr) 3323, 2926, 1698, 1636, 1489, 1396, 1283, 1266, 1142, 1040, 812, 621, cm-1
Example 31
N-(3,5-dichloropyrid-4-yl)-4-difluoromethoxy-8-methanesulfonamido-dibenzo[b,d]furan-l-carboxamide sodium salt

69
Was synthesized from N-(3,5-dichloropyrid-4-yl)-4-difluoromethoxy-8-
methanesulfonamido-dibenzo[b,d]furan-l-carboxamide (Example 30) using 1 % methanolic
sodium hydroxide (1.0 eq.).
*H NMR (300 MHz, DMSO-d6) 8 2.95 (s, 3H), 7.26 (d, 2H, J= 8.7 Hz), 7.40 (t, IH, J= 72
Hz), 7.52 (d, IH, J= 8.4 Hz), 7.95 (d, IH, J = 9.3 Hz), 8.19 (s, 2H), 8.68 (brs, IH), 9.66
(brs, IH).
IR(KBr) 2920,1651,1524,1463,1391,1278,1194,1105,1005,882,815 cm'1
Example 32 and 33 were synthesized using reaction conditions similar to Example 30 except for using the appropriate substituted sulfonyl chloride instead of methane sulfonyl chloride.
Example 32
N-(3,5-dichIoropyrid-4-yl)-4-difluoromethoxy-8-ethanesuIfonamido-dibenzo[b,d]furan-
1-carboxamide
*H NMR (300 MHz, DMSO-d6) 5 1.19 (t, 3H, J= 7.2 Hz), 3.03 (q, 2H, J= 7.2 Hz), 7.49 (dd, IH, J= 8.7 Hz and J= 2.1 Hz), 7.58 (t, IH, J= 73 Hz), 7.81 (d, IH, J = 8.4 Hz), 7.93 (d, IH, J= 8.7 Hz), 8.29 (d, IH, J= 2.4 Hz) 8.82 (s, 2H), 9.85 (s, IH), 11.06 (s, IH). IR(KBr): 3264, 2988, 1672, 1590, 1562, 1472, 1256, 1192, 1134, 1028, 973, 733 cm-1
Example 33
N-(3,5-dichloropyrid-4-yl)-4-difluoromethoxy-8-N,N-dimethylaminosulfonamido-
dibenzo[b,d]furan-l-carboxamide
*H NMR (300 MHz, DMSO-d6) 5 2.7 (s, 6H), 7.49 (dd,lH, J = 8.7 Hz and J = 2.1 Hz), 7.57 (t, IH, J- 73 Hz), 7.59 (d, IH, J = 8.4 Hz), 7.81 (d, IH, J= 8.7 Hz), 7.92 (d, IH, J = 8.4 Hz), 8.28 (s, 2H), 9.93 (s, IH), 11.05(s, IH). IR(KBr) 3274, 3012, 1660, 1602, 1579, 1483, 1279, 1200, 1121, 1009, 823, 623 cm"1
Example 34

70
N-(3,5-dichloropyrid-4-yl)-4-difluoromethoxy-8-acetamido-dibenzo[b,d]furan-l-
carboxamide
N-(3,5-dichloropyrid-4-yl)-4-difluoromethoxy-8-amino-dibenzo[b,d]furan-l-carboxamide (70 mg, 0.159 mmol) (intermediate 2) was treated with acetyl chloride (22 mg, 0.299 mmol) in THF (10 ml) containing pyridine (0.5 ml) at 0°C and allowed to warm to room temperature. The reaction was stirred at room temperature for 2.0 h. THF was evaporated and the residue was washed with saturated sodium bicarbonate solution 5% HC1 and water. The solid obtained was purified by silica gel column chromatography using 10 % acetone-chloroform as eluent to obtain 25 mg of N-(3,5-dichloropyrid-4-yl) - 4-difluoromethoxy-8-acetamido-dibenzo[b,d]furan-l-carboxamide as white solid; mp: 234°C. 'H NMR (300 MHz, DMSO-d6) 8 2.15 (s, 3H), 7.4 (d, 1H, J = 8.4 Hz ), 7.53 (t, 1H, J= 73 Hz), 7.56 (d, 1H, J= 8.4 Hz), 7.77-7.86 (m, 3H), 8.36 (d,lH, J= 2.4 Hz), 8.81 (s, 2H), 10.25 (s, 1H).
IR (KBr) 3344, 2924, 1727, 1712, 1686, 1555, 1390, 1367, 1288, 1269, 1116, 1047, 822, 584 cm"1
Example 35, 36, 37, and 40 were synthesized using reaction conditions similar to Example 34 except for using the appropriate substituted acid chloride instead of acetyl chloride
Example 35
N-(3,5-dichloropyrid-4-yl)-4-difluoromethoxy-8-(l-chloropropylcarboxamido)-
dibenzo[b,d]furan-l-carboxamide
'H NMR (300 MHz, DMSO-d6) 5 2.12 (m, 2H), 2.61 (t, 2H, J = 7.2 Hz ), 3.75 (t, 2H, J = 6.9 Hz ), 7.61 (d, 1H, J= 7.8 Hz), 7.63 (t, 1H, J =13 Hz), 7.79 (d, 1H, J = 8.7 Hz), 8.07 (d, 1H, J = 8.4 Hz), 8.18 (dd, 1H, J = 9.3 Hz and J = 2.4 Hz), 8.65 (d, 1H, J = 2.2 Hz) 8.82 (s, 2H), 10.35 (s, 1H).
IR (KBr) 3281, 3156, 2987, 1664, 1650, 1526, 1496, 1381, 1284, 1217, 1146, 1110,814, 677 cm"1.
Example 36

71
N-(3,5-dichloropyrid-4-yl)-4-difluoromethoxy-8-cyclopropylcarboxamido-dibenzo [b,d] furan-1 -carboxamide
'H NMR (300 MHz, DMSO-d6) 5 0.78 (m, 2H), 1.23 (m, 2H), 1.80 (m, IH), 7.60 (d, IH, J = 8.4 Hz ), 7.58 (t, IH, 7= 73 Hz), 7.76 (d, IH, J= 8.4 Hz), 7.94 (d, IH, J= 8.4 Hz), 8.02 (d, IH, J= 8.4 Hz), 8.44 (s, IH), 8.81 (s, 2H), 10.40 (s, IH), 11.02 (s, IH).
IR (KBr) 3289, 3143, 1660, 1650,1528, 1494, 1400,1279, 1195, 1150, 1106, 1056,819 cm"
l
Example 37
N-(3,5-dichloropyrid-4-yl)-4-difluoromethoxy-8-ethoxycarbonyIcarboxamido-
dibenzo[b,d]furan-l-carboxamide
*H NMR (300 MHz, DMSO-d6) 5 1.33 (t, 3H), 4..32 (q, 2H), 7.57 (t, IH, J= 72 Hz), 7.62 (d, IH, J = 8.7 Hz) , 7.84 (d, IH, J= 8.7 Hz), 7.86-7.96 (m, 2H) , 8.69 (d, IH, J= 1.8 Hz) 8.81 (s,2H,) 11.04 (s,2H).
IR(KBr) 3206, 3107, 2987, 1759, 1702, 1669, 1548, 1499, 1384, 1296, 1279, 1222, 1191, 1118,1055,810 cm"1.
Example 38
N-(3,5-dichloropyrid-4-yl)-4-difluoromethoxy-8-hydroxycarbonyIcarboxamido-
dibenzo[b,d]furan-l-carboxamide
Was synthesized by hydrolysis of N-(3,5-dichloropyrid-4-yl)-4-difluoromethoxy-8-ethoxycarbonylcarboxamido-dibenzo[b,d] furan-1-carboxamide (Example 37) using potassium hydroxide (3 eq.) in methanol.
*H NMR (300 MHz, DMSO-d6) 8 7.58 (t, IH, J= 72 Hz), 7.62 (d, IH, J= 8.4 Hz), 7.86 (d, IH, J= 8.7 Hz), 7.91-7.96 (m, 2H) , 8.76 (d, IH, J= 1.8 Hz) 8.81 (s, 2H,) 10.97 (s, IH), 11.04(s, IH).

72
Example 39
N-(3,5-dichloropyrid-4-yl)-4-difluoromethoxy-8-hydroxycarbonylcarboxamido-dibenzo[b,d]furan-l-carboxamide disodium salt
Was synthesized from N-(3,5-dichloropyrid-4-yl)-4-difluoromethoxy-8-hydroxycarbonylcarboxamido-dibenzo[b,d]furan-l-carboxamide (Example 38) using ethanolic sodium ethoxide (2.0 eq.).
*H nmr (300 MHz, DMSO-d6) 5 7.30 (d, 1H, J= 8.7 Hz) ,7.42 (t, 1H, J= 72 Hz), 7.65 (d, 1H, J= 8.7 Hz), 7.98 (d, 1H, J= 8.7 Hz), 8.06 (dd, 1H, J= 9.0 and 1.8 Hz) 8.21 (s, 2H) 9.08 (d, 1H, J= 2.4 Hz), 10.08 (s, 1H).
Example 40
N-(3,5-dichloropyrid-4-yl)-4-difluoromethoxy-8-fur-2-ylcarboxamido-
dibenzo[b,d]furan-l-carboxamide
lH NMR (300 MHz, DMSO-d6) 5 6.68 (d, 1H, J= 3.3 Hz), 7.35 (d, 1H, J = 3.3 Hz), 7.59 (t, 1H, J = 72 Hz), 7.62 (d, 1H, J= 8.4 Hz), 7.82 (d, 1H, J= 9.0Hz), 7.93-7.99 (m, 3H,), 8.66 (s, 1H, J= 1.8 Hz), 8.81 (s, 2H,). 10.44 (s, 1H), 11.04 (s, 1H)
IR (KBr) 3288, 3031, 1651, 1586, 1556, 1518, 1498, 1386, 1281, 1193, 1117, 1046, 809, 750 cm"1.
Example 41
Nl-phenyl-4-methoxy-8-acetamido-dibenzo[b,d]furan-l-carboxamide
Step 1: Nl -phenyl-4-methoxy-8-nitro-dibenzo [b,d] furan-1-carboxamide
4-methoxy-8-nitro dibenzo[b,d]furan-l-carboxylic acid chloride (200 mg, 0.696 mmol) (from step 5a of intermediate 1) was reacted with aniline (2.0 eq.) in THF (10 ml) in the presence of diisopropylethylamine (3 eq.) at room temperature for 16 h. The yellow suspension was filtered and the solid obtained was washed with 5 % HCl and water to

73
obtain 110 mg of Nl-phenyl-4-methoxy-8-nitro-dibenzo[b,d]furan-l-carboxamide as white
solid.
'HNMR (300 MHz, DMSO-d6) 5 4.15 (s, 3H), 7.18 (t, 1H), 7.43 (m, 3H),7.80 (d, 2H), 7.95
(d, 1H), 8.01 (d, 1H), 8.45 (d, 1H), 9.40 (s,lH), 10.60 (s, 1H).
Step 2: Nl-phenyl-4-methoxy-8-amino-dibenzo[b,d]furan-l-carboxamide
Nl-phenyl-4-methoxy-8-nitro-dibenzo[b,d]furan-l-carboxamide (100 mg) (from stepl) was reduced using raney nickel (100 mg) in methanol (40 ml) and DMF (10 ml) in the presence of hydrazine hydrate (0.5 ml) under gentle reflux for lh. The reaction mixture was fliterd through celite and the filterate was concentrated in vaccuo. The residue was triturated with water, to obtain a solid which was filtered dried to give the product as white solid (90 mg).
'H NMR (300 MHz, DMSO-d6) 5 4.15 (s, 3H), 5.03 (brs, 2H), 6.80 (d, 1H), 7.08 (t, 1H), 7.11 (d, 1H), 7.40 (m, 4H),7.60 (d, 1H), 7.93 (d, 2H), 10.43 (s, 1H).
Step 3: Nl-phenyl-4-methoxy-8-acetamido-dibenzo[b,d]furan-l-carboxamide
Nl-phenyl-4-methoxy-8-amino-dibenzo[b,d]furan-l-carboxamide (69 mg, 0.207 mmol) (step 2) was treated with acetyl chloride (1.1 eq.) in THF (10 ml) containing pyridine (1.1 eq ) at 0°C and allowed to warm to room temperature. The reaction was stirred at room temperature for 2 h. THF was evaporated and the residue was washed ethanol to obtain 40 mg of Nl-phenyl-4-methoxy-8-acetamido-dibenzo[b,d]furan-l-carboxamide as white solid; mp: 252°C.
IR (KBr): 3316, 3237, 2937, 1650, 1531, 1596, 1507, 1472, 1439, 1292, 1195, 187, 1100, 809,753 cm-1.
'H NMR (300 MHz, DMSO) 8 2.03 (s, 3H), 4.05 (s, 3H), 7.14 (t, 1H), 7.28 (d, 1H), 7.39 (t, 2H), 7.66- 7.74 (m, 2H), 7.82 (d, 2H), 7.91 (dd, 1H, J = 9.0 and 2.7 Hz), 8.37 (d, 1H, J = 2.4 Hz), 10. 10 (s, 1H), 10.50 (s, 1H).
Example 42
Nl-(4-methoxyphenyl)-4-methoxy-8-acetamido-dibenzo[b,d]furan-l-carboxamide

74
Step 1: Nl-(4-methoxyphenyl)-4-methoxy-8-nitro-dibenzo[b,d]furan-l-carboxamide
4-methoxy-8-nitro dibenzo[b,d] furan-1-carboxylic acid chloride (200 mg, 0.696 mmol) (from step 5a of intermediate 1) was reacted with 4-methoxy aniline (2.0 eq.) in THF (10 ml) in the presence of diisopropylethylamine (3 eq.) at room temperature for 16 h. The yellow suspension was filtered and the solid obtained was washed with 5 % HCl and water to obtain 153 mg of Nl-(4-methoxyphenyl)-4-methoxy-8-nitro-dibenzo[b,d]furan-l-carboxamide as white solid.
*H NMR (300 MHz, DMSO-d6) 5 3.90 (s, 3H), 4.15 (s, 3H), 6.99 (d, 2H), 7.42 (d, 1H), 7.77 (d, 2H), 7.96 (d, 1H), 8.02 (d, 1H), 8.43 (d, 1H), 9.40 (s,lH), 10.60 (s, 1H).
Step 2: Nl-(4-methoxyphenyl)-4-methoxy-8-amino-dibenzo[b,d]furan-l-carboxamide
N1 -(4-methoxyphenyl)-4-methoxy-8-nitro-dibenzo[b,d] furan-1 -carboxamide (140 mg) (from stepl) was reduced using raney nickel (100 mg) in methanol (40 ml) and DMF (10 ml) in the presence of hydrazine hydrate (1.0 ml) under gentle reflux for lh. The reaction mixture was fliterd through celite and the filterate was concentrated in vaccuo. The residue was triturated with water, to obtain a solid which was filtered dried to give the product as white solid (90 mg).
lK NMR (300 MHz, DMSO-d6) 5 3.88 (s, 3H), 4.05 (s, 3H), 5.03 (brs, 2H), 6.90 (d, 1H), 7.01 (d, 2H), 7.20 (d, 1H), 7.40 (m, 2H),7.60 (d, 1H), 7.88 (d, 2H), 10.43 (s, 1H).
Step 3: l-(4-methoxyphenyl)-4-methoxy-8-acetamido-dibenzo[b,d]furan-l-carboxamide
N1 -(4-methoxyphenyl)-4-methoxy-8-amino-dibenzo [b,d]furan-1 -carboxamide (90 mg, 0.248 mmol) (step 2) was treated with acetyl chloride (1.1 eq.) in THF (10 ml) containing pyridine (1.1 eq ) at 0°C and allowed to warm to room temperature. The reaction was stirred at room temperature for 16 h. THF was evaporated and the residue was washed ethanol to obtain 40 mg of Nl-4-methoxyphenyl)-4-methoxy-8-acetamido-dibenzo[b,d]furan-1-carboxamide as white solid; mp: 285°C
'H NMR (300 MHz, DMSO-d6) 5 2.03 (s, 3H), 3.77 (s, 3H), 4.05 (s, 3H), 6.96 (d, 2H), 7.27 (d, 1H), 7.65-7.74 (m, 4H), 7.91 (dd, 1H, J = 9.0 and 2.7 Hz), 8.37 (d, 1H, J = 2.4 Hz), 10. 10(s,lH), 10.36 (s,lH).

75
IR(KBr) 3256, 2938, 2839, 1645, 1599, 1531, 1514, 1469, 1412, 1291, 1195, 1178, 1099, 1023,825,812 cm4.
Example 43
Nl-benzyl-4-methoxy-8-acetamido-dibenzo[b,d]furan-l-carboxamide
Step 1: Nl-benzyl-4-methoxy-8-nitro-dibenzo[b,d]furan-l-carboxamide
4-methoxy-8-nitro dibenzo[b,d]furan-l-carboxylic acid chloride (200 mg, 0.696 mmol) (from step 5a of intermediate 1) was reacted with benzylamine (2.0 eq.) in THF (10 ml) in the presence of diisopropylethylamine (3.0 eq.) at room temperature for 16 h. The suspension was filtered and the solid obtained was washed with 5 % HC1 and water to obtain 170 mg of Nl-benzyl-4-methoxy-8-nitro-dibenzo[b,d]furan-l-carboxamide as white solid.
*H NMR (300 MHz, DMSO-d6) 5 4.08 (s, 3H), 4.62 (d, 2H), 7.15 (d, 1H), 7.18-7.23 (m, 5H), 7.84 (d, 1H), 8.01 (d, 1H), 8.42 (dd, J= 8.4 and 2.4 Hz), 9.14 (bit, 1H), 9.58 (d, 1H, J= 2.4 Hz)
Step 2: Nl-benzyl-4-methoxy-8-amino-dibenzo[b,d]furan-l-carboxamide
Nl-benzyl-4-methoxy-8-nitro-dibenzo[b,d]furan-l-carboxamide (125 mg, 0.33 mmol) (from stepl) and iron powder (56 mg, 1.0 mmol) was suspended in 50% aqueous ethanol (10 ml) and reflux for 10 min. To this was added a solution of concentrated HC1 (7 ul in 5 ml 50% aqueous ethanol) and refluxed for 4 h. The reaction mixture was filtered hot through celite and the filterate was basified with 15 % ethanolic KOH, filtered and the filterate was concentrated in vaccuo. The residue was triturated with water, to obtain a solid which was filtered dried to give the product as white solid (90 mg) mp: 228°C. *H NMR (300 MHz, DMSO-d6) 8 3.99 (s, 3H), 4.57 (d, 2H), 4.97 (brs, 2H), 6.80 (dd, 1H), 7.12 (d, 1H), 7.29 (d, 1H), 7.34-7.42 (m, 5H),7.51-7.59 (m, 2H), 9.01 (t, 1H).
Step 3: Nl-benzyl-4-methoxy-8-acetamido-dibenzo[b,d]furan-l-carboxamide
Nl-benzyl-4-methoxy-8-amino-dibenzo[b,d]furan-l-carboxamide (80 mg, 0.23 mmol) (step 2) was treated with acetyl chloride (1.1 eq.) in THF (10 ml) containing pyridine

76
(1.0 eq ) at 0°C and allowed to warm to room temperature. The reaction was stirred at room
temperature for 2 h. The reaction mixture was filterd and the filterarte was concentrated.
The residue was triturated with ethanol to obtain 63 mg of Nl-benzyl-4-methoxy-8-
acetamido-dibenzo[b,d]furan-l-carboxamide as white solid; mp: 264-265°C
!H NMR (300 MHz, DMSO-d6) 5 2.07 (s, 3H), 4.03 (s, 3H), 4.58 (d, 2H), 7.21-7.27 (m,
2H), 7.33-7.43 (m, 4H), 7.64 (d, 2H), 7.87 (dd, 1H, J= 8.7 and 2.7 Hz), 8.54 (d, 1H, J= 2.7
Hz), 9.09 (t, 1H), 10. 14 (s, 1H).
IR (KBr) 3313, 3261, 3035, 2925, 2844, 1660, 1637, 1626, 1530, 1506, 1287, 1227, 1192,
1103,1025,810,741,696 cm-1.
Example 44
N-(3,5-dichloropyrid-4-yl)-4-methoxy-8-(ethylaminothiocarboxamido)-
dibenzo [b,d] furan-1-carboxamide
N-(3,5-dichloropyrid-4-yl) - 4-methoxy-8-amino-dibenzo[b,d]furan-l-carboxamide (100 mg, 0.249 mmol) (intermediate 1) was suspended in THF (2 ml) followed by addition of pyridine (29 mg, 0.37 mmol) at room temperature. Reaction mixture was stirred for 10 min. followed addition of solution ethyl isothiocyanate (32 mg, 0.374 mmol) in THF (2 ml). The reaction mixture was stirred at room temperature for 3-4 days. THF was evaporated and the residue was stirred in water (5 ml). After filteration, the solid obtained was purified by silica gel column chromatography using 15 % acetone-chloroform as eluent to obtain 40 mg of N-(3,5-dichloropyrid-4-yl)-4-methoxy-8-(ethylaminothiocarboxamido)-dibenzo[b,d]furan-l-carboxamide as white solid; mp: 260°C
*H NMR (300 MHz, DMSO-d6) 5 1.29 (t, 3H), 3.24 (q, 2H), 4.14 (s, 3H), 7.34 (d, 1H, J = 8.4 Hz), 7.59 (m, 3H), 7.70 (d, 1H, J= 8.1Hz), 7.89 (d, 1H, J = 8.1 Hz), 8.32 (s, 1H), 8.76 (s, 2H), 9.45 (s, 1H), 10.79 (s, 1H).
IR(KBr) 3434, 3200, 3049, 2928, 1656, 1606, 1553, 1493, 1394, 1286, 1257, 1099, 803 cm"1
Example 45
N-(3,5-dichloropyrid-4-yl)-4-methoxy-8-(n-butylaminothiocarboxamido)-
dibenzo[b,d]furan-l-carboxamide

77
'H NMR (300 MHz, DMSO-d6) ) 5 0.92 (t, 3H), 1.24 (m, 2H), 1.54 (m, 2H), 3.34 (m, 2H) 4.14 (s, 3H), 7.34 (d, 1H, J = 8.4 Hz), 7.65 (m, 2H), 7.91(d, 1H, J= 8.1Hz), 8.24 (s, 1H), 8.32 (s, 1H), 8.75 (s, 2H), 9.44 (s, 1H), 10.75 (s, 1H). IR(KBr)3195, 2928, 1658,1606, 1549, 1480, 1393, 1283, 1257, 1194, 1100,1021,807cm-'
Example 46
Nl-(pyrid-3-yl)-4-methoxy-8-acetamido-dibenzo[b,d]furan-l-carboxamide
Step 1: Nl -(pyrid-3-yl)-4-methoxy-8-nitro-dibenzo [b,d] furan-1-carboxamide
4-methoxy-8-nitro dibenzo[b,d]furan-l-carboxylic acid chloride (600 mg, 1.92 mmol) (from step 5a of intermediate 1) was reacted with 3-aminopyridine (1.1 eq.) in THF (20 ml) in the presence of diisopropylethylamine (0.5 ml) at room temperature for 12 h. The suspension was filtered and the solid obtained was washed with 5 % HC1 and water to obtain 500 mg of Nl-(pyrid-3-yl)-4-methoxy-8-nitro-dibenzo[b,d]furan-l-carboxamide as white solid.
'H NMR (300 MHz, DMSO-d6) 8 4.15 (s, 3H), 7.44 (m, 2H), 8.00 (m, 2H), 8.26 (d, 1H, J = 7.5 Hz), 8.35 (d, 1H, J = 4.5 Hz), 8.46 (dd, 1H, J = 9.0, 2.7 Hz), 8.95 (s, 1H), 9.37 (d, 1H, J = 2.7 Hz), 10.77 (s, 1H).
Step 2: Nl-(pyrid-3-yl)-4-methoxy-8-amino-dibenzo[b,d]furan-l-carboxamide
N1 -(pyrid-3 -yl)-4-methoxy-8-nitro-dibenzo[b,d]furan-1 -carboxamide (500 mg) (from stepl) was reduced using raney nickel (150 mg) (30 %w/w aqueous suspension) in methanol (10 ml) in the presence of hydrazine hydrate (0.32 ml) under gentle reflux for 4 h. The reaction mixture was flitered through celite and the filterate was concentrated in vaccuo. The residue was triturated with water, to obtain a solid which was filtered dried to give the product as white solid (300 mg).
Step 3: Nl-(pyrid-3-yl)-4-methoxy-8-acetamido-dibenzo[b,d]furan-l-carboxamide
N1 -(pyrid-3 -yl)-4-methoxy-8-amino-dibenzo[b,d]furan-1 -carboxamide (100 mg, 0.30 mmol) (step 2) was treated with acetyl chloride (1.1 eq.) in THF (10 ml) containing pyridine (1.1 eq ) at 0°C and allowed to warm to room temperature. The reaction was stirred at room temperature for lh. THF was evaporated and the residue was purified by silica gel

78
column chromatography using 25 % acetone-chloroform as eluent to obtain 6 mg of Nl-(pyrid-3-yl )-4-methoxy-8-acetamido-dibenzo[b,d]furan-l-carboxamide as white solid; mp: >250°C
]H NMR (300 MHz, DMSO-d6) 5: 2.04 (s, 3H), 4.07 (s, 3H), 7.31 (d, 1H, J= 8.1 Hz), 7.43-7.47 (dd, 1H J= 8.2, 4.8 Hz), 7.68 (d, 1H, J= 8.7 Hz), 7.78 (d, 1H, J= 8.4 Hz), 7.90 (dd, ,1H, J= 2.4 Hz, 9 Hz), 8.22-8.25 (d, 1H), 8.35 (d, 1H, J= 3.9 Hz), 8.41 (d, 1H, J = 2.4 Hz), 8.98 (s, 1H), 10.10 (s, 1H), 10.71 (s, 1H) IR(KBr): (cm"1) 3271, 2922, 1646, 1289, 1102, 803.
Example 47
N-(3,5-dichloropyrid-4-yl)-4-methoxy-8-acetamido-dibenzo[b,d]furan-l-carboxamide-
N-oxide
N-(3,5-dichloropyrid-4-yl)-4-methoxy-8-acetamido-dibenzo[b,d]furan-l-carboxamide (0.215 gm, 0.49 mole) (Example 4) was suspended in dichloromethane. To this reaction mixture was added 0.507 gm (2.9 mmoles) of meta-chloroperbenzoic acid (50%) and reaction mixture was refluxed for 3 hours and stirred at room temp, for 12 hours. Dichloromethane was removed under vaccum and the crude compound was purified through silica gel column to obtain 0.066 gm (30 %) of the N-oxide.
'H NMR (300 MHz, DMSO-d6) 8: 2.01 (s, 3H), 4.06 (s, 3H), 7.33 (d, 1H), 7.67 (d, 1H), 7.90 (m, 2H), 8.43 (d, 1H), 8.75 (s, 2H), 10.07 (s, 1H), 10.61 (s, 1H) IR(KBr): 3308, 3118,2926,2853, 1656, 1606, 1542, 1489, 1285, 1102, 828, cm-1 Mass: (M+H) = 460.1
Example 48
N-(3,5-dichloropyrid-4-yl)-4-methoxy-8-methanesulfonamido-dibenzo[b,d]furan-l-
carboxamide-N-oxide
Was synthesized by using reaction conditions similar to those for the preparation of Example 47 except for starting with N-(3,5-dichloropyrid-4-yl)-4-methoxy-8-methanesulfonamido-dibenzo[b,d]furan-l-carboxamide (0.2 gm, 4 mmoles) (Example 1) instead of N-(3,5-dichloropyrid-4-yl)-4-methoxy-8-acetamido-dibenzo[b,d]furan-1 -carboxamide (Example 4).

79
Yield = 0.04 gm (19%).
!H NMR (300 MHz, DMSO-d6) 6: 2.93 (s, 3H), 4.082 (s, 3H), 7.373 (d, 1H),7.44 (d, 1H),7.77 (d, 1H), 7.91 (d, 1H), 8.34 (s, 1H), 8.77 (s, 2H), 9.7 (s, 1H), 10.67 (s, 1H) IR(KBr) :-526, 3304, 2926, 2851, 1654, 1606, 1484, 1279, 1235, 1150, 1103, 987, 828 cm-1 Mass: - (M+H) =496.1
Example 49
N-(pyrid-4-yl)-4-methoxy-8-acetamido-dibenzo[b,d]furan-l-carboxamide
A solution of-(3,5-dichloropyrid-4-yl)-4-methoxy-8-acetamido-dibenzo[b,d]furan-1-carboxamide (60 mg) (Example 4) and 25-28%) aqueous ammonium hydroxide (3 ml) in THF (35 ml) was hydrogenated at 50 psi using 10%) Pd/C (60 mg) for 24 h at room temperature. The reaction was filtered through celite and the filtrate was concentrated. The residue was dissolved in DCM, washed with water and brine, dried over anhydrous sodium sulfate and concentrated. The residue was purified by silica gel column chromatography using 2-10 % methanol in DCM as eluent to obtain 21 mg (42 %>) of N-(pyrid-4-yl)-4-methoxy-8-acetamido-dibenzo[b,d]furan-l-carboxamide as white solid, mp: 267-268°C *H NMR (300 MHz, DMSO-d6) 8: 2.04 (s, 3H), 4.07 (s, 3H), 7.30 (d, 2H, J = 8.7 Hz), 7.68 (d, 1H, J = 8.7 Hz), 7.78 (d, 1H, J = 8.4 Hz), 7.82 (d, 2H, J = 6.6 Hz), 7.88 (dd, 1H, J = 1.8 & 8.7 Hz), 8.40 (d, 1H, J = 1.8 Hz), 8.52 (d, 2H, J = 6.0 Hz), 10.11 (s, 1H), 10. 88 (s, 1H). IR (KBr): 3243, 3140, 2976, 2931, 2844, 1696, 1669,, 1633, 1599, 1579, 1509, 1473, 1385, 1330, 1285, 1269, 1202, 1102, 827, 808 cm-1
Example 50
N-(3,5-dichloropyrid-4-yl)-4-methoxy-8-(2-ethoxy-2-oxo-ethylaminocarbonylamino)-
dibenzo [b,d ] fu ran-1 -carboxamide
N-(3,5-dichloropyrid-4-yl)-4-methoxy-8-phenoxycarboxamido-dibenzo[b,d]furan-l-carboxamide (Example 17) (100 mg, 0.19 mmol), was dissolved in DMSO (2.0 ml) and a solution of glycine ethyl ester hydrochloride (26 mg, 0.19 mmol) and triethylamine (1.0 ml) in DMSO (2.0 ml) was added slowly to the above solution. The reaction mixture was stirred at 50°C for 5 h, cooled to room temperature and diluted with ice water (25 ml) and acidified

80
with 5 % hydrochloric acid. The solid that separated as a result was filtered , dried and purified by silica gel column chromatography using 5 % methanol in chloroform as eluent to obtain 30 mg of N-(3,5-dichloropyrid-4-yl)-4-methoxy-8-(2-ethoxy-2-oxo-ethylaminocarbonylamino)-dibenzo[b,d]furan-l-carboxamide as white solid; mp: >250°C
'H NMR (300 MHz, DMSO-d6) -5: 1.19 (t, 3H), 3.87 (d, 2H), 4.08-4..14 (m, 5H), 6.33 (t, 1H), 7.35 (d, 1H, J= 8.7 Hz), 7.65 (d, 1H, J = 9.3 Hz), 7.90-7.94 (m, 2H), 8.19 (d, 1H, J = 2.1 Hz), 8.79 (s, 2H), 8.98 (s, 1H), 10.80 (s, 1H)
IR(KBr) 3339, 3148,2959, 1763, 1659, 1640, 1579, 1489, 1392, 1292, 1199, 1159, 1100, 1022,910,806 cm"1
Example 51
N-(3,5-dichloropyrid-4-yl)-4-methoxy-8-(2-hydroxy-2-oxo-ethylaminocarbonylamino)-
dibenzo[b,d]furan-l-carboxamide
N-(3,5-dichloropyrid-4-yl)-4-methoxy-8-(2-ethoxy-2-oxo-ethylamino carbonylamino)-dibenzo[b,d]furan-l-carboxamide (Example 51 ) (150 mg, 0.28 mmol) was hydrolysed using potassium hydroxide (2 eq.) in 3 ml water and 3 ml methanol for 30 min. at room temperature. The solid precipitated was filtered and washed with methanol to obtain the product as white solid (50 mg).mp: >250°C
'H NMR (300 MHz, DMSO-d6)-5: 3.80 (d, 2H), 4.08 (s, 3H), 6.28 (t, 1H), 7.33 (d, 1H, J = 8.7 Hz), 7.64 (d, 1H, J= 9.3 Hz), 7.93 (m, 2H), 8.18 (d, 1H, J = 2.1 Hz), 8.79 (s, 2H), 8.97 (s, 1H), 10.80 (s, 1H), 12.5 (brs, 1H).
IR(KBr) 3322, 3138,2936, 1740, 1657, 1638, 1567, 1522, 1394, 1293, 1218, 1198, 1098, 1024, 910, 886, 806, 721 cm"1
Example 52
N-(3,5-dichloropyrid-4-yl)-4-methoxy-8-(2-ethoxy-2-oxo-ethylamino)-
dibenzo[b,d]furan-l-carboxamide
N-(3,5-dichloropyrid-4-yl)-4-methoxy-8-amino dibenzo[b,d]furan-l-carboxamide (500 mg, 1.24 mmol) was suspended in ethanol and a 50 % solution of ethyl glyoxalate in toluene (384 mg, 3.72 mmol) was added to the suspension. The reaction mixture was

81
hydrogenated at 40 psi in presence of pre-activated raney nickel (50 %w/w) for 24 h-48 h. The reaction was filtered and the filterate was concentrated in vacuo. The residue was purified by silica gel (100-200) column chromatography using 0.5 % methanol in dichloromethane to obtain the compound as a pale yellow solid (180 mg). mp: >270°C
*H NMR (300 MHz, DMSO-d6) 5: 1.06 (t, 3H), 3.85 (d, 2H), 4.01-4.05 (m, 5H), 6.09 (t, 1H), 6.88(dd, 1H, J= 8.7 and 3.0 Hz), 7.26 (d, 1H, J= 8.7 Hz), 7.43-7.55 (m, 2H), 7.81 (d, 1H, J= 8.7 Hz), 8.79 (s, 2H), 10.75 (s, 1H) IR (KBr): 3405, 3182, 2985, 1741, 1663, 1610, 1487, 1285, 1198, 1096, 1023, 807 cm-1
Example 53
N-(3,5-dichloropyrid-4-yl)-4-methoxy-8-(2-hydroxy-2-oxo-ethylamino)-
dibenzo[b,d]furan-l-carboxamide
N-(3,5-dichloropyrid-4-yl)-4-methoxy-8-(2-ethoxy-2-oxo-ethylamino)-dibenzo[b,d]furan-l-carboxamide (Example 52 ) (100 mg, 0.204 mmol) was hydrolysed using potassium hydroxide (5 eq.) in 3 ml water and 3 ml methanol for 12h at room temperature. The solid precitated was filted and washed with ethanol to obtain the product as pale yellow solid (50 mg). mp: >260°C
*H NMR (300 MHz, DMSO-d6) 5: 3.77 (s, 2H), 4.05 (s, 3H), 6.88 (dd, 1H, J= 9.0 and 2.1 Hz), 7.26 (d, 1H, J= 9.0 Hz), 7.47-7.50 (m, 2H), 7.81 (d, 1H, J= 8.4 Hz), 8.79 (s, 2H), 10.77 (s, 1H) IR (KBr) 3416, 3177,2936, 1726, 1662, 1609, 1487, 1398, 1285, 1196, 1095,802 cm"1.
Example-54
N-(3,5-dichloropyrid-4-yl)-l-methoxy-9-methyl-6-acetamido-9//-4-
carbazolecarboxamide
N-(3,5-dichloropyrid-4-yl)-l-methoxy-9-methyl-6-amino-P//-4-carbazolecarboxamide (75 mg, 0.00018 mol) was suspended in THF (5 ml) and added with pyridine (28 mg, 0.00036 mol) and stirred at room temperature for 10 minutes. The solution obtained, was added with a solution of acetyl chloride in dry THF (5 ml).The reaction mixture was stirred for 1 hr.THF was evaporated and the solid was washed with water to get crude solid which was

82
column chromatographed using 10 % methanol in chloroform to give N-3,5-dichloropyrid-4-yl)-l-methoxy-9-methyl-6-acetamido-P//-4-carbazolecarboxamide(20 mg),mp>250°C. IR(KBr): 3292, 3171,2935,2838, 1658, 1575, 1547, 1483, 1397, 1283, 1260, 1234, 1106, 808 cm'1.
lH NMR (300 MHz, DMSO): 5 2.01 (s, 3H), 4.04 (s, 3H), 4.15 (s, 3H), 7.15 (d, 1H, J= 8.4 Hz), 7.51 (d, 1H, J= 8.7 Hz), 7.62 (d, 1H, J= 8.1 Hz), 7.85 (dd, 1H, J= 9.0 and 2.4 Hz), 8.31 (d, 1H, J = 2.1 Hz), 8.78 (s, 2H), 9.89 (s, 1H ), 10.67 (s, 1H).
Example-55
N-(3,5-dichloropyrid-4-yl)-l-methoxy-9-methyl-6-methanesulphonamido-9Jff-4-
carbazolecarboxamide
N-(3,5-dichloropyrid-4-yl)-1 -methoxy-9-methyl-6-amino-9//-4-carbazolecarboxamide (75 mg, 0.00018 mol) was suspended in THF (5 ml) and added with pyridine (28 mg, 0.00036 mol) and stirred at room temperature for 10 minutes. The solution obtained, was added with a solution of methane sulphonyl chloride (30 mg, 0.00027 mol) in dry THF (5 ml).The reaction mixture was stirred for 1 hr .THF was evaporated and the solid was washed with water to get crude solid which was column chromatographed using 10 % methanol in chloroform to give N-3,5-dichloropyrid-4-yl)-l-methoxy-9-methyl-6-methanesulphon-amido-9//-4-carbazolecarboxamide(20 mg) ,mp>2 5 0 °C.
IR (KBr): 3268, 3138, 2962, 2935, 1655, 1573, 1547, 1483, 1400, 1311, 1257, 1235, 1144, 938, 804 cm"1.
!H NMR (300 MHz, DMSO): 6 2.50 (s, 3H), 4.05 (s, 3H), 4.17 (s, 3H), 7.18 (d, 1H, J= 8.4 Hz), 7.40 (dd, 1H, J= 9.0 and 2.1 Hz), 7.41-7.64 (m, 2H), 8.30 (d, 1H, J = 2.4 Hz), 8.79 (s, 2H),9.41(s,lH), 10.71 (s,lH).
Example-56
N-(3,5-dichloropyrid-4-yl)-l-methoxy-9-methyI-6-ethanesuIphonamido-9fir-4-
carbazolecarboxamide
N-(3,5-dichloropyrid-4-yl)-l-methoxy-9-methyl-6-amino-P//-4-carbazolecarboxamide
(75 mg, 0.00018 mol) was suspended in THF (5 ml) and added with pyridine (28 mg,
0.00036 mol) and stirred at room temperature for 10 minutes. The solution obtained, was

83
added with a solution of ethane sulphonyl chloride (34 mg, 0.00027mol) in dry THF (5 ml).The reaction mixture was stirred for 1 hr .THF was evaporated and the solid was washed with water to get crude solid which was column chromatographed using 10 % methanol in chloroform to give N-3,5-dichloropyrid-4-yl)-l-methoxy-9-methyl-6-ethane sulphonamido-9//-4-carbazolecarboxamide (20 mg), mp>250°C.
IR(KBr): 3270,3140,2935, 1677,1574, 1481, 1325,1256,1144, 1108,949,732 cm-1. 'H NMR (300 MHz, DMSO): 8 1.24 (t, 3H), 2.95 (q, 2H), 4.05 (s, 3H), 4.17 (s, 3H), 7.16 (d, 1H, J= 8.4 Hz), 7.40 (dd, 1H, J= 9.0 and 2.1 Hz), 7.58-7.63 (m, 2H), 8.29 (d, 1H, J = 2.4 Hz), 8.79 (s, 2H), 9.49 (s, 1H), 10.70 (s, 1H).
Example-57
N-(3,5-dichloropyrid-4-yl)-l-methoxy-9-methyl-6-propionamido-9//-4-
carbazolecarboxamide
N-(3,5-dichloropyrid-4-yl)-1 -methoxy-9-methyl-6-amino-9//-4-carbazolecarboxamide
(75 mg, 0.00018 mol) was suspended in THF (5 ml) and added with pyridine (28 mg,
0.00036 mol) and stirred at room temperature for 10 minutes. The solution obtained, was
added with a solution of propionyl chloride (24 mg, 0.00027) in dry THF (5 ml).The
reaction mixture was stirred for 1 hr .THF was evaporated and the solid was washed with
water to get crude solid which was column chromatographed using 10 % methanol in
chloroform to give N-3,5-dichloropyrid-4-yl)-l-methoxy-9-methyl-6-propionamido-P//-4-
carbazolecarboxamide(20mg),mp>250°C.
IR(KBr): 3282, 3138, 2966, 2938, 1656, 1645, 1481, 1397, 1313, 1283, 1260, 1232, 1106,
1087, 802 cm"1.
'H NMR (300 MHz, DMSO): 5 1.15 (t, 3H), 2.15 (q, 2H), 4.04 (s, 3H), 4.14 (s, 3H), 7.15
(d, 1H, J= 8.4 Hz), 7.52 (d, 1H, J= 8.7 Hz), 7.62 (d, 1H, J= 8.1 Hz), 7.88 (dd, 1H, J= 9.0
and 2.4 Hz), 8.33 (d, 1H, J = 2.1 Hz), 8.77 (s, 2H), 9.82 (s, 1H ), 10.66 (s, 1H).
Example-58
N-(3,5-dichloropyrid-4-yl)-4-difluoromethoxy-8-methanesulfonamido-
dibenzo[b,d]furan-l-carboxamide disodium salt

84
Was synthesized from N-(3,5-dichloropyrid-4-yl)-4-difluoromethoxy-8-
methanesulfonamido-dibenzo[b,d]furan-l-carboxamide (Example 30) using ethanolic
sodium ethoxide
'H NMR (300 MHz, DMSO-d6) 5 2.53 (s, 3H), 7.06 (dd, 1H, J= 8.7 & 2.1 Hz), 7.14 (d,
1H, J= 8.4 Hz), 7.29 (d, 1H, J= 8.7 Hz), 7.37 (t, 1H, J= 72 Hz), 7.85 (d, 1H, J= 8.4 Hz),
8.18 (s, 2H), 8.22 (d, 1H, J= 2.4 Hz),
IR (KBr) 2929,1524,1462,1395,1275,1197,1105,1005,890,814 cm"1
Example-59
N-(3,5-dichloropyrid-4-yl)-l-methoxy-6-acetamido-dibenzo[b,d]thiophene-4-
carboxamide
Step 1: 3-nitro-4-(2-methoxy thiophenoxy)-acetophenone
To a stirred suspension of potassium fluoride (2.48 gm, 0.04286 mol) in dry DMSO (10 ml) was added a solution of 2-methoxy thiophenol (5 gm, 0.0357 mol) in DMSO (10 ml). A solution of 4-fluoro 3-nitro acetophenone (7.88 gm, 0.04286 mol) in DMSO (10 ml) was added to the above suspension and the reaction mixture was stirred at 70-80°C under nitrogen for 4 h. The reaction mixture was cooled to room temperature and the contents were poured into water (150 ml) and stirred for 15 minutes. The pale yellow coloured solid appeared was then filtered & washed with saturated sodium bicarbonate solution followed by water & dried under vaccum. The compound was obtained as pale yellow solid (8.1 gm) mp:-136-138°C.
IR (KBr): 3374, 3095, 3054, 2920, 1958, 1831, 1694, 1611, 1538, 1351, 1262, 1104,978, 853, 814, 724 cm'1.
*H NMR (300 MHz, DMSO): 8 2.59 (s, 3H), 3.75 (s, 3H), 6.86 (d, 1 H, J= 8.7 Hz), 7.11 (t, 1H, J= 7.8 Hz), 7.26 (d, 1H, J= 8.4 Hz), 7.65 (m, 2H), 8.05 (d, 1H, J= 8.7 Hz), 8.68 (s, 1H). Step 2: 3-amino-4-(2-methoxy thiophenoxy)-acetophenone
To the solution of 3-nitro-4-(2-methoxy thiophenoxy)-acetophenone (8 gm, 0.02631 mol) in methanol, raney nickel (50%) was added. Then 4-5 kg/cm2 hydrogen pressure was

85
applied for 7 hrs at room temperature. The reaction mixture was filtered through cilites to
remove raney nickel. Filtrate was concentrated. Thick oil obtained (5.12) was used in the
next step.
IR (KBr): 2958, 2922, 2852, 1682, 1557, 1465, 1420, 1261, 1092, 1021, 803, 757 cm'1.
lH NMR (300 MHz, DMSO): 8 2.50 (s, 3H), 3.85 (s, 3H), 5.55 (s, 2 H) 6.65 (d, 1H, J= 7.8
Hz), 6.84 (t, 1H ,J=7.2), 7.03 (d, 1H, J= 8.4 Hz), 7.19 (m, 2H), 7.29 (d, 1H, J =7.8), 8.37(
s,lH).
Step 3: l-methoxy-6-acetyl dibenzo[£,,278.2
38 1.41 26.95
39 0.5981 9.19
40 22.04 11.33
41 156 -
42 959 -
43 17.93% at 1 uM -
44 1.719 3.93
45 0.7732 6.37
46 133.9 -
47 2.437 28.83
48 1.674 11.89
49 13.2 -
50 9.93 146.9
51 1.98 121.8
52 8.13 821
53 1.05 71.45
54 236.9 -
59 126.9 -

92
A compound of general formula (I)
Claims:

P—R1
(1)
wherein:
R1, R2 and R3 are independently selected for each occurrence from the groups consisting of hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstitued alkynyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted cycloalkylakyl, substituted or unsubstituted cycloalkenyl, substituted or unsubstituted aryl, substituted or unsubstituted arylalkyl, substituted or unsubstituted heteroaryl, substituted or unsubstituted heterocyclic group, substituted or unsubstituted heterocyclylalkyl, substituted or unsubstituted heteroarylalkyl , nitro, -OH, cyano, formyl, acetyl, halogen, protecting groups, -C(0)-Ra, -C(0)0-Ra, -C(0)NRaRa, -S(0)q-Ra, -S(0)q-NRaRa, -NRaRa, ,-ORa, -SRa or when two R3 substitutents ortho to each other, may be joined to a form a saturated or unsaturated 3-7 membered ring, which optionally include up to two heteroatoms selected from O, NRa or S;
R is -NR R ; wherein R and R are independently selected for each occurrence from the groups consisting of hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstitued alkynyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted cycloalkylakyl, substituted or unsubstituted

93
cycloalkenyl, substituted or unsubstituted aryl, substituted or unsubstituted arylalkyl, substituted or unsubstituted heteroaryl, substituted or unsubstituted heterocyclic ring, substituted or unsubstituted heterocyclylalkyl, substituted or unsubstituted heteroarylalkyl , nitro, -OH, cyano, halogen, -C(0)-Ra, -C(0)0-Ra, -C(0)NRaRa, -S(0)q-Ra, -S(0)q-NRaRa, -C(=NRa)-Ra, -C(=NRa)-NRaRa, -C(=S)-NRaRa , -C(=S)-Ra, -N=C(RaRa), -NRaRa, -ORa, -SRa, protecting groups or R5 and R6 to each other are joined to a form a saturated or unsaturated cyclic ring, which optionally include up to two heteroatoms selected from O, NRa or S;
Ar is selected from the group consisting of substituted or unsubstituted aryl, substituted or unsubstituted arylalkyl, substituted or unsubstituted heterocyclic ring and substituted and unsubstituted heteroaryl ring;
X is selected from the group consisting of O, S(0)q and NRa;
Y is selected from the group consisting of -C(0)NR7, -NR7S(0)q, -S(0)qNR7 and -
NR7C(0);
R7 is selected from the group consisting of hydrogen, substituted or unsubstituted alkyl,
hydroxyl, -ORa, substituted or unsubstituted aryl, and substituted or unsubstituted
heterocyclic ring;
wherein P is chosen from the group consisting of O and S;
wherein m represents 0-3;
wherein n represents 1 - 4;
wherein q represents 0,1 or 2;
with the proviso that R4 is not NH2
wherein Ra is selected from the group consisting of hydrogen, substituted or unsubstituted
alkyl, substituted or unsubstituted alkenyl, substituted or unsubstitued alkynyl, substituted
or unsubstituted cycloalkyl, substituted or unsubstituted cycloalkylakyl, substituted or
unsubstituted cycloalkenyl, substituted or unsubstituted aryl, substituted or unsubstituted
arylalkyl, substituted or unsubstituted heteroaryl, substituted or unsubstituted heterocyclic
ring, substituted or unsubstituted heterocyclylalkyl , substituted or unsubstituted

94
heteroarylalkyl, nitro, -OH, cyano, formyl, acetyl, halogen, protecting groups, -C(0)-Ra, -C(0)0-Ra, -C(0)NRaRa, -S(0)q-Ra, -S(0)q-NRaRa, -NRaRa, -0Ra or -SRa; and their analogs, their tautomers, their regioisomers, their stereoisomers, their enantiomers, their diastereomers, their polymorphs, their pharmaceutically acceptable salts, their N-oxides their pharmaceutical compositions containing them or a pharmaceutical acceptable salts thereof with the proviso that following structure is not included.
OCHF2
2. The compound as claimed in claim 1, wherein Ar is optionally substituted
phenyl, optionally substituted benzyl, optionally substituted pyrimidine, optionally
substituted pyridyl selected from 4-pyridyl, 3-pyridyl and 2-pyridyl or optionally substituted
pyridyl-N-oxide selected from 4-pyridyl-N-oxide, 3-pyridyl-N-oxide and 2-pyridyl-N-oxide
in which optional substituents (one or more) may be same or different and are independently
selected from the groups consisting of hydrogen, hydroxyl, halogen, cyano, nitro, carboxyl,
trifluoroalkyl, substituted or unsubstituted alkyl, substituted or unsubstituted alkoxy,
substituted or unsubstituted alkoxycarbonyl, substituted or unsubstituted alkylcarbonyl,
substituted or unsubstituted alkylcarbonyloxy, substituted or unsubstituted amino or mono
or di substituted or unsubstituted alkylamino
3. A compound as claimed in claim 1 or 2 , wherein the substituents in the
'substituted alkyl', 'substituted alkoxy' 'substituted alkenyl 'substituted alkynyl'
'substituted cycloalkyl' 'substituted cycloalkylalkyl' 'substituted cyclocalkenyl 'substituted
arylalkyl' 'substituted aryl 'substituted heterocyclic ring', 'substituted heteroaryl ring,'
'substituted heteroarylalkyl', 'substituted heterocyclylalkyl ring', 'substituted amino',
'substituted alkoxycarbonyl', 'substituted cyclic ring' 'substituted alkylcarbonyl',
'substituted alkylcarbonyloxy' and may be the same or different which one or more
selected from the group consisting of hydrogen, hydroxy, halogen, carboxyl, cyano, nitro,
oxo (=0), thio(=S), substituted or unsubstituted alkyl, substituted or unsubstituted alkoxy,

95
substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted aryl, substituted or unsubstituted arylalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted cycloalkenyl, substituted or unsubstituted amino, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, 'substituted heterocyclylalkyl ring' substituted or unsubstituted heteroarylalkyl, substituted or unsubstituted heterocyclic ring, substituted or unsubstiuted guanidine, -COORx, -C(0)Rx, -C(S)RX, -C(0)NRxRy, -C(0)ONRxRy, -NRxCONRyRz, -N(Rx)SORy, -N(Rx)S02Ry, -(=N-N(Rx)Ry), - NRxC(0)ORy, -NRxRy, -NRxC(0)Ry-, -NRxC(S)Ry -NRxC(S)NRyRz, -SONRxRy-, -S02NRxRy-, -ORx, -ORxC(0)NRyRz, -ORxC(0)ORy-, -OC(0)Rx, -OC(0)NRxRy, - RxNRyC(0)Rz, -RxORy, -RxC(0)ORy, -RxC(0)NRyRz, -RxC(0)Rx, -RxOC(0)Ry, -SRX, -SORx, -S02Rx, -ON02, wherein Rx, Ry and RZ in each of the above groups is selected from hydrogen atom, substituted or unsubstituted alkyl, substituted or unsubstituted alkoxy, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted aryl, substituted or unsubstituted arylalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted cycloalkenyl, substituted or unsubstituted amino, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, 'substituted heterocyclylalkyl ring' substituted or unsubstituted heteroarylalkyl, substituted or unsubstituted heterocyclic ring.
4. The compound as claimed in any preceding claim , wherein R1 is substituted or unsubstituted alkyl
5. The compound as claimed in claim 4, wherein R1 is methyl or CHF2.

6. The compound as claimed in any preceding claim , wherein P is O.
7. The compound as claimed in any preceding claim, wherein X is chosen from the group consisting of O, S and N-CH3.
8. The compound as claimed in any preceding claim wherein Y is -C (O)NH
9. The compound as claimed in any preceding claim, wherein Ar is selected from the group consisting of substituted or unsubstituted 4-pyridyl; substituted or unsubstituted 4-pyridyl-N-oxide; substituted or unsubstituted 3-pyridyl.
10. The compound as claimed in claim 9, wherein said substituent is halogen, such as Chloro

96

11. The compound as claimed in claim 9, wherein Ar is selected from the group consisting of

VN/V^
o-
12. The compound as claimed in claim 11, wherein Ar is

13. The compound as claimed in any preceding claim , wherein m=0, n=l and R is selected from the group consisting of

97
0 0 0 H H
Hl1 H II / H II / , N / N ^ ^
ii r ii \ r ii * S ' I
ooo o o



H H 1/ H ? I H 9 . H ? "\N.^ ^^^.p»^OK ''"

o
o
ft
JUA ^ H CF3 ^
h< • ' * ■ ' °
T • ^Nwi . r"T
o // \J o
o

pBY°Y^i kV^ pSY°"CF3 KBYNN
o ^ ■ o ' o o

OH H ' °
HJ^. H rf « rr"" >.%-*

H H H H H H H H
■ vNr • s V^^ , i-V^ fvN-
o * o o ' o
o
H H
H H H

s s
o
J^N^^0/^ and j^y O
OH O
H If J^BvX—„- ^M-^
14. The compound as claimed in claim 13, wherein m=0, n=l and R4 is selected from e group consisting of

98
O O
H 9 U ^ , H " < M UM^^\ H II /
* n J II os o
H H ?~A HA H r^N^
pN^ , l^yK> , piyA and H l|
0 0 O * Q
15. A compound as claimed in claim 1, is selected from
N-(3,5-dichloropyrid-4-yl)-4-methoxy-8-methanesulfonamido-dibenzo[b,d]furan-l-carboxamide or a pharmaceutically acceptable salt thereof;
N-(3,5-dichloropyrid-4-yl)-4-methoxy-8-(N,N-dimethylsulphonamido)-dibenzo[b,d]furan-l-carboxamide or a pharmaceutically acceptable salt thereof;
N-(3,5-dichloropyrid-4-yl)-4-methoxy-8-(ethanesulphonamido)-dibenzo[b,d]furan-1-carboxamide or a pharmaceutically acceptable salt thereof;
N-(3,5-dichloropyrid-4-yl)-4-methoxy-8-acetamido-dibenzo[b,d]furan-l-carboxamide or a pharmaceutically acceptable salt thereof;
N-(3,5-dichloropyrid-4-yl)-4-methoxy-8-(3-chloropropylcarboxamido)-dibenzo[b,d]furan-l-carboxamide or a pharmaceutically acceptable salt thereof;
N-(3,5-dichloropyrid-4-yl)-4-methoxy-8-ethylcarboxamido-dibenzo[b,d]furan-l-carboxamide;
N-(3,5-dichloropyrid-4-yl)-4-methoxy-8-t-butylcarboxamido-dibenzo[b,d]furan-l-carboxamide or a pharmaceutically acceptable salt thereof;
N-(3,5-dichloropyrid-4-yl)-4-methoxy-8-ethoxycarbonylcarboxamido-dibenzo[b,d]furan-l-carboxamide or a pharmaceutically acceptable salt thereof;
N-(3,5-dichloropyrid-4-yl)-4-methoxy-8-hydroxycarbonylcarboxamido-dibenzo[b,d]furan-1 -carboxamide or a pharmaceutically acceptable salt thereof;
N-(3,5-dichloropyrid-4-yl)-4-methoxy-8-hydroxycarbonylcarboxamido-dibenzo[b,d]furan-l-carboxamide sodium salt;
N-(3,5-dichloropyrid-4-yl)-4-methoxy-8-(fur-2-yl-carboxamido)-dibenzo[b,d]furan-1-carboxamide or a pharmaceutically acceptable salt thereof;

99
N-(3,5-dichloropyrid-4-yl)-4-methoxy-8-(cyclopropylcarbonylamino)-dibenzo[b,d]furan-l-carboxamide or a pharmaceutical^ acceptable salt thereof;
N-(3,5-dichloropyrid-4-yl)-4-methoxy-8-(N,N-dicyclopropylcarbonylamino)-dibenzo[b,d]furan-l-carboxamide or a pharmaceutically acceptable salt thereof;
N-(3,5-dichloropyrid-4-yl)-4-methoxy-8-trifluoroacetamido-dibenzo[b,d]furan-l-carboxamide or a pharmaceutically acceptable salt thereof;
N-(3,5-dichloropyrid-4-yl)-4-methoxy-8-ethoxycarboxamido-dibenzo[b,d]furan-l-carboxamide or a pharmaceutically acceptable salt thereof;
N-(3,5-dichloropyrid-4-yl)-4-methoxy-8-isobutyloxycarboxamido-dibenzo[b,d]furan-l-carboxamide or a pharmaceutically acceptable salt thereof;
N-(3,5-dichloropyrid-4-yl)-4-methoxy-8-phenoxycarboxamido-dibenzo[b,d]furan-l-carboxamide or a pharmaceutically acceptable salt thereof;
N-(3,5-dichloropyrid-4-yl)-4-methoxy-8-cyclopropylmethoxycarboxamido-dibenzo[b,d]furan-l-carboxamide or a pharmaceutically acceptable salt thereof;
N-(3,5-dichloropyrid-4-yl)-4-methoxy-8-trifluoromethylmethoxycarboxamido-dibenzo[b,d]furan-l-carboxamide or a pharmaceutically acceptable salt thereof;
N-(3,5-dichloropyrid-4-yl)-4-methoxy-8-N,N-diethylaminocarboxamido-dibenzo[b,d]furan-l-carboxamide or a pharmaceutically acceptable salt thereof;
N-(3,5-dichloropyrid-4-yl)-4-methoxy-8-cyclopentylaminocarboxamido-dibenzo[b,d]furan-l-carboxamide or a pharmaceutically acceptable salt thereof;
N-(3,5-dichloropyrid-4-yl)-4-methoxy-8-(N-methylpiperazin-4-yl carboxamido)-dibenzo[b,d]furan-l-carboxamide or a pharmaceutically acceptable salt thereof;
N-(3,5-dichloropyrid-4-yl)-4-methoxy-8-(N-methylpiperazin-4-ylcarboxamido)-dibenzo[b,d]furan-1 -carboxamide hydrochloride;
N-(3,5-dichloropyrid-4-yl)-4-methoxy-8-(4-hydroxypiperidin-1 -yl carboxamido)-dibenzo[b,d]furan-l-carboxamide or a pharmaceutically acceptable salt thereof;
N-(3,5-dichloropyrid-4-yl)-4-methoxy-8-(morphol-4-yl carboxamido)-dibenzo[b,d]furan-l-carboxamide or a pharmaceutically acceptable salt thereof;
N-(3,5-dichloropyrid-4-yl)-4-methoxy-8-isopropylamino carboxamido-dibenzo[b,d]furan-l-carboxamide or a pharmaceutically acceptable salt thereof;

100
N-(3,5-dichloropyrid-4-yl)-4-methoxy-8-n-hexylamino carboxamido-dibenzo[b,d]furan-l-carboxamide or a pharmaceutically acceptable salt thereof;
N-(3,5-dichloropyrid-4-yl)-4-methoxy-8-ethylamino carboxamido-dibenzo[b,d]furan-l-carboxamide or a pharmaceutically acceptable salt thereof;
N-(3,5-dichloropyrid-4-yl)-4-methoxy-8-methylaminocarboxamido-dibenzo[b,d]furan-l-carboxamide or a pharmaceutically acceptable salt thereof;
N-(3,5-dichloropyrid-4-yl)-4-difluoromethoxy-8-methanesulfonamido-dibenzo[b,d]furan-l-carboxamide or a pharmaceutically acceptable salt thereof;
N-(3,5-dichloropyrid-4-yl)-4-difluoromethoxy-8-methanesulfonamido-dibenzo[b,d]furan-l-carboxamide sodium salt;
N-(3,5-dichloropyrid-4-yl)-4-difluoromethoxy-8-ethanesulfonamido-dibenzo[b,d]furan-l-carboxamide or a pharmaceutically acceptable salt thereof;
N-(3,5-dichloropyrid-4-yl)-4-difluoromethoxy-8-N,N-dimethylaminosulfonamido-dibenzo[b,d]furan-l-carboxamide or a pharmaceutically acceptable salt thereof;
N-(3,5-dichloropyrid-4-yl)-4-difluoromethoxy-8-acetamido-dibenzo[b,d]furan-l-carboxamide or a pharmaceutically acceptable salt thereof;
l,N-(3,5-dichloropyrid-4-yl)-4-difluoromethoxy-8-(l-chloropropylcarboxamido)-dibenzo[b,d]furan-l-carboxamide or a pharmaceutically acceptable salt thereof;
N-(3,5-dichloropyrid-4-yl)-4-difluoromethoxy-8-cyclopropylcarboxamido-dibenzo[b,d]furan-l-carboxamide or a pharmaceutically acceptable salt thereof;
N-(3,5-dichloropyrid-4-yl)-4-difluoromethoxy-8-ethoxycarbonylcarboxamido-dibenzo[b,d]furan-l-carboxamide or a pharmaceutically acceptable salt thereof;
l,N-(3,5-dichloropyrid-4-yl)-4-difluoromethoxy-8-hydroxycarbonylcarboxamido-dibenzo[b,d]furan-l-carboxamide or a pharmaceutically acceptable salt thereof;
N-(3,5-dichloropyrid-4-yl)-4-difluoromethoxy-8-hydroxycarbonylcarboxamido-dibenzo[b,d]furan-l-carboxamide di sodium salt;
N-(3,5-dichloropyrid-4-yl)-4-difluoromethoxy-8-fur-2-ylcarboxamido-dibenzo[b,d]furan-l-carboxamide or a pharmaceutically acceptable salt thereof;
Nl-phenyl-4-methoxy-8-acetamido-dibenzo[b,d]furan-l-carboxamideor a pharmaceutically acceptable salt thereof;

101
Nl-(4-methoxyphenyl)-4-methoxy-8-acetamido-dibenzo[b,d]furan-l-carboxamide or a pharmaceutically acceptable salt thereof;
Nl-benzyl-4-methoxy-8-acetamido-dibenzo[b,d]furan-l-carboxamide or a pharmaceutically acceptable salt thereof;
N-(3,5-dichloropyrid-4-yl)-4-methoxy-8-(ethylaminothiocarboxamido)-dibenzo[b,d]furan-l-carboxamide or a pharmaceutically acceptable salt thereof;
N-(3,5-dichloropyrid-4-yl)-4-methoxy-8-(n-butylaminothiocarboxamido)-dibenzo[b,d]furan-l-carboxamide or a pharmaceutically acceptable salt thereof;
Nl-(pyrid-3-yl)-4-methoxy-8-acetamido-dibenzo[b,d]furan-l-carboxamide or a pharmaceutically acceptable salt thereof;
N-(3,5-dichloropyrid-4-yl)-4-methoxy-8-acetamido-dibenzo[b,d]furan-l-carboxamide-N-oxide or a pharmaceutically acceptable salt thereof;
N-(3,5-dichloropyrid-4-yl)-4-methoxy-8-methanesulfonamido-dibenzo[b,d]furan-l-carboxamide-N-oxide or a pharmaceutically acceptable salt thereof;
N-(pyrid-4-yl)-4-methoxy-8-acetamido-dibenzo[b,d]furan-1 -carboxamide or a pharmaceutically acceptable salt thereof;
N-(3,5-dichloropyrid-4-yl)-4-methoxy-8-(2-ethoxy-2-oxo-ethylaminocarbonylamino)-dibenzo[b,d]furan-l -carboxamide or a pharmaceutically acceptable salt thereof;
N-(3,5-dichloropyrid-4-yl)-4-methoxy-8-(2-hydroxy-2-oxo-ethylaminocarbonylamino)-dibenzo[b,d]furan-l-carboxamide or a pharmaceutically acceptable salt thereof;
N-(3,5-dichloropyrid-4-yl)-4-methoxy-8-(2-ethoxy-2-oxo-ethylamino)-dibenzo[b,d]furan-l-carboxamide or a pharmaceutically acceptable salt thereof;
N-(3,5-dichloropyrid-4-yl)-4-methoxy-8-(2-hydroxy-2-oxo-ethylamino)-dibenzo[b,d]furan-l-carboxamide or a pharmaceutically acceptable salt thereof;
N-(3,5-dichloropyrid-4-yl)-l-methoxy-9-methyl-6-acetamido-9//-4-carbazole carboxamide or a pharmaceutically acceptable salt thereof;
N-(3,5-dichloropyrid-4-yl)-l-methoxy-9-methyl -6-methanesulphonamido -9H-4-carbazole carboxamide or a pharmaceutically acceptable salt thereof;

102
N-(3,5-dichloropyrid-4-yl)-l-methoxy-9-methyl-6-ethanesulphonamido-P//-4-carbazolecarboxamide or a pharmaceutically acceptable salt thereof;
N-(3,5-dichloropyrid-4-yl)-l-methoxy-9-methyl-6-propionamido-P//-4-carbazole carboxamide or a pharmaceutically acceptable salt thereof;
N-(3,5-dichloropyrid-4-yl)-4-difluoromethoxy-8-methanesulfonamido-dibenzo [b,d]furan-l-carboxamide disodium salt;
N-(3,5-dichloropyrid-4-yl)-l-methoxy-6-acetamido-dibenzo[b,d]thiophene -4-carboxamide or a pharmaceutically acceptable salt thereof;
N-(3,5-dichloropyrid-4-y l)-4-difluoromethoxy-8-acetamido-dibenzo [b,d] furan-1 -carboxamide sodium salt or
N-(3,5-dichloropyrid-4-yl)-4-difluoromethoxy-8-fur-2-ylcarboxamido-dibenzo[b,d]furan-l-carboxamide sodium salt;
16. A method for the preparation of compounds of general formula (1)

wherein:
R1, R2 and R3 are independently selected from the groups consisting of hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstitued alkynyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted cycloalkylakyl, substituted or unsubstituted cycloalkenyl, substituted or unsubstituted aryl, substituted or unsubstituted arylalkyl, substituted or unsubstituted heteroaryl, substituted or unsubstituted heterocyclic group, substituted or unsubstituted heterocyclylalkyl, substituted or unsubstituted heteroarylalkyl , nitro, -OH, cyano, formyl, acetyl, halogen, protecting

103
groups, -C(0)-Ra, -C(0)0-Ra, -C(0)NRaRa, -S(0)q-Ra, -S(0)q-NRaRa, -NRaRa, ,-0Ra, -SRa or when two R substitutents ortho to each other, are joined to a form a saturated or unsaturated 3-7 membered ring, which optionally include up to two heteroatoms selected from O, NRa or S;
R4 is NR5R6 ; wherein R5 and R6 are independently selected from the group consisting of hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstitued alkynyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted cycloalkylakyl, substituted or unsubstituted cycloalkenyl, substituted or unsubstituted aryl, substituted or unsubstituted arylalkyl, substituted or unsubstituted heteroaryl, substituted or unsubstituted heterocyclic ring, substituted or unsubstituted heterocyclylalkyl, substituted or unsubstituted heteroaryl alkyl , nitro, -OH, cyano, halogen, -C(0)-Ra, -C(0)0-Ra, -C(0)NRaRa , -S(0)q-Ra, -S(0)q-NRaRa , -C(=NRa)-Ra, -C(=NRa)-NRaRa, -C(=S)-NRaRa, -C(=S)-Ra, -N=C(RaRa), -NRaRa, -ORa, -SRa, protecting groups or R5 and R6 to each other are joined to a form a saturated or unsaturated cyclic ring, which may optionally include up to two heteroatoms which may be same or different selected from O, NRa or S;
Ar is selected from the group consisting of substituted or unsubstituted aryl, substituted or unsubstituted arylalkyl, substituted or unsubstituted heterocyclic ring or substituted or unsubstituted heteroaryl ring;
X is selected from the group consisting of O, S(0)q and NRa;
Y is selected from the group consisting of-C(0)NR7, -NR7S(0)q, -S(0)qNR7 and -
NR7C(0);
R7 is selected from the group consisting of hydrogen, substituted or unsubstituted alkyl,
hydroxyl, -ORa, substituted or unsubstituted aryl, and substituted or unsubstituted
heterocyclic ring ;
wherein P selected from the group consisting of O and S;
wherein m represents 0-3;

104
wherein n represents 1-4; wherein q represents 0,1 or 2; with the proviso that R4 is not NH2
wherein Ra is hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstitued alkynyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted cycloalkylakyl, substituted or unsubstituted cycloalkenyl, substituted or unsubstituted aryl, substituted or unsubstituted arylalkyl, substituted or unsubstituted heteroaryl, substituted or unsubstituted heterocyclic ring, substituted or unsubstituted heterocyclylalkyl , substituted or unsubstituted heteroarylalkyl , nitro, -OH, cyano, formyl, acetyl, halogen, protecting groups, -C(0)-Ra, -C(0)0-Ra, -C(0)NRaRa , -S(0)q-Ra, -S(0)q-NRaRa, -NRaRa, -0Ra or -SRa;
and their analogs, their tautomers, their regioisomers, their stereoisomers, their enantiomers, their diastereomers, their polymorphs, their pharmaceutically acceptable salts, their N-oxides and their pharmaceutical compositions containing them or a pharmaceutical acceptable salts thereof comprising the steps of:
a) reacting the compound of general formula (10) with a compound of the general formula
(11) in the presence of abase
CHO

(02N)/

PR1

(10) (11)
wherein P, X, R1 R2, m and n are the same as described above and wherein Z is a halogen, wherein W is a halogen, to obtain the intermediate of the general formula (12).
CHO
(02N)/ PR1
(12)

105
b) cyclising the intermediate of the general formula (12) using a reagent chosen from the group consisting of palladium acetate in DMF or glacial acetic acid, nickel catalyst in pyridine or DMF, and tetrakistriphenylphosphinepalladium in DMF to the tricyclic intermediate of the general formula (13).

(R3)m
CHO

c) the tricyclic intermediate of the general formula (13) is then oxidized to the intermediate
of the general formula (14) using sodium chlorite or potassium permanganate
COOH -R2
(02N)n'
(14)
d) the intermediate of the general formula (14) is then converted to the intermediate of the
general formula (15), wherein Y is -CONR7, by reacting an activated carboxylic acid
chosen from the group consisting of acid halide, mixed anhydride, and active ester
intermediate of the general formula (14) with the optionally substituted aryl or heteroaryl
amines (ArNHR7) under basic conditions;

Y-Ar
(R3)m-ii/I
(OaN); PR'
(15)

106
e) the intermediate of the general formula (15) is then reduced to the intermediate of the general formula (16).
Y-Ar

(16)
f) the intermediate of the general formula (16) is then converted to the desired compound of the general formula (1) wherein Y is -CONR7, R4 is -NR5R6 ; P, Ar, X, Y, R1, R2, R3, R5, R6 ,R7 m and n are the same as described in the general description.
Y-Ar

(1)
g) optionally the compounds of the general formula (I) are then converted into the corresponding salts and /or the N-Oxides.
17. A method for the preparation of compounds of general formula (1)
©-A,

P—R1
(1)
wherein:
R1, R2 and R3 are independently selected from the groups consisting of hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstitued alkynyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted

107
cycloalkylakyl, substituted or unsubstituted cycloalkenyl, substituted or unsubstituted aryl, substituted or unsubstituted arylalkyl, substituted or unsubstituted heteroaryl, substituted or unsubstituted heterocyclic group, substituted or unsubstituted heterocyclylalkyl, substituted or unsubstituted heteroarylalkyl , nitro, -OH, cyano, formyl, acetyl, halogen, protecting groups, -C(0)-Ra, -C(0)0-Ra, -C(0)NRaRa, -S(0)q-Ra, -S(0)q-NRaRa, -NRaRa, ,-ORa, -SRa or when two R3 substitutents ortho to each other, may be joined to a form a saturated or unsaturated 3-7 membered ring, which may optionally include up to two heteroatoms which may be same or different selected from O, NRa or S;
R4 is-NR5R6 ; wherein R5 and R6 are independently selected from the groups consisting of hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstitued alkynyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted cycloalkylakyl, substituted or unsubstituted cycloalkenyl, substituted or unsubstituted aryl, substituted or unsubstituted arylalkyl, substituted or unsubstituted heteroaryl, substituted or unsubstituted heterocyclic ring, substituted or unsubstituted heterocyclylalkyl, substituted or unsubstituted heteroarylalkyl, nitro, -OH, cyano, halogen, -C(0)-Ra, -C(0)0-Ra, -C(0)NRaRa , -S(0)q-Ra, -S(0)q-NRaRa , -C(=NRa)-Ra, -C(=NRa)-NRaRa, -C(=S)-NRaRa, -C(=S)-Ra, -N=C(RaRa), -NRaRa, -ORa, -SRa, protecting groups or R5 and R6 to each other are joined to a form a saturated or unsaturated cyclic ring, which optionally include up to two heteroatoms indpendentely selected from O, NRa or S;
Ar is selected from the group consisting of substituted or unsubstituted aryl, substituted or unsubstituted arylalkyl, substituted unsubstituted heterocyclic ring and substituted or unsubstituted heteroaryl ring;
X is selected from the group consisting of O, S(0)q and NRa;
Y is selected from the group consisting of -C(0)NR7, -NR7S(0)q, -S(0)qNR7 or -
NR7C(0);
R7 is selected from the group consisting of hydrogen, substituted or unsubstituted alkyl,
hydroxyl, -ORa, substituted or unsubstituted aryl, and substituted or unsubstituted
heterocyclic ring;

108

wherein P is selected from the group consisting of O, and S;
wherein m represents 0-3;
wherein n represents 1 - 4;
wherein q represents 0,1 or 2;
with the proviso that R4 is not NH2
wherein Ra is selected from the group consisting of hydrogen, substituted or unsubstituted
alkyl, substituted or unsubstituted alkenyl, substituted or unsubstitued alkynyl, substituted
or unsubstituted cycloalkyl, substituted or unsubstituted cycloalkylakyl, substituted or
unsubstituted cycloalkenyl, substituted or unsubstituted aryl, substituted or unsubstituted
arylalkyl, substituted or unsubstituted heteroaryl, substituted or unsubstituted heterocyclic
ring, substituted or unsubstituted heterocyclylalkyl , substituted or unsubstituted
heteroarylalkyl, nitro, -OH, cyano, formyl, acetyl, halogen, protecting groups, -C(0)-Ra, -
C(0)0-Ra, -C(0)NRaRa, -S(0)q-Ra, -S(0)q-NRaRa, -NRaRa, -ORa or -SRa;
and their pharmaceutically acceptable salts, their N-oxides and their pharmaceutical
compositions containing them or a pharmaceutical acceptable salts thereof
comprising the steps of:
a) reacting the compound of the general formula (17) with a compound of the general
formula (18) in the presence of a base
FG
W
(R°>
m
3u-^V
(02N)/ PR
(17) (18)
/^Z HX' ABI
wherein P, X, R1, R2, R3, m and n are the same as described in the general description ;wherein Z is a halogen, wherein W is a halogen, ,wherein FG is chosen from the group consisting of CHO, COCH3, CN, COORa, under basic conditions to obtain the intermediate of the general formula (19).

109
FG
(02N)/ PR1
(19)
b) cyclizing the intermediate of the general formula (19) by using a reagent chosen from the group consisting of (palladium acetate in DMF or glacial acetic acid, nickel catalyst in pyridine or DMF, and tetrakistriphenylphosphinepalladium in DMF, to the tricyclic intermediate of the general formula (20).
FG

(O2N); PR1
(20)
c) the tricyclic intermediate of the general formula (20) is then oxidized if FG is CHO or COCH3, or hydrolysed if FG is CN or COORa, to the intermediate of the general formula (14).

(02N)„'
(14)
d) the intermediate of the general formula (14) is then converted to the intermediate of the general formula (15),wherein Y is -CONR7, by reacting an activated carboxylic acid chosen from the group consisting of acid halide, mixed anhydride, and active ester intermediate of the general formula (14) with the optionally substituted aryl or heteroaryl amines (ArNHR7) under basic conditions;

110
Y-Ar

(R3)m—£/jri
rxV,
(02N)n' PR'
(15) e) the intermediate of the general formula (15) is then reduced to the intermediate of the general formula (16).
Y-Ar

(R3),
m (,
>***£,
(H2N)n' PR
(16) f) the intermediate of the general formula (16) is then converted to the desired compound of the general formula (1) wherein Y is -CONR7, R4 is -NR5R6 ; P, Ar, X, Y, R1, R2, R3, R5, R6, R7 ,m and n are as described in the general description;
Y-Ar

■Rz

(1)
g) optionally the compounds of the general formula (I) are then converted into the corresponding salts and /or the N-Oxides.
18. A method for the preparation of compounds of general formula (1)

P—R1
@—Ar

Ill
(1)
wherein:
R\ R2 and R3 are independently selected from the group consisting of hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstitued alkynyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted cycloalkylakyl, substituted or unsubstituted cycloalkenyl, substituted or unsubstituted aryl, substituted or unsubstituted arylalkyl, substituted or unsubstituted heteroaryl, substituted or unsubstituted heterocyclic group, substituted or unsubstituted heterocyclylalkyl, substituted or unsubstituted heteroarylalkyl , nitro, -OH, cyano, formyl, acetyl, halogen, protecting groups, -C(0)-Ra, -C(0)0-Ra, -C(0)NRaRa, -S(0)q-Ra, -S(0)q-NRaRa, -NRaRa, ,-ORa, -SRa or when two R3 substitutents ortho to each other, are joined to a form a saturated or unsaturated 3-7 membered ring, which optionally include up to two heteroatoms independentely selected from O, NRa or S;
R4 is selected from the group consisting of -NR5R6 ; wherein R5 and R6 are independently selected from the groups consisting of hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstitued alkynyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted cycloalkylakyl, substituted or unsubstituted cycloalkenyl, substituted or unsubstituted aryl, substituted or unsubstituted arylalkyl, substituted or unsubstituted heteroaryl, substituted or unsubstituted heterocyclic ring, substituted or unsubstituted heterocyclylalkyl, substituted or unsubstituted heteroarylalkyl , nitro, -OH, cyano, halogen, -C(0)-Ra, -C(0)0-Ra, -C(0)NRaRa, -S(0)q-R\ -S(0)q-NRaRa, -C(=NRa)-Ra, -C(=NRa)-NRaRa, -C(=S)-NRaRa, -C(=S)-Ra, -N=C(RaRa), -NRaRa, -ORa, -SRa, protecting groups or R5 and R6 are joined together to form a saturated or unsaturated cyclic ring, optionally include up to two heteroatoms independentely selected from O, NRa or S;
Ar is selected from the group consisting of substituted or unsubstituted aryl, substituted or unsubstituted arylalkyl, substituted or unsubstituted heterocyclic ring and substituted or unsubstituted heteroaryl ring;

112
X is selected from the group consisting of O, S(0)q or NRa;
Y is selected from the group consisting of -C(0)NR7, -NR7S(0)q, -S(0)qNR7 or -
NR7C(0);
R7 is selected from the group consisting of hydrogen, substituted or unsubstituted alkyl,
hydroxyl, -ORa, substituted or unsubstituted aryl, and substituted or unsubstituted
heterocyclic ring;
wherein P is chosen from the group consissting of O and S;
wherein m represents 0-3;
wherein n represents 1-4;
wherein q represents 0,1 or 2;
with the proviso that R4 is not NH2
wherein Ra is selected from the group consisting of hydrogen, substituted or unsubstituted
alkyl, substituted or unsubstituted alkenyl, substituted or unsubstitued alkynyl, substituted
or unsubstituted cycloalkyl, substituted or unsubstituted cycloalkylakyl, substituted or
unsubstituted cycloalkenyl, substituted or unsubstituted aryl, substituted or unsubstituted
arylalkyl, substituted or unsubstituted heteroaryl, substituted or unsubstituted heterocyclic
ring, substituted or unsubstituted heterocyclylalkyl , substituted or unsubstituted
heteroarylalkyl, nitro, -OH, cyano, formyl, acetyl, halogen, protecting groups, -C(0)-Ra, -
C(0)0-Ra, -C(0)NRaRa, -S(0)q-Ra, -S(0)q-NRaRa, -NRaRa, -OR3 and -SRa;
and their pharmaceutically acceptable salts, their N-oxides and their pharmaceutical
compositions containing them or a pharmaceutical acceptable salts thereof
comprising the steps of:
a) reacting the compound of the general formula (21) with a compound the general formula
(22) in the presence of a base
' PR
H3COC
(21) (22)
wherein P, X, R1 R2 ,R3 and m are the same as described above and wherein Z is a halogen, to obtain the intermediate of the general formula (23).

113
H3COC PR1
(23)
b) reducing the intermediate of the general formula (23) the intermediate of the general formula (24)
(R\,-fYNHV^.R2

H3COC PR1
(24)
c) cyclizing the intermediate of general formula (24) by using diazotization followed by coupling using a reagent chosen from the group consisting of cuprous oxide in O.IN sulfuric acid, and copper in DMSO to a tricyclic intermediate of the general formula (25)
(R3)m
(25) d) the acetyl group of tricyclic intermediate of the general formula (25) is then converted to the acetamido group.
Dated this f£A(-yTday of March — , 2006

(CHERYL PINTO) Director
Glenmark Pharmaceuticals Limited